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4. SCOPE OF THE THESIS
1 PATHOPHYSIOLOGY OF ASTHMA
1.1 Clinical characteristics of asthma
Asthma is a complex disorder that is characterized by reversible narrowing of the 
airways and increased airway reactivity to various specific stimuli, also denoted 
as allergens, and nonspecific stimuli, such as cigarette smoke and fog [1]. Airway 
hyperresponsiveness is a common feature of patients with an obstructive lung 
disease and generally not observed in healthy subjects. Although asthma has long 
time been considered as an airway smooth muscle disease, it is now widely accepted 
that a chronic inflammatory process is underlying the present hyperresponsiveness 
and bronchoconstrictive reaction in the airways of asthma patients. In asthma, 
the airways are characterized by epithelial desquamation, goblet cell hyperplasia, 
thickening of the submucosa and extensive infiltration of lymphocytes, eosinophils 
and mast cells [2,3]. The mechanisms responsible for the development of this 
inflammatory response are multi-factorial, involving both environmental determinants 
and genetic factors, including genes for allergy and hyperresponsiveness. Allergy is 
known as one of the strongest identifiable predispositions, but it cannot explain the 
prevalence of asthma alone. Furthermore, non-atopic forms of asthma exist as well. 
Since the allergen-induced type of asthma is most common in the population, this 
thesis will focus on the development of allergen-induced airway inflammation. 
 Repeated exposure to allergens may lead to the development of airway 
inflammation and hyperresponsiveness, in which an IgE-mediated response is 
thought to play an important role [4-6]. The asthmatic reaction to allergen inhalation 
in a susceptible individual can be divided in the early asthmatic response (EAR) 
and late asthmatic response (LAR). The early bronchoconstrictive response occurs 
immediately, within minutes, after inhalation of the allergen and is characterized 
by mast cell degranulation, mucus production, increased smooth muscle tone and 
bronchoconstriction [7,8]. Between the early and late response, a normal lung 
function can be observed. The late asthmatic response occurs after 3-6 hours and 
can last for up to 24 hours. The LAR is associated with mucus secretion, thickening 
of the bronchial wall, epithelial shedding, more severe bronchoconstriction and 
extensive infiltration of T cells and eosinophils in the lung tissue, [9-13]. Eosinophilia 
is an important characteristic of asthma, increased numbers of eosinophils being 
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Figure 1. Possible mechanism of allergen-induced inflammation in the airways of asthma patients.
observed in the airways of asthma patients compared to healthy controls [14]. While 
mast cells and dendritic cells are thought to mediate the immediate response to 
allergen inhalation, eosinophils play a central role in the late asthmatic reaction. IgE-
mediated crosslinking of the FcεRI receptor on mast cells results in activation and 
production of mediators like histamine, PGD2, LTC4 and PAF, which increase mucus 
secretion and bronchoconstriction during the EAR [8]. Activated eosinophils secrete 
a wide array of mediators that are of potential importance in the allergic airway 
inflammation, e.g. eosinophilic cationic protein (ECP), cytokines, leukotrienes, PGE2 
and PAF (15). Eosinophils are thought to contribute to bronchoconstriction, epithelial 
damage and airway hyperresponsiveness through the release of these mediators 
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[16-19].   An overview of the airway inflammation in asthma is given in figure 1.
1.2 Role of Th2 cells in asthma pathophysiology
T cells are mediators of immune responses and can be divided in cytotoxic T cells 
(CD8+) and helper T cells (CD4+), based on the function of the T cells. Whereas 
CD8+ T cells eliminate infected or tumor cells, CD4+ cells regulate the effector 
functions of immune cells by the secretion of cytokines. CD4+ cells can direct both 
inflammatory reactions (cellular immune response) and antibody driven immune 
responses (humoral immune response). During the activation of naive T cells by 
antigen presentation and costimulatory signals, T cells can differentiate into either 
Th1 or Th2 cells. Th1 cells produce the cytokines interleukin (IL)-2, interferon (IFN)-
γ and tumor necrosis factor (TNF)-β, whereas Th2 cells produce IL-4, IL-5, IL-6, IL-9, 
IL-10 and IL-13. Th1 cells promote cell-mediated immune responses, specifically 
against intracellular pathogens. Th2 cells direct B cell-mediated antibody responses. 
When T cells are activated only once or during short periods, Th0 cells may develop, 
which can produce both Th1 and Th2-like cytokines. Although immune responses 
can retain the Th0 phenotype, immune responses may also polarize towards a 
Th1 or Th2 type, which is dependent on the nature of the allergen as well as the 
cytokine environment. IL-12 is the most potent inducer of Th1 responses, whereas 
IL-4 is known to induce Th2 development [20,21]. T cells are thought to direct the 
allergen-induced airway inflammation in asthma, particularly T cells from the Th2 
activation type. Th2 cytokines play a role in IgE production, mast cell activation and 
eosinophilia. In asthmatic subjects, T cells from both BAL and bronchial biopsies 
express enhanced levels IL-4, IL-5 and IL-13 mRNA compared to healthy controls 
[22-26]. IL-4 has been widely described to induce in initial differentiation of 
uncommitted T cells towards the Th2 phenotype.
 Furthermore, IL-4 promotes the production of IgE antibodies in B cells [27]. 
Indeed, a polymorphism of the IL-4 gene has been shown to correlate with high 
serum IgE levels in asthma and atopy [28]. In addition, it has been described that 
IL-4 is a growth factor for mast cells [29], promotes eosinophilia by the upregulation 
of VCAM-1 expression [30] and is involved in mucus production [31]. A component 
of the IL-4 receptor (IL-4R), i.e. IL-4Rα, is shared by IL-13. Several IL-4Rα 
polymorphisms have been described to be associated with atopy and asthma-related 
phenotypes [32,33]. Furthermore, a significant gene-gene interaction between IL-
4Rα polymorphism IL-13 promoter polymorphism has been observed, suggesting 
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that an interaction between IL-4Rα and IL-13 enhances the susceptibility to develop 
asthma. In addition, IL-13 polymorphisms have been associated with an increased risk 
to develop allergic asthma [34]. Although IL-13 has many overlapping functions to 
IL-4, IL-13 may have important additional effects that contribute to the development 
of the inflammatory reaction in asthma. In this respect, IL-13 has been described to 
promote mucus production, airway hyperresponsiveness and eosinophilia [35].  In 
contrast, IL-5 is thought to be the most potent inducer of eosinophil differentiation, 
activation, attraction and survival [36-38]. Therefore, IL-5 may play a crucial role in 
the development of airway inflammation and hyperresponsiveness. This is supported 
by the findings from a mouse model of asthma, where it was found that IL-5 deficient 
mice did not develop eosinophilia, airway hyperresponsiveness and epithelial 
damage [39] and in guinea pigs, where IL-5 administration induced accumulation of 
eosinophils in the lung [40]. Together, previous studies indicate that an imbalance 
in Th1/Th2 towards a Th2 activation type may contribute to the development and 
severity of the airway inflammation in asthma.
 
1.3 Abnormalities in the cAMP/AC system in asthma
β2-agonists are widely used in asthma for their bronchodilatory effect, which is 
exerted by the relaxant effect on smooth muscle cells. The β2-adrenergic receptor 
(β2-AR) is located throughout the lung and extensively expressed on smooth muscle, 
epithelium, submucosal glands and vessels. In addition, the β2-AR is expressed on 
inflammatory cells in lung tissue, e.g. mast cells, macrophages, eosinophils and 
T cells [41]. In contrast to the use of β-agonists, the use of β-blockers is known 
to induce bronchoconstriction in asthmatic subjects and enhance sensitivity to the 
allergen [42], indicating that endogenous catecholamines play an important role in 
the regulation of smooth muscle tone in asthma. Endogenous catecholamines are 
thought to suppress bronchoconstriction through the inhibitory effect on cholinergic 
nerves, which is most likely mediated by circulating epinephrine [41]. In addition, 
β2-agonists may suppress airway inflammation, since proinflammatory cells express 
β2-receptors and inhibitory effects have been described on mediator release from 
the human lung [43]. The β2-AR belongs to the family of cell surface receptors 
referred to as G protein coupled receptors (GPCR) and primarily associates with 
the Gs protein. Activation of the Gs protein triggers adenylyl cyclase (AC) activity, 
resulting in the formation of intracellular cAMP, which is known as a negative 
regulator of proinflammatory activity. A general defect in the AC/cAMP system as 
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a possible mechanism leading to asthma was first described by Szentivanyi [44]. 
In these studies it was demonstrated that administration of Bordetella pertussis, 
leading to a defect in AC activity, induced an asthma-like phenotype in rats and 
mice. In addition, β-blockers increase the bronchoconstrictive response in asthmatic 
individuals [42,45]. Importantly, β-blockers are known to have a greater effect on 
sensitivity to allergen than to histamine or methacholine. This may be explained 
by the fact that β2-ARs are not only expressed on smooth muscle cells but also on 
a variety of inflammatory cells. These observations led to the hypothesis that an 
impaired function of the β2-adrenergic/AC system contributes to the pathophysiology 
in asthma and suggest that the suppressive action of β2-agonists is required for a 
good lung function. Although administration of β2-adrenergic agonists may improve 
lung function for short periods, the β2-AR can become unresponsive or desensitized 
after longterm treatment with β2-agonists as a result of reduced coupling to the Gs 
protein and the AC/cAMP system [41]. Enhanced sensitivity to the allergen upon 
regular treatment with β2-agonists has been reported, thus indicating the importance 
of good functionality of the AC system. There is evidence for reduced β2-adrenergic 
receptor density and AC response in circulating leukocytes from non-treated asthma 
patients [46-48]. Furthermore, in vitro studies have shown reduced bronchodilator 
responses to β2-agonists by asthmatic airways [49-51]. However, this was not 
observed in all studies and an intrinsic defect in the β2-AR has been controversial for 
a long time. 
 Some studies indicate that the function of the β2-AR may not be impaired 
in stable asthma [52,53], but hyporesponsiveness may be induced in acute 
asthma after inhalation of the allergen [54]. Several mediators of the allergic 
inflammatory reaction have been implicated in the development of β2-adrenergic 
hyporesponsiveness. For instance IL-5 and IL-13 have been shown to reduce β2-
adrenergic responsiveness in smooth muscle cells [55,56]. Because the allergen-
induced β2-adrenergic desensitization may result in reduced suppression of airway 
inflammation as well as bronchoconstriction, it may have important implications for 
asthma.
2 REGULATION OF CYTOKINE PRODUCTION IN T CELLS
2.1 T cell activation
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Activation of T lymphocytes in vivo is accomplished by antigen presentating cells 
(APC).  These cells activate T lymphocytes by presenting the processed antigen 
peptides to the T cell Receptor (TcR)/CD3 complex. For appropriate activation of T 
cells an accessory signal provided by costimulatory molecules is required, of which 
the ligands are also expressed on APCs. Activation in absence of the costimulatory 
signal leads to T cell unresponsiveness, also referred to as anergy (57). The most 
potent accessory signals for T cells activation are provided by CD28 or CTLA-4. 
Signal transduction of the CD3 protein complex is mediated by intrinsic tyrosine 
kinases associated with this complex, e.g. the Src family kinases p56lck and p59fyn 
and ZAP-70 [58, 59].  Activation of these kinases leads to recruitment of PI3-kinase 
to the receptor and activation of phospholipase C. The latter enzyme initiates 
hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) into 1,4,5,-triphosphate 
(IP3) and diaglycerol (DAG).  While DAG activates PKC, IP3 releases intracellular 
Ca2+, leading to the activation of the calmodulin/calcineurin pathway [59], which 
results in activation of the transcription factor NF-AT (nuclear factor for activated T 
cells). NF-AT is required for the production of several cytokines, including IL-2, IL-4 
and IL-5 [60-62]. PKC and protein tyrosine kinases can induce mitogen-activated 
kinases (MAPK), which include extracellular-regulated kinase (ERK), JNK Jun N-
terminal kinase (JNK)/stress activated protein kinase (SAPK) and p38/Mpk2 [63]. 
Activation of PKC results in induction of the Ras/Raf/ERK pathway, through the 
activation of p21Ras [64]. In addition, the activation of Ras during TcR stimulation 
can be accomplished by p56lck and p95Vav [65]. The MAPK kinases Raf and MEK-1 
(MAPKKK and MAKK) operate upstream of ERK and remain in the cytoplasm when 
activated, while activated ERK translocates to the nucleus and induces transcriptional 
regulation and activation of the Jun and Fos components of activator protein AP-1 
[63]. Together with NF-AT, AP-1 forms a transcriptional activation complex, which 
binds to the promoter of many cytokines genes in order to transactivate their 
expression [60]. For appropriate activation of the JNK pathway, costimulation of TcR 
with CD28 is required [66]. Protein tyrosine kinases are involved in CD28 mediated 
signaling and create a binding site for PI3-K upon activation [64-66]. In addition, 
CD28 co-stimulation has been described to be required for appropriate activation 
of Rac-1/p38 MAPK signaling and the subsequent transcriptional regulation of AP-1 
components as well as NF-AT activation, in order to prevent anergy [70]. In addition 
to activation of AP-1 and NF-AT, both Ras and PI3-K dependent signaling have been 
described to induce activation of the transcription factor NF-κB [71,72], which can 
also bind to the promoter of cytokines genes. Together, TcR and CD28 regulate 
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activation of transcription factors involved in cytokine RNA expression. An overview 
of the signaling pathways involved in T cell cytokine production is given in figure 2. 
2.2 Th2 differentiation
Both Th1 and Th2 cytokine genes express NF-AT and AP-1 binding sites in their 
promoter. For the production of a restricted Th1 or Th2 cytokine pattern, the 
Figure 2. Possible signal transuction pathways induced by TCR/CD3 complex and 
CD28 stimulation in T lymphocytes. Triggering of protein tyrosine kinases (PTK’s) 
leads to the activation of the Ca2+/NF-AT pathway as well as the MEK/ERK (MAPK) 
and SEK/JNK (SAPK) pathways and subsequent changes in transcriptional regulation.
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expression of specific transcription factors and epigenetic remodeling (e.g. altering 
the structure of chromatin and methylation patterns) of cytokine gene promoters is 
required. At the initiation of an immune response, naive T cells are primed, start to 
produce IL-2 and proliferate. Differentiation of T helper cells into Th1 or Th2 effector 
cells is induced when the naive cells undergo cell cycle progression in a Th1 or Th2 
specific cytokine environment. As described in paragraph 1.2, the presence of IL-
12 directs a Th1-mediated immune response, while IL-4 directs a Th2-mediated 
immune response. Specific transcription factors induced by IL-12 and IL-4 are 
members of the Jak/STAT pathway, i.e. STAT4 [73] and STAT6 [74], respectively. 
STAT6 is essential for the development of Th2 cells in response to IL-4 [75] and 
has been described to negatively regulate a Th1-specific IL-4 silencer [76]. Other 
transcription factors that are selective for differentiated Th2 cells and Th2 clones 
are NF-IL-6, c-Maf and GATA-3 [77-81]. c-Maf is a potent transactivator of the 
IL-4 promoter and is upregulated upon Th2 differentiation. GATA-3 may be a key 
regulator of Th2 cytokine production, since the expression is enhanced in polarized 
Th2 cells and downregulated in Th1 cells [81]. Moreover, forced expression of GATA-
3 in polarized Th1 cells is sufficient to reduce Th1 cytokine expression and initiate 
Th2 cytokine expression [79,81]. The expression of GATA-3 has been described to 
be capable of inducing IL-4 independent Th2 development [80]. The upregulation 
of GATA-3 may be essential for the expression of Th2 cytokines in asthma, since 
enhanced expression of GATA-3 has been observed in the airways of asthma patients 
[82]. In addition, both c-Maf and GATA-3 mRNA expression has been reported to 
increase after segmental allergen challenge [83]. In addition to the expression of 
Th1 and Th2 specific transcription factors, the composition and the transcriptional 
activity of AP-1 and NF-AT may play an important role in the expression of either Th1 
or Th2 effector cytokines. For instance, stronger AP-1 binding has been observed in 
IL-5 producing cells from asthmatic patients than in non-IL-5 producing cells from 
control subjects [84]. Furthermore, Th2 cells showed higher levels of AP-1 and NF-
AT transcriptional activity compared to Th1 cells [85]. The AP-1 complex in Th2 cells 
has been demonstrated to be composed of JunB dimers and higher levels of JunB 
have been detected in Th2 subsets versus Th1 cells [86]. In accordance, JunB and 
c-Fos are able to bind to the conserved lymphokine element 0 (CLE0) that is present 
in the IL-5 promoter [87]. On the other hand, differentiated Th1 cells display higher 
Jun/ATF2 binding to the IFN-γ promoter than precursor Th cells. Together, epigenetic 
remodeling as well as specific expression and activation patterns of transcription 
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factors determine whether a Th1 or Th2 cytokine profile is produced.
2.3 Regulation of T cell cytokine production by the cAMP-dependent pathway
T cell mediated immune responses are regulated by activation of Gs protein-coupled 
receptors (GPRC, e.g. β2-adrenergic receptor) through the production of cAMP. cAMP 
has been described to inhibit T cell proliferation, expression of the IL-2 receptor and 
both Th1 and Th2 cytokine production, although the ultimate effect on Th2 cells 
depends on stimulatory and costimulatory signals [88-93]. Upregulatory effects on 
Th2 cytokines have been described in T cells activated with the strong PKC inducer 
PMA and in T cells activated in presence of high levels of IL-2 and in Th2 clones [90-
93]. In contrast, in freshly isolated T cells stimulated with the more physiological 
stimulus α-CD3/α-CD28, cAMP exerted inhibitory effects on Th2 cells [94]. Until 
now, it is not completely understood how cAMP accomplishes these effects on 
Th2 cytokines. One of the pathways induced by cAMP is the activation of PKA and 
subsequent phosphorylation of cAMP responsive element binding protein (CREB) 
[95,96]. CREB can bind to the promoter of cytokine genes and thereby regulate 
transcription, for instance by competitively inhibiting c-Jun binding [97,98]. Unlike 
Th1 cytokine IFN-γ, no CREB binding site has been demonstrated in the promoter 
of Th2 cytokine genes IL-4 and IL-5. cAMP may indirectly inhibit the production of 
these cytokines through the interference with signaling pathways. cAMP has been 
described to inhibit the Ras/Raf/ERK and JNK pathways [99], which can be mediated 
in different manners. For instance, cAMP is known to induce the guanine exchange 
factor Epac and thereby activate the small GTPase Rap1 [100]. Rap1 has been 
reported to inhibit Ras-dependent signaling in both PKA-dependent and independent 
manners [101-103]. Furthermore, cAMP may inhibit PLC tyrosine phosphorylation 
[104] and uncouple Raf-1 from p21Ras in a PKA-dependent manner [105]. Inhibitory 
effects of cAMP on MAPK may also be exerted by the inhibition of tyrosine kinases 
from the Src kinase family [106]. In addition to the MAPK pathway, cAMP has been 
described to inhibit Ca2+ influxes and the downstream activation of NF-AT as well 
as NF-κB transcriptional activation [107-110]. Another cAMP effector that may be 
involved in the regulation of T cell proliferation and cytokine production is the cyclin-
dependent kinase 2 (cdk2) inhibitor p27kip, which can induce anergy in T cells [111]. 
One of the ways in which upregulation of p27kip is thought to exert its suppressive 
effect in T cells is the inhibition of AP-1 binding and transactivation. In contrast to 
the effects described above, positive effects of cAMP on signaling pathways have 
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also been reported. cAMP has been described to induce p38-dependent activation of 
GATA-3 in a murine Th2 effector cell line [112] and to promote ERK activity through 
induction of PKA and the Rap1-dependent activation B-Raf [113,114]. The outcome 
of cAMP on the transcriptional regulation of a cytokine may be determined by the 
degree and kinetics of different signaling cascades during T cell stimulation as well 
as the specific transcription factors involved in the regulation of the cytokine. In 
addition, the phosphorylation status of the Gs protein-coupled receptor determines 
the effect of the agonist on AC/cAMP activity and thus the ultimate effect on cytokine 
production. Phosphorylation of the Gs protein-coupled receptor reduces association 
with the Gs protein and can instead induce coupling to the MAPK pathway, thereby 
switching from negative to positive regulation of cytokine gene transcription [115]. 
3 T CELL ACTIVITY IN ASTHMA
3.1 Enhanced activation status of T cells after allergen challenge
Activated T lymphocytes play a key role in the pathophysiology of the airway 
inflammation in asthma. As described in paragraph 1.2, infiltrating T cells orchestrate 
the immune response associated with the asthmatic reaction by the production of 
Th2-like cytokines, e.g. interleukin (IL)-4, IL-5 and IL-13. Abnormalities in T cell 
function have been reported in asthma. Higher levels of activation markers, i.e. CD25, 
HLA-DR and VLA-1, are expressed in lung tissue and peripheral blood lymphocytes 
compared to healthy subjects [116,117]. Furthermore, enhanced expression of the 
Th2 cytokines IL-4, IL-5 and IL-13 has been observed in bronchoalveolar lavage 
(BAL) and bronchial biopsies from asthmatic subjects [22,23]. After allergen 
challenge, T cell activity increases, as reflected by further upregulation of activation 
markers in lung and peripheral blood lymphocytes [118-121], enhanced expression 
of Th2 cytokines in bronchial tissue [24-26] and migration of T cells into the lung 
tissue [122]. It has been reported that allergen-specific T cells infiltrate the lung 
upon allergen challenge [123]. The allergen-specific T cells of asthmatics appear to 
be primed for the production of IL-5 and after allergen challenge the capacity of BAL 
and peripheral blood T cells to produce IL-5 further increases [26,124,125]. Thus, 
allergen challenge might induce the migration of a primed and allergen-specific T cell 
subset from peripheral blood to the lung. Furthermore, it has been described that 
virtually all T cell that enter the lung express the Th2 specific chemokine receptor 
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CCR4 [126,127], indicating that primary Th2 cells infiltrate the lung tissue. Until 
now, it is not clear which mechanism is responsible for the enhanced Th2 activity 
in asthma. While cytokines secreted by macrophages, dendritic cells and bronchial 
epithelium might direct Th2-like cell development, another mechanism contributing 
to the enhanced activation status of the T cells in asthma is reduced negative 
regulation by the cAMP dependent pathway. 
3.2 β2-adrenergic dysfunction in T cells after allergen challenge
Circulating epinephrine is thought to negatively regulate peripheral blood 
lymphocytes. As described in paragraph 1.3 and 2.3, the β2-adrenergic system 
normally serves to suppress activity of peripheral T cells. Upon binding of β2-
agonists (e.g. epinephrine) to their cognate receptor, the β2-AR associates with the 
Gs protein, which triggers adenylyl cyclase (AC) activity and subsequently results 
in the formation of intracellular cAMP. Through the activation of the Gs protein 
and subsequent induction of the AC/cAMP system, β2-agonists can inhibit cytokine 
production, reduce expression of the activation marker CD25 [128] and block 
proliferation [129] of peripheral T cells. 
 Despite the Szentivanyi hypothesis of an impaired β2-AR function underlying 
the development of asthma, a general dysfunctionality of this system in asthma 
has remained controversial for a long time. However, it has been demonstrated 
that β2-AR function is normal in stable asthma, but that allergen exposure induces 
dysfunctionality of the β2-adrenergic system in peripheral lymphocytes from 
asthmatic subjects [54]. Twentyfour hours after allergen inhalation a 40-50% 
reduction in the cAMP response to β2-agonist isoproterenol occurs in lymphocytes of 
asthmatic subjects. Remarkably, this could already be observed at three hours after 
allergen challenge [130]. The number of β2-ARs reduced by approximately 20%, 
indicating that changes in receptor function play a role in the reduced β2-adrenergic 
responsiveness. The origin of the impaired β2-AR function has remained unclear. 
 β2-adrenergic hyporesponsiveness can be induced by prolonged or repeated 
agonist binding, resulting in uncoupling of the β2-AR from the Gs protein and 
AC/cAMP system. This is known as desensitization and regulated by receptor 
phosphorylation. After phosphorylation, dissociation from the Gs protein as well as 
internalization of the receptor can be induced. The latter is thought to be an early 
step in β2-AR downregulation and/or resensitization [131-133]. The kinases involved 
in agonist-induced phosphorylation of the β2-AR are the G-coupled receptor kinases 
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(GRK) and protein kinase A (PKA). GRKs and PKA are activated upon stimulation 
of the GPCRs through the release of Gβγ units and the increase in intracellular cAMP 
formation, respectively [134]. When β2-AR phosphorylation is mediated by GRK2 
and GRK3, also called βARK1 and βARK2, a binding site for β-arrestin is created 
[135-138], which sterically inhibits β2-AR function by preventing association with 
the Gs protein [138]. Additionally, β-arrestin has been described to recruit c-Src to 
the receptor, thereby linking the receptor to Ras/Raf/ERK activation [115]. Next to 
βARK and PKA, other kinases have described to induce β2-AR phosphorylation, i.e. 
PKC, tyrosine kinases and PI3-kinase [139- 141]. While GRKs have been implicated 
in agonist-induced phosphorylation of GPCRs (homologous desensitization), PKC 
has been described to induce desensitization that is not restricted to the β2-AR 
(heterologous desensitization) [142]. An overview of the action and the mechanism 
of desensitization of the β2-AR in T cells is given in figure 3.
 In contrast to allergen exposure, the inhalation of histamine, which 
Figure 3. Proposed action and mechanism of desensitization of the β2-AR
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induces an obstructive reaction as well, does not result in reduced responsiveness 
to isoproterenol in lymphocytes from asthma patients [143]. This suggests that 
mediators of the allergen-induced airway inflammation rather than the stress 
induced by an obstructive reaction are responsible for the β2-AR impairment. The 
involvement of allergen-induced process is further supported by the fact that non-
allergic asthma attacks, e.g. noctural asthma and exacerbations of asthma due 
to withdrawal of medication, do not show altered T cell responses or changes in 
β2-adrenergic responsiveness. Moreover, the study of Larsson et al demonstrated 
that epinephrine levels are not increased upon allergen exposure [144]. Several 
heterologous stimuli, e.g. growth factors and cytokines, have been implicated in 
β2-adrenergic desensitization [140,53]. For instance, β2-AR hyporesponsiveness 
in smooth muscle cells has been demonstrated to occur after exposure to the 
cytokines IL-1β, IL-5 and IL-13 [145,53,52]. Thus, one might speculate that the 
release of inflammatory mediators from the lung into the circulation is involved 
in the impaired β2-AR function in peripheral lymphocytes after allergen exposure. 
Consequently, peripheral T cells might lose their negative feedback control and 
display an enhanced activation pattern. Indeed, it has been demonstrated that β2-
adrenergic desensitization 24 hours after allergen provocation results in a complete 
loss of control over T cell cytokine production [122]. It is still unclear whether the 
allergen-induced β2-adrenergic desensitization contributes to the dysregulation of 
T cell activity as observed in asthma and which mechanisms are involved in the 
enhanced Th2 activation in asthma.
4 SCOPE OF THE THESIS
A chronic inflammatory process is underlying the pathophysiology of asthma. T 
cells from the Th2-type are thought to play a crucial role in the development of the 
inflammatory reaction in the asthmatic airways in response to allergen exposure. 
Asthmatic subjects display enhanced activity of T(h2) cells, as reflected by enhanced 
expression of Th2-like cytokines in lung tissue and enhanced expression of activation 
markers. After allergen inhalation, T cell activity is further upregulated and peripheral 
blood T cells are recruited to the lung tissue.  Until now, the mechanisms responsible 
for enhanced Th2 activity in asthma are poorly understood. In this thesis, we 
examine the possible mechanisms leading to the dysregulation of T cell activity and 
the enhanced Th2-like activation profile. 
CHAPTER 1
24
 We propose that the release of inflammatory mediators into circulation 
is responsible for the dysregulation of T cell activity upon allergen exposure. For 
instance, the release of cytokines could be of interest in this respect. Cytokines 
play a pivotal role in the direction of T cell responses during allergen exposure. 
In addition, the activation profile of T cells is determined by negative regulatory 
mechanisms. In asthma, impaired negative feedback control by the β2-adrenergic/
AC system has been reported. We hypothesize that a dysfunction in the AC/cAMP 
system and possibly additional signal transduction pathways contributes to the 
aberrant activation of T cells as observed in asthma.  In this thesis we investigate the 
effect of various soluble proinflammatory mediators on Th2-like cytokine expression 
and on the regulation of these cytokines by the cAMP-dependent pathway, in T cells 
from healthy controls as well as asthma patients and describe the involved signaling 
pathways.
 In chapter 2 we describe the role of interleukin-6 in the shift towards a 
Th2-like activation pattern. The most extensively described cytokine involved in 
Th2 development is IL-4 [21,22]. In addition, the multifunctional cytokine IL-6 may 
direct Th2 development. The source of IL-4 in asthma is elusive, while T cells have 
ample opportunity to encounter IL-6 secreting cells at the sites of allergen-induced 
inflammation. For instance, alveolar macrophages and bronchial epithelial cells are 
well-known IL-6 producers. Therefore, we investigated the effect of IL-6 on T cell 
cytokine production and studied the pathways involved in the IL-6-induced effects.
 In chapter 3, we investigate whether sensitivity of cytokine production 
to the cAMP-dependent pathway is reduced in presence of interleukin-2, in order 
to elucidate possible mechanisms involved in the dysregulation of T cell activity 
in asthma. The control of Th2 cytokines by cAMP is known to be dependent on IL-
2 levels and (co)-stimulatory signals. In addition, enhanced IL-2 levels and IL-2 
receptor (CD25) expression have been observed in asthma. Therefore, we examined 
whether IL-2 reduces cAMP-mediated inhibition of Th2 cytokine expression and we 
studied the downstream signaling pathways involved in this effect.
 Effector Th2 cells are thought to orchestrate the inflammatory response in 
asthma. In chapter 4 we describe the effects of cAMP elevating agents in T cells 
polarized towards effector Th1 and Th2 cells. Differentiation of naive T cells into 
effector cells may induce alterations in the regulation of cytokine production. We 
studied whether the cAMP-mediated regulation of cytokine production is different in 
polarized Th1 and Th2 effector cells and furthermore, we investigated the underlying 
mechanisms leading to differential effects of GPCR activation in polarized T cells. 
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 In chapter 5 we examine β2-adrenergic regulation of T cell activity before 
and after allergen challenge in asthmatic subjects. A loss of β2-adrenergic control 
has been observed in peripheral lymphocytes from asthma patients after allergen 
exposure, although the origin of this dysfunctionality is unclear. We hypothesized 
that β2-adrenergic desensitization contributes to the enhanced T cell activity in 
asthma. Therefore, we investigated the effects of β2-agonist fenoterol on Th1 
and Th2 cytokine production, T cell migration and signaling pathways in vitro in 
lymphocytes isolated before and after allergen challenge in vivo. We discuss the 
possible mechanisms involved in the allergen-induced loss of β2-adrenergic control 
over T cell activity.
 In chapter 6 we further study the possible mechanisms responsible for 
β2-adrenergic desensitization in T cells. Because of the characteristics of chemokine 
receptors and the implications for the chemokine TARC in asthma, we focused on 
the effects of TARC on β2-adrenergic signaling in T cells and describe the mechanism 
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Chapter 2
INTERLEUKIN-6 PROMOTES THE PRODUCTION OF INTERLEUKIN-4 AND 
INTERLEUKIN-5 BY INTERLEUKIN-2-DEPENDENT AND -INDEPENDENT 
MECHANISMS IN FRESHLY ISOLATED HUMAN T CELLS 





Th2 cytokines (IL-4 and IL-5) play a central role in the development of allergic 
immune responses. After allergen provocation, the expression of Th2 cytokines is 
rapidly upregulated in atopy and asthma. IL-6 is a multifunctional cytokine that is 
able to direct Th2 immune responses and is secreted by multiple tissue cell types. 
This study shows that IL-6 induces upregulation of IL-4 and IL-5 after short (5 
min) preincubation periods in freshly isolated, α-CD3/α-CD28 stimulated T cells. 
After longer preincubation periods with IL-6 (12 and 24 hr) the priming effect on 
IL-4 production gradually disappears, whereas the effect on IL-5 becomes more 
pronounced. In contrast, a small but significant inhibitory effect is found on the 
production of the Th1 cytokine interferon (IFN)-γ. Additional experiments indicate 
that the long-term priming effect of IL-6 on IL-5 production is dependent on IL-2 
signaling. This is not the case for the short-term IL-6 effect on IL-5 secretion, where 
the p38 mitogen-activated protein kinase (MAPK)-dependent induction of activator 
protein (AP)-1 DNA-binding activity is involved, independent of Signal Transducer 
and Activator of Transcription (STAT) 3 phosphorylation. In summary, these data 
demonstrate that the short-term and long-term priming effects of IL-6 on Th2 
cytokine production are regulated by different mechanisms. 
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INTRODUCTION
The development of allergic immune responses, like atopic dermatitis, allergic 
rhinitis and atopic asthma is mediated by T helper 2 (Th2)-like cytokines, particularly 
by interleukin-4 (IL-4) and IL-5. IL-4 plays a central role in Immunoglobulin E (IgE)-
mediated responses, whereas IL-5 is crucial for eosinophil recruitment and activation, 
which is observed in the inflammatory reaction of cutaneous late phase reactions 
and asthma. Increased numbers of CD4+ T cells expressing IL-4 and IL-5 mRNA have 
been found in bronchoalveolar lavage (BAL) of asthmatic subjects [1-3] and elevated 
levels of IL-4 and IL-5 expression have been observed in nasal and bronchial mucosa 
from allergic subjects [4-7]. Furthermore, it has been demonstrated that peripheral 
blood lymphocytes from asthmatic subjects are primed for enhanced productions 
of IL-4 and IL-5 mRNA [8]. Thus, a primed T cell subset may migrate to sites of 
allergen-induced reactions. At present, it is not clear which factors are responsible 
for priming of peripheral T cells to produce higher amounts of Th2 cytokines. Possibly, 
soluble mediators produced during the inflammatory reaction are released into the 
circulation and prime the T lymphocytes for enhanced Th2 cytokine production.
 In this respect, IL-6 might be of interest. IL-6 is a multifunctional cytokine 
produced at sites of tissue inflammation. It has been demonstrated that IL-6 derived 
from antigen-presenting cells (APCs) is able to induce initial IL-4 production in naive 
CD4+ T cells, thereby polarizing these cells into Th2 cells [9]. Furthermore, IL-6 protein 
levels secreted by alveolar macrophages positively correlate with the enhancement 
of IL-5 production in CD4+ T cells [10]. The capacity of alveolar macrophages from 
atopic asthmatics to increase IL-5 production in CD4+ T cells was abolished in the 
presence of neutralizing antibodies to IL-6 [10], clearly demonstrating that IL-6 has 
Th2-like promoting capacity. Moreover, monocytes from newborns with a high risk to 
develop allergy produced significantly larger amounts of IL-6 than monocytes from 
newborns with a low risk to develop allergy [11]. These findings suggest that IL-6 
might have an important role in the development of Th2 mediated diseases, like 
allergy. In addition, it has been demonstrated that IL-6 plays a role in regulation of 
Th1 responses by inhibition of IFN-γ production [12,13]. In this study we investigate 
the ability of IL-6 to promote the production of Th2 type cytokines IL-4 and IL-5 in 




Isolation of the T cells
Peripheral blood cells were obtained from healthy volunteer platelet donors. 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque 
(Lymphoprep; Nycomed, Oslo, Norway) density-gradient centrifugation. T cells were 
isolated by rosetting with 2-aminoethylisothioronium bromide (AET) treated sheep 
red blood cells (SRBC). The SRBC were lysed with 155 mmol/L NH4Cl, 10 mmol/L 
KHCO3 and 0.1 mmol/L EDTA. The remaining cell preparations contained more than 
98% T cells, as assesed by flow cytometric analysis after staining with α-CD2 (Becton 
Dickinson, Erebodegem-Aalst, Belgium). To obtain naive T cells, CD4+/CD45RO- cells 
were sorted using a MoFloTM flow cytometer (Cytomation, Fort Collins, CO, USA), 
as previously described [14]. After isolation, T cells were incubated overnight at 
37°C in RPMI 1640 (BioWhittaker, Verviers, Belgium) containing 5% fetal calf serum 
(FCS; Hyclone, Logan, UT, USA), supplemented with 100 U/ml penicillin and 100 
µg/ml streptomycin. CD4+/CD45RO- cells were cultured for 7 days in RPMI 1640 
medium containing 10% FCS, in presence of PHA, IL-2, irradiated allogenic PBMC 
(feeder cells) and either IL-12 (2 ng/ml, R&D systems, ITK diagnostics, Uithoorn, the 
Netherlands) plus α-IL-4 (200 ng/ml, Becton Dickinson) to generate polarized Th1 
cells, or IL-4 (200 U/ml, Becton Dickinson) and α-IL-12 (2 µg/ml, R&D systems) to 
generate polarized Th2 cells, as described before [14].
Stimulation of the T cells
Freshly isolated T cells, naive CD45RO- cells, or polarized Th2 cells were incubated in 
RPMI 1640 medium containing 5% FCS and stimulated with 50 µl/ml of α-CD3 and 
α-CD28 antibodies as previously described by Borger et al [8], which evokes a T cell-
specific response. T cells were stimulated in the presence or absence of inhibitors of 
the p38 mitogen-activated protein (MAP) kinase pathway, the phosphatidylinositol 
3-kinase (PI3-kinase) pathway, the calcineurin dependent pathway and the MAPK/
extracellular signal-related kinase (ERK)-1 (MEK-1) pathway; SB203580 (SmithKline 
Beecham Pharmaceuticals, King of Prussia, PA, USA) LY294002 (Alexis Corporation, 
Läufelfingen, Switzerland), Cyclosporin A (CsA) and PD98059 (New England Biolabs, 
Beverly, MA, USA), respectively, in a final concentration of 10 µM. Antibodies against 
IL-2 (Diaclone research, Besançon, France) or isotype-matched antibodies (IgG1) 
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were added in a final concentration of 2 µg/ml. To investigate priming mechanisms 
of IL-6 and IL-2, cells were preincubated  for 5 min, 6 hr, 12 hr or 24 hours before 
stimulation in presence or absence of  10 ng/ml rhIL-6 or 2 ng/ml rhIL-2.
Measurement of cytokine protein 
3 x 106/ml T cells were stimulated with α-CD3/α-CD28 during 8 hr. Secreted IL-
4, IL-5 and IFN-γ protein were measured in cell-free supernatants, using enzyme 
linked immunosorbent assay (ELISA) kits for IL-4 and IFN-γ (CLB, Amsterdam, The 
Netherlands). The IL-5 ELISA was performed as previously described previously 
[15].
FACS analysis of intracellular IFN-γ and IL-4
Intracellular IFN-γ and IL-4 accumulation was studied as previously described [14], 
using the Cytodetect kit (a gift from Immune Quality Products (IQP), Groningen, 
the Netherlands). In short, 1 x 106/ml cells were stimulated for 4 hours with 
PMA (10 ng/ml) and ionomycin (1 µg/ml) in the presence of monensin (2 µM, 
IQP). Cells were harvested, fixed with 4% paraformaldehyde and permeabilized 
in 0.1% saponin/0.1% azide. Cells were stained with anti-CyQ-CD4(B-F5, IQP), 
anti-CD45RO-FITC (UCHL1), anti-IFN-γ-FITC (45-15, IQP) and anti-IL-4-PE (B-T4, 
IQP). Irrelevant isotype-matched antibodies were used for gate setting. Analysis 
was performed usong an Elite flow cytometer (Beckman Coulter, Florida, USA) 
calibrated using Flow-Check Fluorospheres (Beckman Coulter) in combination 
with Winlist software (Verity, Topsham, USA). Lymphocyte events were gated on 
the basis of forward and sideward scatter characteristics. To confirm that Th1 and 
Th2 phenotypes were obtained after 7 days of culture under polarizing conditions, 
the polarized T helper cells were replated in RPMI medium containing 5% FCS and 
cultured overnight before stimulation.  The intracellular cytokine stainings indicated 
that highly divergent cytokine production patterns were obtained after one week 
of culture. Virtually all cells became CD45RO+ after culturing under polarizing 
conditions. In the cell population polarized under Th1 conditions, approximately 40% 
of the CD4+ cells was IFN-γ+/IL-4-, whereas in the cell population cultured under Th2 
conditions, approximately 10% was IL-4+/IFN-γ-. In both cell populations, only a 
small percentage of the cells was positive for both cytokines.
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Immunodetection by western blotting
Phosphorylation of p38 and STAT3 was analyzed by western blotting. T cells (3 x 
106/ml) were cultured overnight in RPMI 1640 medium containing 0.5% FCS. T cells 
were stimulated with IL-6 alone, with α-CD3/α-CD28 alone or with the combination 
for 60 min in presence or absence of SB203580, PD98059 or Cyclosporin A (CsA). 
T cells were harvested and spun down at maximum speed during 30 s. Next, total 
cell lysates were obtained by resuspension of the pellets in 1x Sample buffer 
(containing 2% SDS, 10% glycerol, 2% β-mercapoethanol, 60 mM Tris-Cl PH 6.8 and 
bromophenol blue) and boiling for 5 min. Samples were loaded on a SDS 10% PAGE 
gel (acrylamide:bisacrylamide 173:1) and transferred to a cellulosenitrate membrane 
(Schleicher & Schuell, Germany). Immunodetection of phospho-p38, phospho-Stat3 
(New England Biolabs, Hitchin, Herts, UK), pan-p38 and pan-Stat3 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was performed by standard procedures and the 
detection was performed according the manufacturer's guidelines (ECL, Amersham, 
Buckinghamshire, UK). Relative protein levels were quantified using the gelscan 
program Diversity One (Pharmacia).
Electrophoretic mobilily shift assay  
T cells (5 x 106/ml) cells were stimulated during 4 hours in presence or absence of IL-
6 and in presence or absence of SB203580, PD98059 and CsA. Cells were harvested 
and nuclear extracts were produced according to the mini-scale procedure described 
[16].  In short, cells were harvested by centrifugation at 500 x g for 5 min, washed 
once with PBS and resuspended in Buffer A (10mM HEPES PH 7.9, 10 mM KCl, 0.1 M 
EDTA, 0.1 mM EGTA, 1 mM DTT) supplemented with protease inhibitors (Complete TM, 
Boehringer, Mannheim, Germany). After 15 min of incubation on ice, cells were lysed 
by adding Nonidet P-40 (25 µl). T cell lysates were centrifuged at maximal speed 
for 1 min at 4°C and nuclear pellets were resuspended in buffer C (20 mM HEPES, 
400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) supplemented with CompleteTM. 
The suspension was incubated on ice for 20 min with regular vortexing to extract the 
nuclear proteins. Finally pellets were spun down at maximum speed for 30 s and the 
supernatants containing nuclear extracts were stored at -80°C. The concentration 
of the nuclear proteins was determined using the Bradford assay [17]. A double 
stranded oligonucleotide probe (5'-AGC TCG CGT GAC TCA GCT G3') containing 
the AP-1 binding sequence was used in the gel retardation assay. Annealing of the 
IL-6 PROMOTES THE PRODUCTION OF IL-4 AND IL-5 IN HUMAN T CELLS
39
two strands was performed by heating for 2 min at 94 °C and slow cooling down 
to room temperature. Hundred ng of the double stranded oligo was labeled with P32 
α-ATP (3000 Ci/mmol, Amersham) and separated from nonincorporated radiolabel 
by Sephadex G50 chromatography. Next, 5 µg of nuclear extract and 0.1 ng double 
stranded labeled oligo were incubated in 20 mM HEPES (pH 7.9), 60 mM KCl, 0.06 
mM EDTA, 0.6 mM DTT, 2 mM spermidine and 10% glycerol, supplemented with 2 
µg poly dI-dC) at 26 °C for 30 min. The supershift experiment was performed by 
incubating the nuclear extracts with 1 µg of  polyclonal antibody against JunB (Santa 
Cruz Biotechnology). The samples were loaded on pre-run (30 min, 100 V) 4% 
polyacrylamide gels and run for 1.5 hr at 150 V in 1.0 x TBE at room temperature. 
Gels were dried and quantification of the binding signals was performed using a 
Phosphor Imaging (Molecular Dynamics, Sunnyvale, CA, USA).
Reverse Transcription (RT)-Polymerase Chain Reaction (PCR)
T cells (5-10 x 106 11⁄2/ml) were incubated with and without IL-2 or IL-6 for 24 hr or 
stimulated for 6 hr with IL-6 alone, with α-CD3/α-CD28 or with IL-6 in combination 
with α-CD3/α-CD28, in presence and absence of SB203580 and CsA. After 
stimulation, cells were harvested and RNA was isolated using the TRIzol method 
(GIBCOBRL, Burlington, Ontario, Canada). Total cellular RNA was resuspended in 
diethyl-pyrocarbonate (DEPC; Sigma, St. Louis, MO, USA) treated H2O. 1-3 µg RNA 
was used for cDNA synthesis. First, the samples were incubated during 10 min at 65 
°C with random hexamer (pdN6). After cooling on ice, RT mix containing 5x RT buffer 
(GIBCOBRL), 0.1 M DTT, 5 mM of each dNTP and 3 units of Reverse Transcriptase 
(GIBCOBRL) was added and the samples were incubated at 37°C for 1 hr. For the PCR 
reaction, 10x PCR buffer (GIBCOBRL), 50 µM of forward and reverse primer, 0.25 µl 
Taq polymerase, 2 mM dNTP’s, and 75 µl MgCl2 in 25 µl total volume were added. The 
following specific primer pairs for β-2-microglobuline (β2µG, housekeeping gene), 
GATA-3 and JunB were obtaind from Biolegio BV (Malden, The Netherlands): β2µG: 
5’CCA GCA GAG AAT GGA AAG TC3’ sense and 5'GAT GCT GCT TAC ATG TCT CG3' 
antisense. SOCS1: 5'CAC GCA CTT CCG CAC ATT CC3' sense and 5'TCC AGC AGC 
TCG AAG AGG CA3' antisense. JunB: 5'CCA GTC CTT CCA CCT ACC TCG ACG TTT ACA 
A3' sense and 5'GAC TAA GTG CGT GTT TCT TTT CCA CAG TAC3' antisense. GATA3: 
5' GAA CAT CAT CTC GGG3' sense and 3' CAC GTA CTG AGT GAC CTT TC5' antisense. 
PCR conditions were a denaturation step at 94°C for 5 min followed by 20 cycles of 
94°C, 30 s; 55°C, 30s; 72°C, 30 s for detection of β2µG, 25 cycles of 94°C, 30s; 
CHAPTER 2
40
60°C, 30s; 72°C, 30s for detection of SOCS1, 30 cycles of 94°C, 30s; 55°C, 30s; 
72°C, 30s for detection of GATA-3 and 35 cycels of  94°C, 30s; 57°C, 45s; 72°C, 45s 
for detection of JunB. With these primers the amplified products were 268 bp, 300 
bp, 150 bp and 257 bp long for β2µG, SOCS1, GATA-3 and JunB respectively. After 
PCR, 10 µl of the reaction mixture was run on a 1.5% agarose gel, containing 0.2 µg 
ethidium bromide in 1x TAE buffer. A 100 bp ladder (Pharmacia, Uppsala, Sweden) 
was used as DNA marker. Relative mRNA levels of the PCR products were quantified 
using the gelscan program Diversity One (Pharmacia).
Statistical analysis
For the protein measurements, statisical analysis was performed using the Wilcoxon’s 
signed rank test for paired observations. Statistical significance of the secretion data 
was set at p<0.05.
RESULTS
Preincubation with IL-6 upregulates IL-4 and IL-5 protein secretion
Freshly isolated T cells were preincubated with or without IL-6 for 5 min, 6 hr, 12 
hr or 24 hr and subsequently stimulated. Incubation of T cells with IL-6 alone did 
not induce a detectable amount of cytokines (data not shown). Because there was 
a wide range in the levels of cytokines secreted by the different blood donors, yet 
IL-6 exerted similar effects in low and high cytokine producers, the cytokine protein 
levels are expressed as a percentage of the cytokine secretion upon stimulation 
in absence of IL-6. Fig.1A shows that IL-6 preincubation for 5 min followed by α-
CD3/α-CD28 stimulation significantly enhanced IL-4 secretion 1.9±0.3 fold (from 
16±12 to 29±22 pg/ml, p<0.01) and IL-5 secretion 1.5±0.2 fold (from 56±53 to 
86±71 pg/ml, p<0.01) compared to α-CD3/α-CD28 stimulation alone.  After 6 hr 
of preincubation, IL-6 had a similar effect on IL-4 protein secretion (fold increase 
1.8±0.3, p<0.01), which was reduced after 12 hr and completey abolished after 24 
hr of preincubation. In contrast, the priming effect of IL-6 on IL-5 secretion was most 
pronounced after 24 hr of preincubation (fold increase 1.8±0.1, p<0.01). No effect 
of IL-6 was observed on IFN-γ secretion within 12 hr, whereas a slight but significant 
inhibitory effect on IFN-γ protein secretion was observed after 24 hr of preincubation 
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(from 4.1±5.8 to 2.8±3.6 ng/ml, p<0.05, fig. 1A). 
 We also examined the effect of IL-6 in naive (CD45RO-/ CD4+) T cells, 
however, in these cells no cytokine secretion could be detected after α-CD3/α-CD28 
stimulation in absence or presence of IL-6. This indicates that in our setting CD45RO+ T 
cells are responsible for the effects of IL-6 on cytokine secretion, although we cannot 
Figure 1. A) IL-6 upregulates the production of Th2-like cytokines. Effects of different IL-6 (10 ng/ml) 
preincubation periods (5 minutes, 6 hr, 12 hr or 24 hr) on IL-5, IFN-γ and IL-4 secretion were studied 
in T lymphocytes from healthy donors. After preincubation with or without IL-6, T cells were stimulated 
with α-CD3/α-CD28 during 8 hr. Cytokine protein levels are expressed as percentage (x ± SEM, n=9) 
of the secretion after stimulation with α-CD3/α-CD28 in absence of IL-6. † = p<0.05 and †† = p<0.01 
for the IL-5 secretion level after preincubation with IL-6 compared to the level after preincubation 
without IL-6. # = p<0.05 for the IFN-γ secretion level after preincubation with IL-6 compared to the 
level after preincubation without IL-6.** = p<0.01 for the IL-4 secretion level after preincubation with 
IL-6 compared to the level after preincubation without IL-6. B) IL-6 does not affect cytokine production 
in polarized T helper cells. The effect of IL-6 (10 ng/ml) on IFN-γ, IL-4 and IL-5 secretion was studied 
in naive CD4+T cells from healthy donors that were cultured under Th1 and Th2 polarizing conditions 
for 7 days, rested overnight in RPMI 1640 containing 5% FCS, preincubated for 6 or 24 hr with or 
without IL-6 and stimulated with α-CD3/α-CD28 during 6 hr. Cytokine protein levels are expressed as 
percentage (x ± SEM, n=4) of the secretion after stimulation with α-CD3/α-CD28 in absence of IL-6. 
C) Characterization of cytokine profiles in freshly isolated T cells and polarized Th2 cells. Intracellular 
cytokine stainings were performed after stimulation of the T cells with PMA/ionomycin for 4 hr, in presence 
or absence of IL-6 (10 ng/ml). Results shown are representative of two independent experiments. 
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exclude that interactions between naive and memory T cells could be involved in the 
effect of IL-6. Furthermore, fig. 1B demonstrates that IL-6 did not significantly alter 
the cytokine secretion in polarized Th1 and Th2 cells (absolute amounts: 96±31 
pg/ml for IL-4 and 471±252 pg/ml for IL-5 in Th2 cells and 15.3±9.8 ng/ml for IFN-
γ in Th1 cells, n=4). This indicates that the T cells affected by IL-6 are rather of an 
intermediate phenotype (Th0) than highly restricted to a Th1 or Th2 phenotype. In 
polarized Th2 cells 10.3% of the CD4+ cells expressed IL-4, while in freshly isolated T 
cells only approximately 2% of the CD4+ cells expressed IL-4, which was not clearly 
different in presence of IL-6 (Fig. 1C). In addition, presence of IL-6 did not clearly 
alter the percentage of IFN-γ+ cells in CD4+ cells, nor the percentages of IL-4+ and 
IFN-γ+ cells in CD4- cell populations (2.0% versus 2.0% for IL-4 and 7.3% versus 
6.1% for IFN-γ, in absence and presence of IL-6, respectively).  Accordingly, it has 
been demonstrated that expression of effector cytokines in T helper cells is cell cycle 
dependent and the induction of IL-4 expression requires at least three cell divisions 
[18]. Thus, instead of inducing the expression of Th2 cytokines in naive T cells, IL-6 
appears to enhance the capacity to produce Th2 cytokines in T cells unrestricted to 
a T helper phenotype, possibly by modulating intracellular pathways that lead to Th2 
cytokine gene transcription. 
Long-term effect of IL-6 on IL-5 production is dependent on IL-2
Th2 cytokine production has been reported to be dependent on IL-2 activation 
[19]. Neutralizing antibodies to IL-2 (α-IL-2) significantly inhibited the secretion of 
α-CD3/α-CD28 induced IL-4 and IL-5 (See fig. 2A, p<0.001). As a control, isotype-
matched antibodies (IgG1) were added prior to stimulation, which did not result in 
a reduction in IL-5 secretion (data not shown). Fig. 2a shows that the immediate 
early upregulatory effect of IL-6 on IL-5 secretion was not blocked by the addition of 
α-IL-2. Similarly, the early upregulatory effect of IL-6 on IL-4 protein secretion was 
not dependent on the endogenous levels of IL-2, since 5 min of preincubation with 
IL-6 still significantly upregulated IL-4 in presence of neutralizing α-IL-2 antibodies 
(p<0.05, fig. 2B).
 In contrast, the IL-6 induced upregulation of IL-5 secretion after 24 hours of 
preincubation (1.6±0.3 fold, p<0.01) was abrogated by addition α-IL-2; in presence 
of α-IL-2, IL-6 was no longer able to induce a significant increase in IL-5 secretion, 
see fig. 2a. These results indicate that the long-term preincubation effect of IL-6 on 
IL-5 production is dependent on the presence of endogenously produced IL-2. 
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 To further underscore the role of IL-2 in IL-5 protein secretion, T lymphocytes 
were preincubated with IL-2 for 5 min or 24 hr. 5 minutes of preincubation with IL-
2 followed by α-CD3/α-CD28 stimulation did not significantly alter IL-5 production 
compared to α-CD3/α-CD28 stimulation alone (data not shown). Preincubation with 
2, 10 and 100 ng IL-2 during 24 hr followed by α-CD3/α-CD28 stimulation resulted 
in significantly higher levels of IL-5 protein secretion compared to preincubation 
without IL-2. Furthermore, an additional enhancement of IL-5 secretion was 
observed with all IL-2 concentrations when IL-6 was added as well (p< 0.05, fig. 
2C). These data suggest that the effect of IL-6 exposure to T lymphocytes is not due 
to additional production of IL-2, but the intracellular IL-2 signaling is more likely to 
be involved. In vitro, IL-2 is required for Th2 differentiation and IL-2 may therefore 
be of importance for the expression of Th2 specific transcription factors. Previously, 
it has been demonstrated that GATA-3, a Th2 specific transcription factor, is crucial 
Figure 2. The long-term preincubation 
effect of IL-6 on IL-5 secretion is 
dependent on IL-2 availability. A) Effects of 
preincubation with IL-6 on IL-5 production 
in freshly isolated T lymphocytes during 5 
min or 24 hr in the absence and presence 
of neutralizing antibodies to IL-2. After 
preincubation with or without IL-6, T cells 
were stimulated with α-CD3/α-CD28 during 
8 hr. IL-5 protein levels are expressed 
as percentage (x ± SEM, n=8) of the 
production after stimulation in absence of 
IL-6 and α-IL-2. B) Effects of preincubation 
with IL-6 on IL-4 production in freshly 
isolated T lymphocytes during 5 min in 
the absence and presence of neutralizing 
antibodies to IL-2. After preincubation with 
or without IL-6, T cells were stimulated 
with α-CD3/α-CD28 during 8 hr. IL-4 
protein levels are expressed as percentage 
(x ± SEM, n=5) of the production after 
stimulation in absence of IL-6 and α-IL-2. 
C) Effect of IL-6 preincubation during 24 
hr on IL-5 production in T lymphocytes, in 
presence of increasing IL-2 concentrations 
(0, 2, 10, 100 ng). After preincubation 
with IL-6, T cells were stimulated with 
α-CD3/α-CD28 during 8 hr. IL-5 protein 
levels are expressed as a percentage 
(x ± SEM, n=4) of the production after 
stimulation with α-CD3/α-CD28 alone. * 
= p<0.05 between values of relative IL-5 
protein in presence and in absence of IL-6. 
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Figure 3. GATA-3 mRNA expression is upregulated by IL-2. 
Freshly isolated T cells were incubated with IL-2 (2 ng/ml) 
or without exogenously added IL-2 for 6 hr and 24 hr. In 
the upper panel the GATA-3 signal is shown. In the lower 
panel the β2µG signal shows that comparable amounts of 
product were amplified for each condition. Results shown 
are representative of three independent experiments.
for activation of the IL-5 promoter and that ectopic expression of GATA-3 is sufficient 
to drive IL-5 gene expression [20]. As shown in fig. 3, GATA-3 mRNA expression is 
upregulated by IL-2 already after 6 hours but more strongly after 24 hr of incubation 
(induction ± 2-fold), compared to 6 and 24 hours of culture in absence of IL-2. Thus, 
one of the events induced by IL-2 leading to enhanced production of IL-5 may be 
the upregulation of GATA-3 expression. In contrast to IL-2, IL-6 did not elevate the 
expression of GATA-3 mRNA. Furthermore, IL-6 did not increase the IL-2 induced 
GATA-3 mRNA expression (data not shown). Whether the expression levels of GATA-
3 are of relevance for the long-term effect of IL-6 on IL-5 secretion still remains to 
be elucidated.
 IFN-γ secretion was also inhibited in presence of α-IL-2 by approximately 
40%. However, the production of IFN-γ was not altered by exogenously added IL-2 
in absence or presence of IL-6, demonstrating that the effect of IL-2 is not a general 
effect on cytokine production (data not shown). In addition, the results indicate that 
the inhibitory effect of IL-6 on IFN-γ production is regulated independently from IL-2 
signaling. A plausible explanation for the inhibitory effect of IL-6 on IFN-γ might be 
the upregulation of suppressor of cytokine signaling 1 (SOCS1) expression. SOCS1 
inhibits STAT1 mediated activation of the IFN-γ promoter, which may be crucial 
for IFN-γ expression. IFN-γ production was strongly enhanced in SOCS deficient 
mice. Moreover, IL-6 was not able to inhibit IFN-γ production in these mice [12]. As 
demonstrated in fig. 4, incubation with IL-6 during 24 hr results in upregulation (± 
2.0-fold) of SOCS1 mRNA expression compared to culturing for 24 hr without IL-6 in 
freshly isolated T cells. 
Effect of IL-6 on signal transduction 
The short-term (5 min) preincubation effect of IL-6 on Th2-like cytokine secretion 
is most likely a direct effect, which could not be inhibited by α-IL-2. This suggests 
the involvement of alternative IL-6 specific signaling pathways. To study this in more 
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detail, the upregulatory effect of IL-6 was investigated in presence of inhibitors of 
several well-known signal transduction pathways. The inhibitors used were: 1 µM 
SB203580 (specific for the p38 MAP kinase pathway), 1 µg/µl Cyclosporin A (CsA, 
specific for the calcineurin dependent pathway), 10 µM PD98059 (specific for the 
MEK-1 pathway) and 10 µM LY294002 (specific for the PI3-kinase pathway) [21-
23]. As depicted in fig. 5A, all inhibitors reduced the secretion of IL-5, indicating 
that the pathways that are blocked by these inhibitors are essential for optimal IL-5 
production. Furthermore, in presence of SB203580 we did not observe a significant 
upregulation of IL-5 production in response to IL-6 (fold induction 1.1±0.2, N.S.), 
indicating that the upregulatory effect of IL-6 is dependent on p38 activity.  Similarly, 
in presence of CsA no significant increase in IL-5 secretion could be induced by IL-6. 
In contrast, when inhibitors of the MEK-1 pathway (PD98059) and the PI3-kinase 
pathway (LY294002) were added, IL-6 was still able to induce an increase in the IL-
5 protein levels when compared to the levels in the absence of IL-6 (fold induction 
Figure 4. SOCS1 mRNA expression is upregulated by IL-6. 
Freshly isolated T cells were incubated with IL-6 (10 ng/ml) or
without IL-6 for 24 hr. In the upper panel the SOCS1 signal is 
shown. In the lower panel the β2µG signal shows that comparable 
amounts of product were amplified for each condition. Results 
shown are representative of three independent experiments.
Figure 5. The upregulatory effect of IL-6 on IL-
5 production is blocked by inhibition of the p38 
MAPK pathway. A) Effect of IL-6 preincubation 
(5 min) in absence and presence of inhibitors 
of the p38, calcineurin-dependent, ERK-1/2 and 
PI3-kinase pathway (SB203850, CsA, PD98059 
and LY294002, respectively) on α-CD3/α-CD28 
stimulated IL-5 production by freshly isolated T 
lymphocytes. After preincubation with IL-6, T cells 
were stimulated with α-CD3/α-CD28 during 8 hr 
and IL-5 protein was measured in supernatants. 
Protein levels are expressed as a percentage (x 
±SEM, n=6) of the production after stimulation with 
α-CD3/α-CD28 alone. *=p<0.05 between relative 
IL-5 protein in presence and in absence of IL-6. 
B) Effect of IL-6 on α-CD3/α-CD28 induced p38 
phosphorylation, in presence and absence of CsA. T 
cells were cultured overnight in RPMI 1640 medium 
containing 0.5% FCS and subsequently stimulated 
with α-CD3/α-CD28 for 60 min in presence and 
absence of IL-6 and CsA. Total celllysates were 
prepared. Phosphorylated p38 is depicted in the 
upper panel and total p38 is shown in the lower 
panel (marked by arrows). Results shown are 
representative of three independent experiments.
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Figure 6. The effect of IL-6 on AP-1 binding 
activity, but not STAT3 phosphorylation, is inhibited 
by SB203580 and CsA. A) Effect of IL-6 on DNA 
binding activity of AP-1. Freshly isolated T cells were 
stimulated for 4 hr with α-CD3/α-CD28, in presence 
and absence of IL-6, SB203580 and CsA. Supershifts 
were carried out using 1 µg of polyclonal α-JunB or 
α-c-Jun antibody. Results shown are representative 
of three independent experiments. B) JunB RNA 
expression is upregulatedby IL-6. Freshly isolated 
T cells were incubated with IL-6 (10 ng/ml) for 
1 hr, in presence and absence of SB203580 or 
CsA, or preincubated with IL-6 during 5 min and 
subsequently stimulated with α-CD3/α-CD28 during 
1 hr. In the upper panel the JunB signal is shown. 
In the lower panel the β2µG signal shows that 
comparable amounts of product were amplified for 
each condition. Results shown are representative 
of three independent experiments. C) Effect of IL-
6 on STAT3 serine and tyrosine phosphorylation. T 
cells were cultured over night in RPMI containing 
0.5% FCS and subsequently stimulated with IL-6, 
α-CD3/α-CD28 or their combination in presence and 
absence of SB203580 and CsA. Total celllysates were 
prepared. Serine phosphorylated STAT3 is depicted 
in the upper panel, tyrosine phosphorylated STAT3 is 
shown in the middle panel and total STAT3 is depicted 
in the lower panel (marked by arrows). Results shown 
are representative of two independent experiments.
1.5±0.1 and 1.6±0.3, respectively, p<0.05). This indicates that the PI3-K and MEK-
1 pathways are not crucial for the upregulatory effect of IL-6.
 Because the p38 pathway seems to be involved in the effects of IL-6, western 
blot analysis was performed using phospho-specific p38 antibodies. Antibodies for 
total p38 were used as a control for equal loading. Preincubation with IL-6 followed 
by α-CD3/α-CD28 stimulation resulted in an increase in p38 phosphorylation 
compared to the effect of α-CD3/α-CD28 alone (fold upregulation ± 1.75). This 
promotive effect of IL-6 could be inhibited by CsA (Fig. 5B). In contrast, no effect of 
IL-6 was observed on JNK and ERK-1/2 phosphorylation (data not shown).
CsA is an immunosuppressive agent that affects the Ca2+-mediated intracellular 
signaling pathways, including MAP kinases, SAP kinases and the calcineurin-
dependent activation of NFAT transcriptional activity. The nuclear component of 
the NFAT complex is composed of AP-1 (Fos/Jun) and non-AP-1 components, which 
may bind cooperatively [24]. We carried out EMSA's to reveal DNA-binding activitiy 
to the AP-1 oligonucleotide induced by IL-6. IL-6 enhanced DNA-binding of an α-
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CD3/α-CD28 induced AP-1 complex to its specific oligonucleotide (fold induction ± 
2.0, fig. 6A), which was inhibited by CsA and SB203580. Supershift experiments 
with monoclonal antibodies against JunB demonstrated that the IL-6 induced AP-
1 binding activity was strongly inhibited by treatment with excessive α-JunB, but 
not α-c-Jun, indicating that JunB is the major component of the IL-6 induced AP-1 
binding complex. In accordance with these data, RT-PCR showed that IL-6 induces 
expression of JunB mRNA in unstimulated T cells (fold induction ± 4, fig. 6B) and 
5 minutes of preincubation with IL-6 also increased JunB mRNA expression in α-
CD3/α-CD28 stimulated T cells (fold upregulation ± 1.5, fig. 6B). Furthermore, 
these studies revealed that blocking of the p38 pathway with SB203580 or CsA also 
strongly reduced IL-6 induced JunB expression (Fig. 6B). Together, these results 
indicate that the p38-dependent upregulation of JunB may be involved in the 
upregulatory effect of IL-6 on IL-5 production, since IL-6 enhances the α-CD3/α-
CD28 stimulated JunB mRNA expression, AP-1 binding activity and IL-5 production 
in a p38-dependent manner. 
 An additional transcription factor relevant for IL-6 mediated signaling is 
STAT3. The role of STAT3 in transcriptional activation of Th2 cytokine genes is still 
unclear, but STAT3 activation might be involved in the induction of JunB expression 
[25], thereby enhancing AP-1 binding activity. Western blotting showed that IL-
6 alone induces STAT3 tyrosine phosphorylation in T cells. For optimal serine 
phosphorylation of STAT3 the presence of α-CD3/α-CD28 is required (Fig. 6C). In 
contrast to p38 phosphorylation and AP-1 binding activity, STAT3 phosphorylation 
- both serine and tyrosine- was not susceptible to CsA and SB203580 inhibition. This 
indicates that the abrogation of the IL-6-induced effects by CsA and SB203580 is not 
caused by inhibition of the STAT3 pathway.
 
DISCUSSION
Effector Th2 cells play an important role in the development of atopic diseases. 
Although it is known that cytokines are crucial for the differentiation towards a Th1 
or Th2 phenotype, the mechanisms by which gene transcription and differentiation 
are regulated remain largely unclear. In our present report we demonstrate that 
IL-6 primes for enhanced production of IL-4 and IL-5 in T cells. In atopic asthma, 
peripheral T cells are primed to produce a two-fold higher level of Th2 cytokines 
compared to healthy controls, which is further enhanced after allergen challenge 
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[8]. Our data show that IL-6 may be involved in this enhanced capacity to produce 
Th2 cytokines and that exposure to IL-6 may promote a Th2-like immune response. 
Short preincubation with IL-6 upregulated the α-CD3/α-CD28 induced production 
of both IL-4 and IL-5 protein, whereas the production of IFN-γ was not affected. 
After 24 hours of preincubation with IL-6, the upregulatory effect on IL-5 secretion 
became most pronounced. At that time, a slight but significant inhibitory effect was 
found on IFN-γ secretion, implicating a negative feedback mechanism on the Th1-
type immune response by IL-6. 
 The immediate upregulatory effect of IL-6 found for both IL-4 and IL-
5 production  suggests a direct effect of IL-6. Our results indicate that the p38 
dependent upregulation of JunB is one of the early events in IL-6 signaling resulting 
in the elevation of IL-5 production. The upregulatory effect of IL-6 was blocked 
by specific p38 MAPkinase inhibitor SB203580 and in addition by CsA. The latter 
effect is at least partly mediated by the p38 pathway, since CsA inhibited the IL-6-
induced p38 phosphorylation. We further show that IL-6-induced signaling results in 
enhanced binding of the AP-1 complex to its binding site in the promoter region of 
Th2 cytokines, thereby possibly enhancing transcriptional activity of these cytokine 
genes. In agreement with our data, it has been reported that binding of AP-1 was 
stronger in IL-5 producing cells from asthmatic patients than in non-IL-5 producing 
cells from control subjects [26], implicating that AP-1 is involved in expression 
of IL-5. Furthermore, it has been shown that transcriptional activity of AP-1 is 
enhanced in Th2 cells compared to Th1 cells [27]. The AP-1 complex in Th2 cells 
was demonstrated to be composed of JunB dimers, which do not accumulate in Th1 
cells [27]. The inducible AP-1 moiety of the conserved lymphokine element 0 (CLE0) 
in the IL-5 promoter has been demonstrated to consist of JunB and c-Fos [28]. In 
addition, JunB was selectively induced in Th2 cells, but not in Th1 cells and able to 
activate IL-4 promoter activity [29]. Thus, expression of JunB might contribute to a 
Th2 profile. In accordance, our data demonstrate that JunB expression is upregulated 
by IL-6. It has also been reported that STAT3 may enhance AP-1 activity by induction 
of JunB [24]. In contrast to AP-1 binding, our results demonstrate that STAT3 
phosphorylation is not inhibited by SB203580 and CsA, in accordance with recent 
findings demonstrating that STAT3 serine phosphorylation is dependent on Vav, Rac 
and protein kinase Cδ (PKCδ) activation [30]. This implicates that the reduced AP-
1 binding activity as a result of incubation with SB203580 and CsA is caused by 
inhibition of other pathways than the STAT3 pathway. Since both CsA and SB203580 
block p38 activity, the p38 MAP kinase pathway might be involved in this effect and 
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be required for optimal binding activity of the AP-1 complex. Accordingly, it has been 
described that p38 MAPK activity is required for the induction of JunB expression in 
primary murine T cells and that JunB is phosphorylated by p38 MAPK [31]. 
 The priming effect of IL-6 on IL-4 (but not IL-5) secretion gradually 
disappeared after 12 hours of preincubation, suggesting that nuclear components 
responsible for increased IL-4 production are downregulated after long-term 
incubation with IL-6. Furthermore, these data indicate that signaling events crucial 
for IL-5 but not IL-4 expression are involved in the long-term preincubation effect of 
IL-6. Although IL-4 and IL-5 expression are regulated by similar nuclear components 
(AP-1, NFATc) [31,32], expression of these cytokines is regulated differentially. For 
example, c-Maf was demonstrated to be critical for IL-4 but not IL-5 expression [33], 
whereas GATA-3 seems to be more important for antigen-induced IL-5 production 
[20,34]. Thus, this transcription factor might be involved in the long-term priming 
effect on IL-5 production, which was found in our study. In contrast to the short-term 
effect of IL-6, the long-term effect on IL-5 production was shown to be dependent 
on the presence of IL-2. Indeed, IL-6 has been reported to be capable of increasing 
IL-2 production and IL-2 receptor expression [35,36]. However, an additional effect 
of IL-6 was found in presence of high levels of IL-2, suggesting that the effect of IL-6 
is mediated in conjunction with activation of the IL-2 dependent signaling pathway. 
Our study shows that upregulation of GATA-3 mRNA expression is one of events 
in IL-2 signaling which may lead to enhanced IL-5 secretion. This observation has 
clinical relevance, since enhanced GATA-3 mRNA expression has been observed in 
the airways of asthmatic subjects compared to healthy controls [37]. In addition, 
increased IL-2 mRNA expression was found in bronchial mucosa from asthmatic 
patients [5], indicating that IL-2 is produced at the site of allergen-induced reactions. 
It is remains unclear whether the effect of IL-6 is dependent on the levels of GATA-3 
expression. One might speculate that IL-6 is able to upregulate transcription factors 
that cooperatively bind GATA-3 and thereby enhance activity of the IL-5 promoter, 
which has been described for the AP-1 complex and Ets [38,39]. This needs further 
investigation, however.
 In addition to our findings concerning IL-6, IL-4 has been widely described 
to induce the differentiation towards a Th2 phenotype. However, the source of IL-4 
in vivo often remains elusive, while T cells have ample opportunity to encounter IL-
6 secreting cells. It has been demonstrated that alveolar macrophages from atopic 
asthmatics produce higher levels of IL-6 than alveolar macrophages from healthy 
controls [10,11]. IL-6 produced by macrophages or epithelial cells at sites of tissue 
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inflammation may prime local lymphocytes for enhanced production of Th2 cytokines. 
While 24 hours of preincubation with IL-4 did not enhance the levels of Th2 cytokines 
in α-CD3/α-CD28 stimulated T cells (data not shown), the priming effect of IL-6 on 
Th2 cytokines was observed after short preincubation periods. The rapid priming 
for enhanced production of Th2-like cytokine IL-4 by IL-6 may be sufficient to lead 
to stable Th2 differentiation under local circumstances. The results from our study 
seem to be in accordance with the in vivo findings in atopic asthmatic subjects after 
house dust mite induced obstructive reactions; 24 hours after allergen challenge the 
capacity of peripheral T cells to produce IL-5 is enhanced [40]. In the same setting, 
the capacity of T cells to produce IFN-γ was not significantly affected, but tended to 
be decreased 24 hours after allergen challenge. In addition, it has been demonstrated 
that monocytes from newborns with a high risk to develop allergy show increased 
capacity to produce IL-6, which is associated with a decreased capacity of cord 
blood mononuclear cells to produce IFN-γ [11]. This is compatible with our findings 
demonstrating that IL-6 inhibits secretion of Th1-like cytokine IFN-γ. This effect may 
be mediated by upregulation of SOCS1 and subsequent inhibition of STAT1 induced 
IFN-γ production. Together, these and our findings indicate that IL-6 may contribute 
to the development of allergic reactions such as atopic asthma, by inducing a shift in 
the immune response towards a Th2 type. 
 In summary, our data demonstrate that IL-6 promotes the production of 
Th2-like cytokines, but not Th1-like cytokines. Two different mechanisms appear to 
mediate the short-term and the long-term effect. The p38-dependent upregulation 
of JunB expression and AP-1 binding activity seem to be involved in the short-term 
effect, whereas the long-term effect is dependent on the endogenous production of 
IL-2.
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Chapter 3
SENSITIVITY OF IL-5 PRODUCTION TO THE cAMP-DEPENDENT PATHWAY IN 
HUMAN T CELLS IS REDUCED BY EXOGENOUS IL-2 IN A PHOSPHOINOSITIDE 
3-KINASE-DEPENDENT WAY
IH Heijink , HF Kauffman, DS Postma, JGR de Monchy, E Vellenga




The cAMP dependent pathway plays an important role in the regulation of T cell 
mediated immune responses by the inhibition of T cell proliferation, activation 
and production of Th1-like cytokines. Depending on costimulatory signals and 
the activation status of T cells, cAMP also regulates the production of Th2-like 
cytokines, yet the mechanism is not completely defined. We investigated the effect 
of costimulation with IL-2 on cAMP-mediated inhibition of IL-5 secretion and the 
signaling pathways involved in these effects in freshly isolated, α-CD3/α-CD28 
stimulated human T lymphocytes. We demonstrate that IL-2 counteracts the cAMP 
mediated inhibitory effects on IL-5 secretion by the modulation of phosphoinositide 
3-kinase (PI3-K) dependent signaling. Our results indicate that the phosphorylation 
of CREB and the activity of small GTPase Rap1 are unlikely involved in the protective 
effect of IL-2. Instead, the effect of IL-2 may be mediated by the PI3-K dependent 
inactivation of the forkhead-related transcription factor FKHR-L1, downregulation 
of p27kip and abrogation of the cAMP mediated inhibition of AP-1 binding activity. 
Together, our results indicate that increased IL-2 dependent PI3-K signaling leads 
to impaired negative feedback control of the cAMP dependent pathway over the 
production of Th2-type cytokine IL-5.
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INTRODUCTION
cAMP is known to play an important role in the negative feedback control 
of inflammatory responses. Activation of Gs protein-coupled receptors (e.g. 
prostaglandin E2 receptors and β2-adrenoceptors) induces adenylyl cyclase activity, 
resulting in intracellular cAMP formation [1]. In T lymphocytes, cAMP has been 
described to inhibit cell cycle progression, trigger apoptotic pathways [2,3] and 
negatively regulate transcriptional activity of cytokine genes. cAMP induces activation 
of protein kinase (PK)-A  and subsequent phosphorylation of cAMP-responsive 
element (CRE)-binding protein (CREB), resulting in inhibition of genes containing a 
CRE in their promoter, including  Th1-type cytokine IFN-γ [4,5]. No binding site for 
CREB has been found in the promoter of Th2-type cytokine IL-5. However, cAMP can 
also indirectly regulate cytokine gene expression by the inhibition of the Ras/Raf-1/
mitogen-activated protein kinase (MAPK) pathway [6], which might be accomplished 
by activation of the small GTPase Rap1 through the guanine exchange factor (GEF) 
Epac [7,8]. In addition, it has been described that cAMP induces T cell anergy by 
blocking proliferation upon antigenic stimulation [9]. Anergy is induced by the 
upregulation of p27kip, a cyclin-dependent kinase 2 (cdk2) inhibitor. Overexpression 
of p27kip resulted in reduced clonal expansion, activator protein (AP)-1 transactivation 
and IL-2 production [9]. Thus, the upregulation of p27kip expression might constitute 
an alternative mechanism to inhibit T cell proliferation and activation.
 It is of importance to study the regulatory mechanisms of IL-5 production, 
because IL-5 plays a central role in the development of eosinophilia in asthma 
[10] and an impaired cAMP control over IL-5 production has been implicated in 
the pathogenesis of this disorder [11]. cAMP can upregulate IL-5 production in Th2 
clones and cell lines [12], but from studies in freshly isolated T cells it is clear that 
the ultimate effect on Th2 cytokines  is dependent on (co)stimulatory signals [13]. 
In PMA/ionomycin activated T cells, promotive effects of cAMP on IL-5 production 
have been observed, whereas inhibitory effects were found upon stimulation with 
the more physiological stimulus α-CD3/α-CD28 [13]. In addition, the effect of cAMP 
on IL-5 production has been demonstrated to be dependent on the availability of IL-
2; upregulatory effects were observed when endogenous levels of IL-2 were high, 
whereas inhibitory effects were found when IL-2 levels were low [14]. Until now, the 
mechanisms that determine the ultimate effect of cAMP on IL-5 production remain 
unclear. Therefore, we studied the regulation of IL-5 production by cAMP in presence 
of IL-2. We demonstrate that exogenously added IL-2 reduces the sensitivity of IL-5 
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production to cAMP elevating agents and discuss the involvement of phosphoinositide 
3-kinase (PI3-K) and downstream events.
MATERIALS AND METHODS
T cell cultures, cytokines and reagentia
Peripheral blood cells were isolated from healthy volunteer platelet donors by Ficoll-
Hypaque (Lymphoprep, Nycomed, Oslo, Norway) density-gradient centrifugation and 
rosetting with 2-aminoethylisothioronium bromide (AET)-treated sheep red blood 
cells (SRBC) as previously described by Borger et al [13]. After isolation, T cells 
were incubated overnight at 37°C in RPMI 1640 (BioWhittaker, Verviers, Belgium) 
containing 0.5 or 5% FCS (Hyclone, Logan, UT, USA), supplemented with 100 U/ml 
penicillin and 100 µg/ml streptomycin. T cells were incubated with or without 50 
µl/ml of α-CD3 and α-CD28 antibodies as described by Borger et al [13], in absence 
and presence of fenoterol (10 µM, ICN, Aurora, OH, USA), PGE2 (10 µM, 100 nM or 
1 nM, Sigma, St. Louis, MO, USA) db-cAMP (500 µM, 100 µM or 50 µM, Boehringer-
Mannheim GmbH, Germany), α-IL-2 (2 µg/ml, Diaclone research, Besançon, 
France), rhIL-2 (50 U/ml) or LY294002 (10 mM, Alexis Corporation, Läufelfingen, 
Switzerland).
Measurement of cytokine protein 
T cells (3 x 106) were stimulated with α-CD3 and α-CD28 antibodies during 8 h, 
in absence and presence of fenoterol, PGE2, db-cAMP, α-IL-2, rhIL-2 or LY294002. 
Secreted IL-5 proteins were measured in cell-free supernatants. The IL-5 ELISA was 
performed as described by Hoekstra et al [34]. 
Immunodetection by western blotting
The expression of p27kip and phosphorylation of CREB, ERK, PKB and FKHR-L1 was 
analyzed by western blotting. For detection of p27kip, T cells (3 x 106) were stimulated 
with α-CD3/α-CD28 in presence and absence of IL-2, LY294002 or PGE2 for 4, 8 or 
24 h. For detection of activated CREB, T cells (3 x 106) were incubated with PGE2 for 
10, 30 or 60 min, in presence or absence of IL-2 or H-89. For detection of activated 
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PKB and ERK, T cells were stimulated for 60 min with α-CD3/α-CD28 in presence and 
absence of IL-2, PGE2 or LY294002. Total cell lysates were prepared and separated 
by SDS-PAGE using 10% gels and transferred to a nitrocellulose membrane. The 
immunodetection of phospho-CREB, phospho-ERK, phospho-PKB (New England 
Biolabs, Hitchin, Herts, UK), pan-ERK and p27kip (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) was performed according the manufacturer’s guidelines (ECL, 
Amersham, Buckinghamshire, UK).
Rap1 assay 
T cells (15 x 106) were stimulated with α-CD3/α-CD28 for 30 min in presence and 
absence of IL-2 or PGE2. Cells lysed in 50 µl lysis buffer (10% glycerol, 1% NP-40, 
50 mM Tris/HCL, pH7.5, 200 mM NaCl, 2mM MgCl2, 2 µg/ml aprotinin and protease 
inhibitors).  The lysates were incubated for 1 h with 10 µg of Ral-GDS GST-RBD 
precoupled to gluthatione speharose beads (Pharmacia, Uppsala, Sweden). 20 ml 
SDS-sample buffer was added to the beads and the Rap1 proteins bound to the Ral-
GDS were resolved on 15% SDS-PAGE gel and detected by immunoblotting.
Reverse Transcription (RT)-Polymerase Chain Reaction (PCR)
T cells (5 x 106) were stimulated during 4 h with α-CD3/α-CD28 in presence and 
absence of IL-2, PGE2 or LY294002. After stimulation, cells were harvested and RNA 
was isolated using the TRIzol method (GIBCOBRL, Burlington, Ontario, Canada). 
cDNA synthesis and the PCR reaction were performed as described before by 
Borger et al [13]. The following specific primer pairs for β−2-microglobuline (β2µG, 
housekeeping gene), p27kip, c-Jun, JunB and c-Fos were obtained from Biolegio BV 
(Malden, The Netherlands): β2µG: 5’CCA GCA GAG AAT GGA AAG TC3’ sense and 
5’GAT GCT GCTT ACA TGT CTC G3’ antisense. p27kip: 5’GCA ACC GAC GAT TCT TCT 
AC3’ sense and 5’GTC CAT TCC ATG AAG TCA GC3’ antisense. c-Jun: 5’GGA AAC 
GAC CTT CTA TGA CGA TGC CCT CAA3’ sense and 5’GAA CCC CTC CTG CTC ATC TGT 
CAC GTT CTT3’ antisense JunB: 5’CCA GTC CTT CCA CCT ACC TCG ACG TTT ACA 
A3’ sense and 5’GAC TAA GTG CGT GTT TCT TTT CCA CAG TAC3’ antisense. c-Fos: 
5’GAA TAA GAT GGC TGC AGC CAA ATG CCG CAA3’ sense and 5’CAG TCA GAT CAA 
GGG AAG CCA CAG ACA TCT3’ antisense. With these primers the amplified products 
were 268, 275, 325, 257 and 236 bp long for β2µG, p27kip, c-Jun, JunB and c-Fos, 
respectively. PCR conditions were a denaturation step at 94°C for 5 min followed by 
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20 cycles of 94°C, 30 s; 55°C, 30 s; 72°C, 30 s for detection of β2µG, 25 cycles for 
detection of p27kip and c-Fos, 30 cycles for detection of c-Jun and 30 cycles of 94°C, 
30 s; 57 °C, 30 s; 72°C, 30 s for detection of JunB. After PCR, 10 ml of the reaction 
mixture was run on a 1.5% agarose gel, containing 0.2 mg ethidium bromide in 1x 
TAE buffer. A 100 bp ladder (Pharmacia) was used as DNA marker.
Electrophoretic mobility shift assay  
T cells (5 x 106) cells were stimulated during 2-4 h in presence and absence of IL-
2, PGE2 and LY294002. Nuclear extracts were produced according to the mini-scale 
procedure described before by Borger et al [13]. A double- stranded oligonucleotide 
probe (5’-AAA TTC CAA AGA GTC ATCA GA3’) containing the AP-1 binding sequence 
was labeled with P32 α-ATP (3000 Ci/mmol, Amersham) and used in the gel 
retardation assay. 5 µg of nuclear extract and 0.1 ng double-stranded labeled oligo 
were incubated in 20 mM HEPES (pH 7.9), 60 mM KCl, 0.06 mM EDTA, 0.6 mM 
DTT, 2 mM spermidine and 10% glycerol, supplemented with 2 µg poly dI-dC) at 26 
°C for 30 minutes. The samples were loaded on pre-run (30 minutes, 100 V) 4% 
polyacrylamide gels and run for 1.5 h at 150 V in 1.0 x TBE at room temperature. 
Gels were dried and quantification of the binding signals was performed using a 
PhosphorImaging system and the Image Quant software (molecular dynamics).
Statistical analysis
For the protein measurements, statistical analysis was performed using the 
Wilcoxon’s Signed Rank test for paired observations. Statistical significance of the 
secretion data was set at p<0.05.
RESULTS
IL-2 reduces sensitivity of IL-5 secretion to cAMP elevating agents 
The addition of IL-2 prior to α-CD3/α-CD28 stimulation had no significant effect on 
IL-5 production (Fig. 1A). However, the inhibitory effect of β2-agonist fenoterol was 
completely abolished in presence of IL-2. On the other hand, a stronger inhibitory 
effect of fenoterol was found when IL-2 was neutralized by adding anti-IL-2 
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antibodies (Fig. 1B). Similar to the effect of fenoterol, the inhibitory effects of low 
concentrations of PGE2 and cAMP analogue db-cAMP were abolished in the presence of 
IL-2. Although high concentrations of PGE2 and db-cAMP still inhibited IL-5 secretion 
in the presence of IL-2, the inhibitory effect of PGE2 was significantly reduced (Fig. 
1C). These results indicate that IL-2 does not, or not exclusively, reduce receptor-
mediated cAMP production, but rather reduces the downstream effects of cAMP. IL-2 
is known to activate the PI3-kinase pathway [15], which can induce cAMP-specific 
phosphodiesterase (PDE)-4 activity and thus reduce intracellular cAMP levels [16]. 
To test the involvement of PDE4-mediated cAMP degradation in the effect of IL-2, we 
Figure 1. A) IL-5 secretion is not significantly altered by 5 min of preincubation with IL-2. T lymphocytes 
were stimulated with α-CD3/α-CD28 for 8 h, in presence and absence of IL-2. IL-5 protein levels are 
expressed as percentage (x ± SEM, n=8) of the secretion after stimulation with α-CD3/α-CD28 in absence 
of IL-2. B) The β2-adrenergic control over IL-5 secretion is dependent on the levels of IL-2. T cells were 
stimulated with α-CD3/α-CD28 for 8 h, in presence and absence of IL-2,  neutralizing antibodies to IL-
2 or β2-agonist fenoterol. Protein levels are expressed as percentage (x ± SEM, n=4) of the secretion 
after stimulation with α-CD3/α-CD28 in absence of fenoterol. §=p<0.05 for the IL-5 secretion level after 
preincubation with fenoterol compared to the level without fenoterol. *=p<0.05 for the IL-5 secretion 
level  after preincubation with IL-2 compared to the level without IL-2. C) The inhibitory effects of PGE2 
and db-cAMP on IL-5 secretion are reduced in presence of exogenously added IL-2. T cells were stimulated 
with α-CD3/α-CD28 for 8 h, in presence and absence of IL-2 , PGE2 (10 µM, 100 nM, 1 nM) and db-cAMP 
(500 µM, 100 µM, 50 µM). Protein levels are expressed as percentage (x ± SEM, n=6) of the secretion 
after stimulation with α-CD3/α-CD28 in absence of cAMP elevating agents. §=p<0.05 and §§=p<0.01 for 
the IL-5 secretion level after preincubation with cAMP elevating agents compared to the level without and 
*=p<0.05 for the IL-5 secretion level after preincubation with IL-2 compared to the level without IL-2. 
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used the PDE4 inhibitor rolipram to prevent cAMP degradation. Addition of rolipram 
(10 µM) induced an increase in intracellular cAMP levels and strongly inhibited the 
IL-5 secretion (data not shown).
 Similar to the effect of PGE2, this inhibitory effect was significantly reduced 
when IL-2 was added (from 91±6% to 67±10% inhibition, p<0.05), indicating that 
the effect of IL-2 cannot simply be explained by inducing an increase in PDE4-
mediated cAMP degradation. Together, our findings indicate a cross-talk between 
IL-2 and cAMP-dependent signaling pathways and downstream effectors.
The protective effect of IL-2 is not likely mediated by affecting CREB or ERK 
phosphorylation 
To analyze in more detail the downstream targets of IL-2, the effect on CREB 
phosphorylation was studied. As depicted in fig. 2A, PGE2 strongly induced CREB 
phosphorylation, which was blocked by PKA inhibitor H-89. Incubation with IL-
2 alone did not affect CREB phosphorylation. Furthermore, no effect of IL-2 was 
observed on the degree and kinetics of PGE2-induced CREB phosphorylation (Fig. 
2B). Similar results were obtained with fenoterol and db-cAMP (data not shown). 
These findings suggest that the effects of IL-2 are not mediated by the inhibition of 
PKA-dependent CREB activation. This is further supported by the finding that the 
Figure 2. A) CREB phosphorylation 
induced by PGE2 is inhibited when PKA is 
blocked by H-89. T cells were stimulated 
with PGE2 (100 nM) for 60 min, in presence 
and absence of H-89. Phospho-CREB is 
depicted in the upper panel and total 
protein levels (ERK1/2) are shown in the 
lower panel (marked by arrows). B) CREB 
phosphorylation induced by PGE2 is not 
reduced in presence of IL-2. T cells were 
stimulated with PGE2 (100
 nM) for 10, 30 
and 60 min, in presence and absence of IL-
2. Phospho-CREB is depicted in the upper 
panel and total protein levels (ERK1/2) 
are shown in the lower panel (marked by 
arrows). Results shown are representative 
of two independent experiments.
inhibitory effect of PGE2 on IL-5 secretion could not be blocked by PKA inhibitor H-89 
(10 µM, data not shown). 
 Because cAMP has been described to inhibit the Ras/Raf/ERK pathway in a 
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PKA independent manner [17], we studied the effects of PGE2 on ERK phosphorylation 
in presence and absence of IL-2. The α-CD3/α-CD28-induced phosphorylation of ERK 
was clearly inhibited by PGE2 (Fig. 3A). However, the presence of IL-2 could not 
prevent this inhibitory effect, indicating that activation of ERK is not likely involved 
in the protective effect IL-2. Additionally, we examined the activation of another 
effector of cAMP, i.e. the small GTPase Rap1, which is thought to exert at least some 
of its inhibitory effects by inhibition of the Ras/Raf-1/MAPK pathway [8]. However, 
PGE2 did not activate Rap1, but instead inhibited α-CD3/α-CD28-induced Rap1 
GTPase activity in our setting (Fig. 3B). Furthermore, the addition of IL-2 did not 
alter this effect of PGE2 on Rap1 activity, indicating that Rap1 is not directly involved 
in the effect of IL-2 on the cAMP dependent pathway. 
Figure 3. A) The inhibitory effect of PGE2 on 
ERK phosphorylation remains in presence of 
IL-2. T cells were stimulated with α-CD3/α-
CD28 for 60 min, in presence and absence 
of PGE2 (100 nM) or IL-2. Phospho-ERK 
is depicted in the upper panel and total 
protein levels (ERK1/2) are shown in the 
lower panel (marked by arrows). B) Rap1 
activity is inhibited by the presence of 
PGE2 in α-CD3/α-CD28 stimulated T cells 
and not altered by the presence of IL-2. T 
cells were stimulated for 30 min in presence 
and absence of PGE2 (100 nM) and IL-2. A 
pulldown for activated Rap1 was performed 
and GTP-bound Rap1 is depicted (marked by 
an arrow). Results shown are representative 
of three independent experiments.
PI3-kinase activity is involved in the protective effect of IL-2 
To examine the involvement of PI3-K in the effects of IL-2, phosphorylation of 
the downstream kinase PKB was analyzed. After incubation with IL-2 alone, 
phosphorylation of PKB was hardly detectable (data not shown). In fig. 4A, 
we demonstrate that incubation with α-CD3/α-CD28 induced phosphorylation 
of PKB, which was slightly enhanced by IL-2  (Fig. 4A) and inhibited by PI3-K 
inhibitor LY294002. In addition, PGE2 inhibited the α-CD3/α-CD28-induced PKB 
phosphorylation (Fig. 4A). Interestingly, the inhibitory effect of PGE2 on PKB 
activation was completely abrogated in the presence of IL-2. 
 To further investigate the role of PI3-K activity in the protective effect of IL-
2, we used LY294002 in the IL-5 secretion assay. As shown in fig. 4B, the inhibitory 
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effects of fenoterol and db-cAMP were abolished in the presence of IL-2. The 
addition of LY294002 inhibited IL-5 secretion. Furthermore, IL-2 did no longer exert 
its protective effect; fenoterol and db-cAMP induced a strong additional decrease in 
IL-5 secretion, which was not modulated by IL-2 costimulation (Fig. 4B). Similarly, 
a strong additional inhibitory effect of PGE2 was observed in presence of LY294002 
(data not shown). These results indicate that the protective effect of IL-2 on IL-5 
secretion is dependent on PI3-K activity, which opposes the effects of cAMP. 
IL-2 regulates the expression of cAMP effector p27kip in a PI3-K dependent manner
Next, we studied the possible downstream targets of PI3-K/PKB that might be 
involved in the transcriptional regulation of IL-5. Whereas IL-2 has been described 
to reduce the expression of p27kip in T cells, cAMP may promote p27kip expression 
[9]. The activation of p27kip transcription can be regulated by Forkhead-related 
transcription factor FKHR-L1. FKHR-L1 is inactivated upon phosphorylation [18], 
which can be induced by IL-2 in a PI3-K/PKB-dependent manner [19]. In our 
setting, the phosphorylation of FKHR-L1 was induced by α-CD3/α-CD28 stimulation, 
Figure 4. A) The inhibitory effect of PGE2 on PKB phosphorylation is abolished in presence of IL-2. T cells 
were stimulated with α-CD3/α-CD28 for 60 min, in presence and absence of PGE2 (100 nM) and IL-2. 
phospho-PKB is depicted in the upper panel and total protein levels (ERK1/2) are shown in the lower panel 
(marked by arrows). Protein levels were analyzed using densitometry and normalised for total protein 
evels (ERK1/2). Data are expressed as percentage (x ± SEM, n=3) of the levels after stimulation with 
α-CD3/α-CD28 alone. B) A strong inhibitory effect of cAMP elevating substances is found in presence of 
IL-2 when the PI3-K pathway is blocked. T cells were stimulated with α-CD3/α-CD28 for 8 h in presence 
and absence of IL-2, LY2904002, fenoterol and db-cAMP (100 µM). IL-5  protein levels are expressed 
as percentage (x ± SEM, n=6) of the secretion after stimulation with α-CD3/α-CD28/IL-2 in absence of 
cAMP elevating agents. *=p<0.05 for the IL-5 secretion level after preincubation with cAMP elevating 
agents compared to the level without these agents and **=p<0.01 between the indicated values.
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while PGE2 inhibited this effect. Similar to the effect on PKB, IL-2 abolished the 
inhibitory effect of PGE2 on FKHR-L1 phosphorylation (Fig. 5A). In addition, FKHR-L1 
phosphorylation was inhibited by LY294002. 
Figure 5. A) The inhibitory effect of PGE2 on FKHR-L1 phosphorylation is abolished in presence of IL-2. T 
cells were stimulated with α-CD3/α-CD28 for 20 min, in presence and absence of PGE2 (100 nM) or IL-2. 
Ser-phospho-FKHR-L1 is depicted in the upper panel and total protein levels (ERK1/2) are shown in the 
lower panel (marked by arrows). B) IL-2 and PGE2 exert opposite effects on p27
kip mRNA expression. T 
cells were stimulated for 4 h with α-CD3/α-CD28 in presence and absence of IL-2, PGE2 (100 nM) and 
LY294002. In the upper panel the p27kip mRNA signal is shown. In the lower panel the β2µG signal shows 
that comparable amounts of product were amplified for each condition. C) PGE2 and IL-2 exert opposite 
effects on p27kip protein levels. T cells were stimulated with α-CD3/α-CD28 for 24 h, in presence and 
absence of PGE2 (100
 nM or 1 nM), IL-2 or LY294002. p27kip is depicted in the upper panel and total 
protein levels (ERK1/2) are shown in the lower panel (marked by arrows). D) IL-2 induces translocation 
of p27kip to the cytoplasm. T cells were incubated with or without α-CD3/α-CD28 for 120 min, in presence 
and absence of PGE2 (100 nM) or IL-2. Expression of p27
kip in nuclear and cytoplasmic fractions is 
depicted in the upper panel and total protein levels (ERK1/2) are shown in the lower panel (marked 
by arrows). Results shown are representative of three independent experiments. Protein levels were 
analyzed using densitometry and normalised for total protein levels (ERK1/2). Data are expressed as 
percentage (x ± SEM, n=3) of the levels in unstimulated T cells or after stimulation with α-CD3/α-CD28.
 The transcriptional regulation of p27kip was studied using RT-PCR. In 
unstimulated T cells, p27kip mRNA was clearly expressed. α-CD3/α-CD28 stimulation 
downregulated p27kip mRNA levels, which was promoted by IL-2 costimulation and 
blocked by LY294002 (Fig. 5B). In contrast, PGE2 enhanced p27
kip mRNA expression 
in α-CD3/α-CD28 stimulated T cells, which was again downregulated by IL-2. 
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In addition to transcriptional regulation, p27kip expression is regulated at post-
translational level [20] and therefore we studied protein levels of p27kip. As 
demonstrated in figure 5C, p27kip levels were high in unstimulated T cells and were 
reduced upon α-CD3/α-CD28 stimulation. This was seen after 4 and 8 h (data not 
shown), but most pronounced after 24 h of stimulation (Fig. 5C). In accordance to the 
mRNA levels, p27kip protein levels were further downregulated by IL-2 costimulation, 
in a PI3-K dependent manner. PGE2 strongly increased p27
kip levels (Fig. 5C). 
Costimulation with IL-2 blocked this, although this was only clearly observed at 
the lowest concentration of PGE2 (Fig. 5C). However, at higher PGE2 concentrations 
IL-2 may affect p27kip function through the regulation of its subcellular localization. 
Figure 6.  A) The inhibitory effect of PGE2 on DNA binding activity of AP-1 is prevented by IL-2. T 
cells were stimulated with α-CD3/α-CD28 for 3 h, in presence and absence of PGE2 (100 nM), IL-2 
or LY294002. B) The inhibitory effect of PGE2 on c-Jun and JunB transcription is lost in presence of 
IL-2. Freshly isolated T cells were stimulated for 4 h with α-CD3/α-CD28 in presence and absence 
of IL-2, PGE2 (100 nM) and LY294002. The c-Jun, JunB and c-Fos mRNA signals are marked by 
arrows. In the lowest panel the β2µG signal shows that comparable amounts of product were 
amplified for each condition. Results shown are representative of two independent experiments. 
Nuclear expression is critical for the inhibitory effect of p27kip [21]. In our setting, 
p27kip was detected in both nucleus and cytoplasm. In the presence of PGE2, p27
kip 
was preferentially localized in the nucleus. Incubation with IL-2 promoted cytoplasmic 
translocation of p27kip, most effectively in unstimulated T cells or T cells stimulated 
in the presence of PGE2 (Fig. 5D). This cytoplasmic translocation was reduced when 
LY294002 was added as well (data not shown). Together, these data indicate that 
p27kip might be a downstream target of PI3-K/PKB in the cross-talk between IL-2 
and cAMP.
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IL-2 prevents the inhibitory effect of PGE2 on AP-1 binding activity
One of the ways in which p27kip might affect T cell cytokine production is the 
competitive interaction with the AP-1 co-activator Jab1, thereby reducing AP-1 
binding and transcriptional activity [9]. Therefore, we examined the effects of PGE2 
and IL-2 on AP-1 DNA-binding using EMSA. In fig. 6A it is demonstrated that the 
α-CD3/α-CD28-induced binding activity of AP-1 is inhibited by PGE2. IL-2 prevented 
this effect of PGE2, although IL-2 itself did not have a clear effect on AP-1 binding. 
In addition to PGE2, AP-1 binding was inhibited by LY294002. Similar results were 
observed on the transcriptional regulation of the AP-1 components c-Jun and JunB, 
but not c-Fos (Fig. 6B). mRNA expression of these components was induced by α-
CD3/α-CD28 stimulation and inhibited by PGE2 and LY294002. IL-2 abolished the 
inhibitory effect of PGE2 on c-Jun and JunB mRNA expression, but not c-Fos, while 
IL-2 did not upregulate the expression c-Jun and JunB itself. Thus, in accordance 
with the IL-5 secretion data, IL-2 induces a PI3-K-dependent loss of cAMP control 
over AP-1 activation.
DISCUSSION
The cAMP dependent pathway has been widely described to control T cell-mediated 
responses by negative regulation of T cell activity. Until now, it is largely unknown 
how cAMP regulates the production of Th2 cytokines (e.g. IL-5), which do not contain 
a CRE in their promoter region, and how costimulatory signals modulate the effects 
of cAMP on Th2 cytokines. In this study we demonstrate that the sensitivity to cAMP 
is dependent on IL-2 signaling and that the PI3-K pathway plays an important role 
in the IL-2 effects. In accordance with the effects observed by Borger et al [13], we 
show that exogenously added IL-2 abolishes the cAMP-mediated downregulation of 
IL-5 production. In addition, an inverse effect is found in the presence of neutralizing 
anti-IL-2, indicating that endogenously produced IL-2 determines the ultimate effect 
of cAMP elevating agents. The production of IL-5 is known to be dependent on the IL-
2 levels [22] and IL-2 production is inhibited by cAMP [14]. Yet, our results indicate 
that the inhibition of IL-5 by cAMP is not a consequence of reduced IL-2 levels, 
but due to a direct effect involving a cross-talk between IL-2 and cAMP dependent 
signaling. This appears to be independent of PKA-mediated CREB phosphorylation; 
IL-2 did not alter the PGE2-induced CREB phosphorylation and the inhibitory effect of 
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cAMP on IL-5 production could not be blocked by PKA inhibitor H-89. 
 In addition to CREB phosphorylation, cAMP is known to induce GEF activity, 
thereby enhancing the binding of small GTPase Rap1 to GTP [7]. This GTPase can 
induce inhibition of the Raf/MAPK pathway [6,8]. However, in accordance with 
the findings of Staples et al and Grader-Beck et al [17, 23], we found that Rap1 
is inhibited instead of activated by cAMP. Hereby no effect of IL-2 was observed, 
indicating that the protective effect of IL-2 is not  mediated by Rap1. 
 The precise role of Rap1 in the effects of cAMP is not well defined and 
requires further study. In C6 cells it has been demonstrated that cAMP inhibits both 
ERK and PI3-K pathways, which is mediated by the inhibition instead of activation 
of Rap1 [24]. Accordingly, our results demonstrate that PGE2 inhibits ERK and PKB 
Figure. 7. Putative signaling pathways involved in the effects of IL-2 and cAMP on the regulation 
of IL-5 gene transcription in T lymphocytes. The TcR/CD3 complex and CD28 induce protein 
tyrosine kinase (PTK) mediated activation of the MAPK/SAPK pathways, leading to the induction 
of AP-1 components (Jun/Fos). cAMP inhibition is thought to take place at different levels and 
may include the regulation of p27kip . IL-2 signaling may counteract cAMP signaling by preventing 
the inhibition of PI3-kinase, leading to inactivation of  FKHR-L1 and negative regulation of p27kip.
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phosphorylation in α-CD3/α-CD28 stimulated T cells, although the role of Rap1 in 
these effects is unclear. The inhibitory effect of PGE2 on ERK phosphorylation could 
not be prevented by addition of IL-2, indicating that the protective effect of IL-2 is 
ERK independent. In contrast, the inhibitory effect of PGE2 on PI3-K downstream 
kinase PKB was abolished in presence of IL-2, indicating that the PI3-K pathway 
is involved in the protective effect of IL-2. The results from the IL-5 secretion 
assay emphasize the importance of these findings. Blocking of the PI3-K pathway 
abolished the protective effect of IL-2 and resulted in more pronounced cAMP-
mediated inhibition of IL-5 secretion. This suggests that the ultimate effect of cAMP 
on IL-5 secretion is dependent on the level of PI3-K activation and that PI3-K activity 
counteracts the effects of cAMP.
 Further results indicate that IL-2 dependent PI3-K activation leads to 
inactivation of FKHR-L1 and negative regulation of p27kip. p27kip expression is 
regulated at transcriptional and post-translational level [20]. Phosphorylation 
of p27kip induces cytoplasmic translocation and ubiquitin/proteasome-dependent 
degradation [25-27]. cAMP can induce dephosphorylation of p27kip [28], thereby 
promoting the nuclear localization required for its inhibitory effect [21]. In contrast, 
the PI3-kinase pathway has been implicated in p27kip protein degradation [29] as well 
as mRNA downregulation. The latter may be mediated by the phosphorylation and 
inactivation of FKHR-L1 [19]. In our present report we demonstrate that PGE2 inhibits 
the phosphorylation of FKHR-L1, which is prevented by IL-2 in a PI3-K-dependent 
manner. Additionally, IL-2 and cAMP exert opposite effects on p27kip expression. PGE2 
increased, while IL-2 downregulated p27kip mRNA and protein levels, in a PI3-K-
dependent manner. Thus, through persisted PKB and FKHR-L1 phosphorylation, IL-2 
may interfere with cAMP’s effects on p27kip expression. PGE2 induced an additional 
increase in p27kip expression in presence of LY294002, indicating that cAMP also in 
part regulates p27kip expression in a PI3-K independent way. Although IL-2 could not 
completely prevent the upregulation of p27kip levels, IL-2 promoted the cytoplasmic 
translocation of p27kip in the presence of PGE2, which might protect T cells from 
p27kip-mediated inhibitory effects of cAMP. These inhibitory effects may include 
effects on cytokines but also anti-proliferative effects, since p27kip has been widely 
described to regulate cell cycle progression.
 The above-described PI3-K-mediated effects of IL-2 might affect IL-5 
promoter activity through the transcription factor AP-1. AP-1 is known to play a 
crucial role in the transcription of many cytokine genes and it has been demonstrated 
that AP-1 activity in IL-5 producing cells from asthmatic subjects is significantly 
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enhanced compared to non-IL-5 producing cells [30]. Previous studies have 
described that p27kip is capable to downregulate AP-1 activity by binding to Jab1, a 
co-activator of the Jun components of the AP-1 complex [9,27]. In our study, both 
PGE2 and LY294002 incubation reduced AP-1 binding activity. In accordance with the 
effect on IL-5 secretion, the inhibitory effect of PGE2 on AP-1 binding activity was 
prevented by IL-2 costimulation. In addition to AP-1, PGE2 also reduced the binding 
activity of transcription factor NF-κB, yet this inhibitory effect was not abolished by 
IL-2 (data not shown). An additional transcription factor involved in T cell activation 
and regulated by cAMP is NF-AT [23, 31]. However, it is unlikely that the regulation 
of NF-AT is involved in our findings, since cAMP has been described to inhibit NF-AT 
in a PKA-dependent manner [32], while we found that the effects of cAMP and IL-2 
on IL-5 production are PKA-independent. An overview of the possible effects of cAMP 
and IL-2 on signaling pathways leading to IL-5 transcriptional activation is given in 
figure 7. 
 Our findings may have important implications, given the prominent role 
of the cAMP dependent pathway in the regulation of T cell-mediated immune 
responses. Our results suggest that enhanced IL-2 signaling may lead to a loss of 
control over IL-5 production at the sites of inflammatory responses, where T cells 
become activated in the presence of cells that secrete cAMP elevating substances. In 
asthma, increased IL-2 signaling [32,33] may thus lead to enhanced IL-5 expression 
at the site of the allergen-induced reaction. In summary, our data demonstrate that 
high levels of IL-2 abolish the inhibitory effect of cAMP elevating agents on IL-5 
secretion, which appears to be a direct effect of IL-2. While two well-known effectors 
of cAMP, CREB and Rap1, were not affected by IL-2, the effects of IL-2 on cAMP 
signaling appear to be dependent on the activation of the PI3-kinase pathway.
Acknowledgements: We thank the department of Tumor Immunology for providing 
the α-CD3/α-CD28 antibodies and Bas Bossenga for his contribution to the 
experimental work. We also thank P. Borger (Department of Pharmacology and the 
Institute of Respiratory Medicine, Royal Prince Alfred Hospital, University of Sydney, 
Australia) for the helpful discussions.
IL-2 PROTECTS IL-5 PRODUCTION FROM cAMP-MEDIATED INHIBITION
69
REFERENCES
1) Nigg EA, Hilz H, Eppenberger HM, Dutly F. Rapid and reversible translocation of the catalytic subunit of cAMP-
dependent protein kinase type II from the Golgi complex to the nucleus. EMBO J. 1985; 4:2801-06.
2) Gu C, Ma YC, Benjamin J, Littman D, Chao MV, Huang XY. Apoptotic signaling through the β-adrenergic receptor. A 
new Gs effector  pathway.  J Biol  Chem. 2000; 275:20726-33.
3) Johnson KW, Davis BH, Smith KA. cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete 
point in early G1. Proc Natl Acad Sci U S A. 1988; 85:6072-76.
4) Gonzalez GA,Montminy MR. cAMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 
133. Cell. 1889; 59:675-80.
5) Masquilier D, Sassone-Corsi P. Transcriptional cross-talk: nucelar factors CREM and CREB bind to AP-1 sites and 
inhibit activation by Jun. J Biol Chem. 1992; 267:22460-66.
6) Tamir A, Granot Y, Isakov N. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of 
two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal 
kinase. J Immunol. 1996; 157:514-22.
7) de Rooij J FJ, Zwartkruis MH, Verheijen RH, Cool SM, Nijman A, Wittinghofer, Bos JL. Epac is a Rap1 guanine-
nucleotide-exchange factor directly activated by cAMP. Nature. 1998; 396:474-77.
8) Schmitt M, Stork PJ. Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1. Mol Cell Biol. 
2001; 21:3671-83.
9) Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass A, Lazar BR, Nadler LM. p27kip functions as an 
anergy factor inhibiting   interleukin 2 transcription and clonal expanion of alloreactive human and mouse  helper T 
lymphocytes. Nature Medicine.  2000; 6:290-97.
10) Humbert M, Corrigan CJ, Kimmit P, Till SJ, Kay AB, Durham SR. Relationship between IL-4 and IL-5 mRNA expression 
and disease severity in atopic asthma. Am J Resp Crit Care Med. 1997; 156:704-08. 
11) Borger P, Jonker GJ, Vellenga E, Postma DS, De Monchy JG,  Kauffman HF. Allergen challenge primes for IL-5 mRNA 
production and abrogates beta-adrenergic function in peripheral blood T lymphocytes from  asthmatics. Clin Exp 
Allergy. 1999; 29:933-40.
12) Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 
1991; 146:108-13.
13) Borger P, Vellenga E, Gringhuis SI, Timmerman AB, Lummen C,  Postma DS, Kauffman HF.  Prostaglandin E2 differently 
modulate interleukin-5 gene expression in activated human T lymphocytes depending on the costimulatory signal. 
J Allergy Clin Immunol. 1998; 101:231- 40.
14) Hilkens CM, Vermeulen UMH, Van Neerven RJJ, Snijdewint FGM, Wierenga EA, Kapsenberg ML. Differental 
modulation of T helper type  (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically 
depends on Interleukin-2. Eur J Immunol. 1995; 25:59-63.
15) Truitt KE, Mills GB, Turck, CW, Imboden JB. SH2-dependent association of phosphatidylinositol 3’-kinase 85-kDa 
regulatory subunit with the interleukin-2 receptor beta-chain. J Biol Chem. 1994; 269:5937-43. 
16) MacKenzie SJ, Yarwood SJ, Peden AH, Bolger GB, Vernon RG, Houslay MD. Stimulation of p70S6 kinase   
via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic 
AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. Proc Natl Acad Sci USA. 1998; 95:3549-54.
17) Staples KJ, Bergmann M, Tomita K, Houslay MD, McPhee I, Barnes PJ, Giembycz MA, Newton R. Adenosine 3’,5’-
cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated  by the 
cAMP-dependent protein kinase A. J Immunol. 2001; 167:2074-80.
18) Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers, JW, 
Koenderman L, Coffer PJ. Forkhead transcription factor FKHR-L1 modulates cytokine dependent transcriptional 
regulation of p27KIP1. Mol Cell Biol. 2000; 20:9138-48.
CHAPTER 3
70
19) Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, Medema RH. The forkhead transcription factor FoxO 
regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol. 2002; 168:5024-31.
20) Pagano M, Tam SW, Theodoras AM, Beer RP, Del SG, Chau V, Ywe PR, Draetta GF, Rolfe M. Role of the ubiquitin-
proteasomepathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.  Science. 1995; 269:682-
85. 
21) Reynisdottir I, Massague J. The subcellular locations of p15lnk4b and p27Kip1 coordinate their inhibitory interactions 
with cdk4 and cdk2. Genes Dev.  1997; 11:492-503. 
22) Mori A., Suko M, Kaminuma O, Nishizaki Y, Mikami T, Ohmura T,  Hoshino A, Inoue S, Tsuruoka N, Okumura Y, Sato 
G, Ito K,  Okudaira H. A critical role of IL-2 for the production and gene transcription of IL-5 in  allergen-specific 
human T cell clones. Int Immunol. 1996; 8:1889-95. 
23) Grader-Beck T, van Puijenbroek AAFL, Nadler LM, Boussiotis VA. cAMP inhibits both Ras and Rap1 activation in 
primary human T  lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression Blood. 
2003; 101:998-1006.
24) Wang L, Liu F, Adamo ML. Cyclic AMP inhibits extracellular signal-regulated kinase and phosphatidylinositol 3-kinase/
Akt pathways by inhibiting Rap1. J Biol Chem. 2001; 276:37242-49.
25) Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 
complex through phosphorylated Thr187 in p27. Curr Biol. 1999; 9:661-64.
26) Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of  the cyclin-dependent kinase inhibitor p27. 
EMBO J. 1997; 16:5334-44.
27) Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent kinase inhibitor p27kip1 is instigated by Jab1. 
Nature. 1999; 398:160-65.
28) Kim TY, Kim WI, Smith RE, Kay ED. Role of p27Kip1 in the cAMP- and TGF- beta2-mediated antiproliferation in rabbit 
corneal endothelial cells.  Invest Ophthalmol Vis Sci. 2001; 42:3142-49.
29) Mamillapalli R., Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H, Sun H. PTEN regulates the ubiquitin-
dependent degradation of CDK inhibitor p27KIP1 through ubiquitin E3 ligase SCFSKP2. Curr Biol. 2001; 11:263-67.
30) Mori A, Kaminuma O, Ogawa K, Okudaira H, Akiyama K. Transcriptional regulation of IL-5 gene by nontransformed 
human T cells through the proximal promoter element. Intern Med. 2000; 39:618-25. 
31) Chow CW, Davis RJ. Integration of calcium and cyclic AMP signaling pathways by 14-3-3. Mol Cell Biol. 2000; 
20:702-12.
32) Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Phenotype of cells expressing mRNA for Th2-type (interleukin-
4 and interleukin-5) and Th1-type (interleukin-2 and interferon-gamma) cytokines in bronchoalveolar lavage and 
bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol. 1995; 12:477-87.
33) Virchow JC Jr, Walker C, Hafner D, Kortsik C, Werner P, Matthys H, Kroegel C. T cells and cytokines in bronchoalveolar 
lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med. 1995; 151:960-68.
34) Hoekstra MO, Hoekstra Y, de Reus D, Rutgers B, Gerritsen J, Kauffman HF. Interleukin-4 (IL-4) and Interferon-g and 
interleukin-5 (IL-5) in peripheral blood of children with moderate atopic asthma. Clin Exp Allergy. 1997;27:1254-
60.
Chapter 4
POLARIZED TH1 AND TH2 CELLS ARE LESS RESPONSIVE TO NEGATIVE 
FEEDBACK BY RECEPTORS COUPLED TO THE AC/cAMP SYSTEM COMPARED TO 
FRESHLY ISOLATED  T CELLS
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The adenylyl cyclase (AC)/cAMP system is known to negatively regulate transcriptional 
activity of T cells, thereby possibly modulating T cell mediated responses at the sites of 
inflammation. Effects of cAMP have been widely studied in freshly isolated T cells and T 
cell clones, yet effects in differentiated Th1 and Th2 cells are largely unknown. To obtain 
differentiated T helper cells, we activated naive T cells for 1 week in the presence of 
IL-12 plus α-IL-4 to generate Th1-type cells and in the presence of IL-4 plus α-IL-12 to 
generate Th2-type cells.We demonstrate that, in contrast to freshly isolated T cells, the 
production of Th1 (IFN-γ) and Th2 (IL-4, IL-5) cytokines in polarized T helper cells is not 
strictly controlled by the activation of AC/cAMP linked β2-adrenergic and prostaglandin 
(PG)E2 receptors. In Th2 cells, PGE2 could still activate the Gs protein coupled AC/cAMP 
system and subsequently induce CREB phosphorylation, whereas PGE2 was unable to 
activate the cAMP dependent pathway in Th1 cells. In both Th1 and Th2 cells, the 
induction of CREB phosphorylation by β2-agonist fenoterol was impaired. The loss of 
control over cytokine production by cAMP elevating agents in differentiated Th1 and Th2 
subsets may have important implications for the regulation of Th1 and Th2 mediated 
diseases, in particular those associated with ongoing immune responses. 
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INTRODUCTION
The cyclic adenosine monophosphate (cAMP)-dependent pathway is an important 
negative feedback system in the regulation of inflammatory activity. Expression of 
cytokine production in T lymphocytes is regulated by prostaglandin (PG)E2 and β2-
agonists, which activate receptors coupled to the cAMP dependent pathway. Upon 
receptor binding, the associated Gs protein triggers adenylyl cyclase (AC) activity, 
resulting in the formation of intracellular cAMP. Cytokine genes containing a cAMP-
responsive element (CRE) in their promoter, like the IFN-γ gene, can be regulated by 
the protein kinase A (PKA) mediated phosphorylation of cAMP-responsive element 
binding protein (CREB) [1-3]. Not all cytokine genes that are controlled by the 
cAMP dependent pathway contain a CRE in their promoter. For instance, no binding 
site for CREB has been found in the IL-5 promoter region. Expression of cytokine 
genes lacking this binding site can be affected indirectly by cAMP, most likely by the 
modulation of the signal transduction pathways, including the mitogen activated 
protein (MAP) kinase pathways [4-6]. 
 In T cells, cAMP elevating substances are known to dose-dependently control 
the production of both Th1 and Th2 cytokines [7-12], although the ultimate effect 
on Th2 cytokines appears to be dependent on the activation state and costimulatory 
signals [8,9,12]. cAMP has been described to inhibit Th2 cytokine production in 
freshly isolated T cells activated with CD3 plus CD28 antibodies [9], whereas it 
slightly enhances the production of IL-5 in the presence of potent PKC activators 
or high concentrations of IL-2 [8,9] and strongly upregulates IL-5 in Th2 clones 
[11,13]. Because T cell clones may be dysregulated due to many cell divisions, this 
effect in Th2 clones may not be representative for in vivo conditions. Furthermore, 
the existence of strictly separated Th1 and Th2 subsets in the human immune 
system has been under discussion. However, polarized Th1 and Th2 cells may exist 
at the sites of tissue inflammation; several immune responses are associated with 
the presence of Th1 and Th2 subsets, including Th1 mediated autoimmune diseases 
and Th2 mediated allergies [14,15]. At the initiation of an immune response, 
autocrine IL-2 induces the proliferation of naïve helper cells. Subsequently, the 
specific cytokine environment determines the final outcome of the T helper subtype 
[14,15]. From in vitro studies, it has become clear that naive CD4+ cells differentiate 
into polarized Th1 and Th2 during activation in the appropriate environment, e.g. 
in presence of IL-12 [16,17] or IL-4 [18], respectively. In addition, when T cells are 
only activated for a short period or in the absence of specific cytokine environment, 
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nonpolarized intermediates or Th0 cells develop, which are able to produce various 
patterns of cytokines. Recent studies have demonstrated that entering the cell 
cycle is essential to induce epigenetic remodeling, that is, alterations in chromatin 
structure, which is crucial for differentiation towards a Th1 or Th2 phenotype and 
the efficient production of the associated cytokines [19,20]. The effects of cAMP 
have not been examined thoroughly in polarized Th1 and Th2 subsets, although this 
may provide insight in the regulation of Th1 and Th2-associated immune responses. 
We investigated the regulation of cytokine production by cAMP in Th1 and Th2 cells 
and demonstrate that control over cytokine production by cAMP elevating agents 
operating via AC-coupled receptors is partially lost in Th2 subsets and completely 
lost in Th1 subsets. 
EXPERIMENTAL PROCEDURES
Isolation of T cells
Peripheral blood cells were obtained from healthy volunteer platelet donors. 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque 
(Lymphoprep; Nycomed, Oslo, Norway) density-gradient centrifugation. T cells were 
isolated by rosetting with 2-aminoethylisothioronium bromide (AET) treated sheep 
red blood cells (SRBC). The SRBC were lysed with 155 mmol/L NH4Cl, 10 mmol/L 
KHCO3 and 0.1 mmol/L EDTA. After isolation, T cells were incubated overnight at 
37°C in RPMI 1640 (BioWhittaker, Verviers, Belgium) containing 5% fetal calf serum 
(FCS; Hyclone, Logan, UT, USA), supplemented with 100 U/ml penicillin and 100 
µg/ml streptomycin. 
Th1/Th2 polarization
T lymphocytes were isolated from peripheral blood of healthy volunteer platelet 
donors as described above. The T cells were differentiated into Th1 and Th2 subsets as 
described before [21]. In short, naive helper T lymphocytes were sorted after staining 
with α-CD45RO-FITC (UHCL-1) and α-CD4 CyQ (B-F5) (Immune Quality Products 
(IQP), Groningen, the Netherlands), using a MoFlow Flow cytometer (Cytomation, 
Fort Collins, CO, USA) calibrated using Flow-Check Fluorospheres (Beckman Coulter, 
Paris, France). Purity was above 98% by re-analysis. Cells were cultured in RPMI 
1640 medium containing 10% FCS, in presence of PHA, IL-2, irradiated allogenic 
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PBMC (neutral conditions) and either IL-12 (2 ng/ml, R&D systems, ITK diagnostics, 
Uithoorn, the Netherlands) plus α-IL-4 (200 ng/ml, Becton Dickinson, Erebodegem-
Aalst, Belgium) to generate polarized Th1 cells, or IL-4 (200 U/ml, Becton Dickinson) 
and α-IL-12 (2 µg/ml, R&D systems) to generate polarized Th2 cells. To confirm that 
Th1 and Th2 phenotypes were obtained after 7 days, the cells were analyzed for 
intracellular cytokines as described before [22]. In short, the polarized T helper cells 
were replated in RPMI medium containing 5% FCS and cultured overnight. Next, the 
cells were stimulated with PMA (10 ng/ml) and ionomycin (1 µg/ml) for 4 hours in 
the presence of monensin (2 µM, Alexis, Läufelfingen, Switzerland). Cells were fixed 
in 4% paraformaldehyde, permeabilized in 0.1% saponin/0.1% azide and stained 
using α-CD4-CyQ (B-F5, IQP, Groningen), α-IFN-γ-FITC (45-15, IQP), and α-IL-4-PE 
(B-T4, CLB, Amsterdam, the Netherlands). Irrelevant specificity antibodies of the 
same isotype were used for gate setting. Analysis was performed using an Elite 
flow cytometer (Beckman Coulter). Lymphocyte events were gated on the basis of 
forward and sideward scatter characteristics. The intracellular cytokine stainings 
indicated that highly divergent cytokine production patterns were obtained after one 
week of culture. Virtually all cells became CD45RO+ after culturing under polarizing 
conditions. In the cell population polarized under Th1 conditions, approximately 40% 
of the CD4+ cells was IFN-γ+/IL-4- and 0.5% was IL-4+/IFN-γ-, whereas in the cell 
population cultured under Th2 conditions, approximately 10% was IL-4+/IFN-γ- and 
0.5% was IL-4-/IFN-γ+. In both cell populations, only a small percentage of the cells 
was positive for both cytokines.
Stimulation of the T cells
After 7 days of culture under polarizing conditions, the cells were rested overnight in 
RPMI medium containing 5% FCS. For stimulation, polarized T helper cells or freshly 
isolated T cells (1-3 x 106/ml) were incubated in RPMI 1640 medium containing 
5% FCS with 50 µl/ml of α-CD3 and α-CD28 antibodies, as previously described by 
Borger et al [7] in the presence or absence of PGE2 (Sigma, St. Louis, MO, USA) in a 
final concentration of 10 µM, β2-agonist fenoterol (Sigma) in a final concentration of 
10 µM, cAMP analogue dibutyryl (db)-cAMP (Boehringer-Mannheim GmbH, Germany) 
in a final concentration of 0.5 mM or phosphodiesterase (PDE) inhibitor 1-methyl-3-
isobutylxantine (IBMX, Alexis) in a final concentration of 100 µM. 
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Measurement of cytokine protein 
Polarized T cells or freshly isolated T cells (1-3 x 106/ml) were left unstimulated 
or stimulated with α-CD3/α-CD28 during 6-8 hours. Secreted IL-4, IL-5 and 
IFN-γ proteins were measured in cell-free supernatants, using enzyme linked 
immunosorbent assay (ELISA) kits for IL-4 and IFN-γ (CLB). The IL-5 ELISA was 
performed as previously described by Hoekstra et al [23]. 
Measurement of intracellular cAMP accumulation
After resting overnight, T lymphocytes (3 x 106/ml) were suspended in RPMI 1640 
medium. Stimulation of cAMP production was performed as described before [24]. 
In short, the samples were incubated with IBMX (0.1 mM) for 10 minutes to prevent 
cAMP degradation. After preincubation, the samples were stimulated for 10 minutes 
with PGE2 (10 µM). Reactions were terminated by adding 2 N HCl-0.1 M EDTA 
followed by incubating the samples at 80°C for 10 minutes. After centrifugation 
of precipitated protein, the samples were neutralized by CaCO3 and cAMP was 
measured using an enzyme immunoassay (Biotrak, Amersham, Buckinghamshire, 
UK) according to the manufacturers guidelines. cAMP concentrations are expressed 
as fmol cAMP/106 T lymphocytes.
Immunodetection by western blotting
Phosphorylation of CREB and expression of G protein-coupled receptor kinase 3 
(GRK3/βARK2) were analyzed by western blotting. T cells (1-3 x 106) were cultured 
overnight in 11⁄2 ml RPMI 1640 medium containing 0.5% FCS. The cells were 
incubated with PGE2 (10 µM), fenoterol (10 µM), db-cAMP (0.5 mM), IBMX (100 
µM) or Sodium Fluoride (NaF, Sigma, 10 mM), to directly activate the G protein, in 
final a concentration of 10 mM for 60 minutes to study CREB phosphorylation, or 
left unstimulated to study βARK expression. T cells were harvested and spun down 
at maximum speed during 30 seconds. Next, total cell lysates were obtained by 
resuspension of the pellets in 1x Sample buffer (containing 2% SDS, 10% glycerol, 
2% β-mercaptoethanol, 60 mM Tris-Cl PH 6.8 and bromophenol blue) and boiling for 
5 minutes. Samples were loaded on a SDS 10% PAGE gel (acrylamide:bisacrylamide 
173:1) and transferred to a cellulosenitrate membrane (Schleicher & Schuell, 
Germany). Immunoblotting was performed by standard procedures and the detection 
REGULATION OF CYTOKINES BY cAMP IN POLARIZED T HELPER CELLS
77
was performed according the manufacturer’s guidelines (ECL, Amersham). Relative 
protein levels were quantified using the gelscan program Diversity One (Pharmacia, 
Uppsala, Sweden).
Reverse Transcription (RT)-Polymerase Chain Reaction (PCR)
Polarized T cells (5 x 106) were rested overnight in RPMI medium containing 5% FCS, 
harvested and RNA was isolated using the TRIzol method (GIBCOBRL, Burlington, 
Ontario, Canada). Total cellular RNA was resuspended in diethyl-pyrocarbonate 
(DEPC; Sigma) treated H2O. 1 µg RNA was used for cDNA synthesis. First, the 
samples were incubated during 10 minutes at 65 °C with random hexamer (pdN6). 
After cooling on ice, RT mix containing 5x RT buffer (GIBCOBRL), 0.1 M DTT, 5 mM 
of each dNTP and 3 units of Reverse Transcriptase (GIBCOBRL) was added and the 
samples were incubated at 37°C for 1 hour. For the PCR reaction, 10x PCR buffer 
(GIBCOBRL), 50 µM of forward and reverse primer, 0.25 µl Taq polymerase, 2 mM 
dNTP’s, and 75 µl MgCl2 in 25 µl total volume were added. The following specific 
primer pairs for β2microglobuline (β2µG, housekeeping gene), EP2 (an AC coupled 
subtype of the PGE2 receptor) EP3 (a Gi coupled subtype of the PGE2 receptor) 
and β2-adrenergic receptor (β2AR) were obtained from Biolegio BV (Malden, The 
Netherlands): 
β2µG: 5’CCA GCA GAG AAT GGA AAG TC3’ sense and 5’GAT GCT GCT TAC ATG TCT 
CG3’ antisense. β2AR: 5’CCT TCT TGC TGG CAC CCC AT3’ sense and 5’GGA AGT CCA 
AAA CTC GCA CCA3’ antisense. EP2: 5’CCT CCT GAG AAA GAC AGT GCT3’ sense and 
5’AAG ACA CTC TCT GAG TCC T3’ antisense. EP3: 5’TGC TGG GCG TGG GCC GCT 
ACA3’ sense and 5’GAC CAA CAG ACG GAC AGC ACA3’ antisense. PCR conditions 
were a denaturation step at 94°C for 5 min followed by 20 cycles of 94°C, 30 s; 55°C, 
30s; 72°C, 30 s for detection of β2µG, 35 cycles of 94°C, 30s; 58°C, 30s; 72°C, 30s 
for detection of β2AR, 25 cycles of 94°C, 30s; 55°C, 30s; 72°C, 30s for detection of 
EP2 and 30 cycles of 94°C, 30s; 55°C, 30s; 72°C, 30s for detection of EP3. With these 
primers the amplified products were 268 bp, 295 bp, 395 bp, 300 bp long for β2µG, 
β2AR, EP2 and EP3, respectively. After PCR, 10 ml of the reaction mixture was run on 
a 1.5% agarose gel, containing 0.2 mg ethidium bromide in 1x TAE buffer. A 100 bp 
ladder (Pharmacia) was used as DNA marker. Relative mRNA levels were quantified 




For the protein measureme nts, statistical analysis was performed using a nonparametric 
test for paired observations (Wilcoxon signed ranks test). Statistical significance of the 
secretion data was set at P<0.05.
RESULTS
Control over cytokine production by cAMP elevating agents in polarized helper T cells is 
reduced compared to freshly isolated T cells
There was a wide range in the levels of cytokines secreted by the different blood donors. 
Absolute values (mean ± SEM) of cytokine secretion are given in table I. Since similar 
effects were exerted by cAMP elevating agents in low and high cytokine producers, 
cytokine protein levels are expressed as a percentage of the cytokine secretion upon 
stimulation in absence of the cAMP elevating agents. As demonstrated in fig. 1A, 
secretion of IFN-γ was strongly inhibited by 10 µM PGE2 (from 100% to 4±3%, p<0.001, 
n=8) and to a smaller extent by 10 µM of short-acting β2-agonist fenoterol (from 100% 
to 20±12%, p<0.001, n=8) in freshly isolated, α-CD3/α-CD28 stimulated T cells. The 
secretion of the Th2 cytokines IL-4 and IL-5 was also under firm control of 10 mM PGE2 
in these cells (inhibition from 100% to 32±9% and 15±10% respectively, p<0.001). 
10 mM fenoterol moderately, but significantly reduced IL-4 and IL-5 secretion (from 
100% to 71±17% and 64±20% respectively, p<0.03, fig. 1A). Dose-dependent effects 
of fenoterol and PGE2 on cytokine production in stimulated freshly isolated T cells are 
depicted in fig. 1B (n=4). The secretion of IFN-γ appeared to be more sensitive to 
fenoterol and PGE2 compared to the secretion of IL-5; whereas IFN-γ production was still 
significantly inhibited by 10 nM fenoterol and PGE2 (p<0.01), IL-5 was only significantly 
inhibited when fenoterol and PGE2 were used in higher concentrations (from 100 nM  to 
10 mM). 
 Interestingly, cytokine production appeared to be differently regulated by cAMP 
elevating agents in polarized T helper cells. In contrast to the strong inhibitory effects on 
IFN-γ protein secretion in freshly isolated T cells (Fig. 1A), there was a complete absence 
of control over IFN-γ secretion by PGE2 and fenoterol (10 µM) in polarized Th1 cells 
(Fig. 1B). In polarized Th2 cells, the control of IL-4 and IL-5 secretion was also reduced 
compared to freshly isolated T cells. No inhibitory effect was found upon stimulation of 
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Figure 1. A) Th1 and Th2-like cytokine production 
is significantly inhibited by cAMP elevating agents 
in freshly isolated T cells. T lymphocytes were 
isolated from healthy donors and rested overnight. 
PGE2 and fenoterol were added in a concentration 
of 10 µM and cells were subsequently stimulated 
with α-CD3/α-CD28 for 8 h. IFN-γ, IL-4 and IL-
5 protein secretion were measured in cell-free 
supernatants. Protein levels are expressed as 
percentage (x ± SEM, n=8) of the secretion after 
stimulation with α-CD3/α-CD28 in absence of cAMP 
elevating agents. *=p<0.05 and **=p<0.001 for 
the cytokine secretion levels after preincubation 
with cAMP elevating agents compared to the 
level without these agents. B) Dose-response 
curves for PGE2 and fenoterol on the secretion 
of IFN-γ and IL-5. Freshly isolated T cells were 
incubated with different concentrations of PGE2 
and subsequently stimulated with α-CD3/α-CD28 
for 8 h. IFN-γ, IL-4 and IL-5 protein secretion were 
measured in cell-free supernatants. Protein levels 
are expressed as percentage (x ± SEM, n=4) 
of the secretion after stimulation with α-CD3/α-
CD28 in absence of cAMP elevating agents. C) 
Cytokine production in polarized Th1 and Th2 
cells is not under strict control of cAMP elevating 
agents. Polarized Th1 and Th2 cells were rested 
overnight in RPMI medium containing 5% FCS 
and stimulated for 6 h with α-CD3/α-CD28. PGE2 
and fenoterol were added prior to stimulation, in 
a concentration of 10 µM. IFN-γ, IL-4 and IL-5 
proteins were measured in supernatants. Protein 
levels are expressed as percentage (x ± SEM, 
n=8) of the secretion after stimulation with α-
CD3/α-CD28 in absence of cAMP elevating agents. 
*=p<0.05 for the cytokine secretion levels after 
preincubation with cAMP elevating agents 
compared to the level without these agents.
the β2-adrenoceptor with fenoterol (10 µM). In contrast, the secretion of IL-4 and 
IL-5 protein was still modestly, but significantly, inhibited by 10 µM PGE2 (from 100% 
to 62±19% and 74±10%, p<0.05 and p<0.01, respectively). The loss of control 
in Th2 and Th1 subsets may be due to differential regulation of the cytokine gene 
promoters or by impaired activation of the cAMP dependent pathway. 
CREB phosphorylation induced by different cAMP elevating agents
To investigate whether the cAMP dependent pathway can still be efficiently 
activated in polarized Th1 cells and Th2 cells, we studied the phosphorylation of 
downstream effector CREB. In freshly isolated T cells, both PGE2 and fenoterol (10 
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µM) clearly induced CREB phosphorylation (Fig. 2), the effect of PGE2 being most 
pronounced. In contrast, in Th1 cells no phosphorylation of CREB could be observed 
upon stimulation with PGE2 and fenoterol. These results suggest that the defective 
regulation of cytokine production by fenoterol and PGE2 in Th1 cells is because of 
impaired activation of the cAMP downstream pathway. In Th2 cells, PGE2 was able 
to induce a clear increase in CREB phosphorylation, whereas fenoterol only slightly 
enhanced the levels of phosphorylated CREB. Thus, the ability of PGE2 to activate 
the cAMP dependent pathway is impaired in Th1 cells and still intact in Th2 cells, 
whereas β2-adrenergic activation of this pathway appears to be disturbed in both Th1 
and Th2 cells. To study if this β2-adrenergic hyporesponsiveness in polarized cells is a 
consequence of the proliferation and activation induced by culturing under polarizing 
conditions, we studied the effect of neutral (Th0) conditions, that is, PHA, IL-2 and 
irradiated APC. In T cells cultured under these conditions for 7 days, fenoterol was not 
able to induce phosphorylation of CREB either. In contrast, PGE2 could still enhance 
CREB phosphorylation. These data suggest that β2-adrenergic hyporesponsiveness 
may develop by polyclonal activation of T cells during polarization. 
Figure 2. CREB phosphorylation in 
presence of fenoterol and PGE2 in 
freshly isolated T cells and T cells 
polarized under Th1, Th2 and Th0 
conditions. T cells were stimulated 
with 10 µM PGE2 or 10 µM fenoterol 
for 60 min. Total cell lysates were 
prepared and phosphorylated CREB 
was detected by western blotting. 
Phospho-CREB is depicted in the upper 
panel and total protein levels (actin) 
are shown in the lower panel (marked 
by arrows). The corresponding diagram 
shows the relative phospho-CREB 
values after normalisation for actin. 
Results shown are representative 
of three independent experiments. 
Impaired formation of intracellular cAMP by PGE2 in Th1 cells 
To study in more detail the defects of PGE2 and β2-receptor function, we measured 
the capacity of these agents to enhance the accumulation of intracellular cAMP in 
freshly isolated and polarized T cells. To prevent degradation of cAMP during the 
assay, cells were incubated with phosphodiesterase inhibitor IBMX. Addition of 
IBMX strongly enhanced accumulation of intracellular cAMP in both polarized and 
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freshly isolated T cells; from 0.32±0.06 to 2.09±0.58 pmol cAMP in Th1 cells, from 
0.18±0.07 to 1.83±1.0 pmol cAMP in Th2 cells and from 0.22±0.09 to 1.93±0.58 
pmol cAMP in freshly isolated T cells (Fig. 3A). In both Th1 and Th2 cells, fenoterol 
was unable to increase intracellular cAMP levels (data not shown). Addition of PGE2 
(10 µM) induced a significant increase in cAMP production in both freshly isolated T 
cells and polarized Th2 cells (fold increase 263±71% and 208±49%, p<0.05 and 
p<0.01, respectively), but not in Th1 cells (110±41%, fig. 3B). Thus, these data 
show a difference in PGE2 functionality in Th1 cells versus Th2 and freshly isolated 
T cells. Together, our findings suggest that the defective regulation of cytokine 
production by cAMP elevating in polarized T helper is caused by the inability of PGE2 
receptor and/or β2-AR stimulation to increase intracellular cAMP levels. 
As previously described, one of the mechanisms responsible for the impaired 
capacity to increase cAMP accumulation may be the upregulation of cAMP-specific 
PDE’s [25], which are responsible for the degradation of cAMP. However, basal levels 
of cAMP were not reduced in polarized T helper cells compared to freshly isolated T 
cells, indirectly indicating that basal activity of phosphodiesterases is not enhanced. 
Additionally, the responsiveness of cytokine production to PDE inhibitors was not 
enhanced in polarized T cells compared to freshly isolated T cells (data not shown). 
Thus, PDE’s are unlikely to play a role in the reduced responsiveness to cAMP 
elevating substances.
Figure 3. A) Incubation with IMBX strongly enhances cAMP accumulation in Th1, Th2 and freshly isolated 
T cells. Basal intracellular cAMP accumulation (fmol) and cAMP accumulation in presence of IBMX (100 
µM) was measured in freshly isolated T cells and polarized Th1 and Th2 cells. Values are presented as the 
means ± SEM of 4 independent experiments. *=p<0.001 for the values with IBMX compared to the values 
without IBMX. B) PGE2 enhances cAMP formation in freshly isolated T cells and polarized Th2 cells, but not 
in polarized Th1 cells. cAMP accumulation was induced by PGE2 (10 µM) in presence of IBMX and measured 
in freshly isolated T cells and Th1 and Th2 cells. cAMP levels are expressed as percentage (x ± SEM, n=4) of 
the formation in abesence of PGE2 .*=p<0.05 for the values with PGE2 compared to the values without PGE2.
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CREB phosphorylation is induced and cytokine production is strongly inhibited by 
db-cAMP, IBMX and  stimulation of the G protein in polarized Th1 and Th2 cells
Next, it was of interest to study whether cAMP is still able to activate its downstream 
pathway and to negatively regulate cytokine production in polarized T helper cells. 
As demonstrated in fig. 4A, strong induction of CREB phosphorylation was observed 
when db-cAMP was added to Th1 cells. These results clearly demonstrate that cAMP-
induced signaling is not impaired in these cells. Moreover, addition of IBMX increased 
both cAMP accumulation (see results described above) and CREB phosphorylation in 
Th1 cells, indicating that intracellular cAMP generation is not disturbed. Finally, direct 
activation of the AC-coupled Gs protein by NaF resulted in strong induction of CREB 
phosphorylation, indicating that the defective induction of CREB phosphorylation by 
PGE2 and fenoterol is most likely caused at receptor level. Similar results with db-
cAMP, IBMX and NaF were observed in Th2 cells (Fig. 4A) and freshly isolated T cells 
(data not shown). 
 In addition, we examined whether IBMX or db-cAMP could also inhibit IFN-γ 
and IL-5 protein secretion in Th1 and Th2 cells, respectively. Indeed, enhancement 
Figure 4. A) CREB phosphorylation is induced by cAMP elevating agents in polarized Th1 and Th2 
cells. T cells subsets were stimulated with db-cAMP, IBMX or NaF for 60 min. Total cell lysates were 
prepared and phosphorylated CREB was detected by western blotting. Phospho-CREB is depicted in the 
upper panel and total protein levels (actin) are shown in the lower panel (marked by arrows). Results 
shown are representative of three independent experiments. B) Cytokine production in polarized Th1 
and Th2 cells is under strict control of potent activators of the cAMP dependent pathway. Polarized Th1 
and Th2 cells were cultured overnight in RPMI medium containing 5% FCS and stimulated for 6 hours 
with α-CD3/α-CD28. IBMX or db-cAMP were added prior to stimulation, in a concentration of 100 µM 
and 0.5 mM, respectively. IFN-γ and IL-5 protein secretion was measured in cell-free supernatants. 
Protein levels are expressed as percentage (x ± SEM, n=3) of the secretion after stimulation 
with α-CD3/α-CD28 in absence of cAMP elevating agents. *=p<0.05 for the cytokine secretion 
level after preincubation with cAMP elevating agents compared to the level without these agents.
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of intracellular levels of cAMP by the addition of IBMX reduced α-CD3/α-CD28 
stimulated IL-5 and IFN-γ protein secretion by approximately 85%. Similar results 
were obtained with cAMP analogue db-cAMP (Fig. 4B). These data demonstrate that 
cytokine production can still be efficiently regulated by the cAMP dependent pathway 
in polarized T helper cells, supporting the findings that the reduced responsiveness 
to PGE2 and/or β2-agonist fenoterol in polarized Th cells is due to impaired activation 
of the AC system and not differential regulation of cytokine production.
Enhanced expression of βARK (GRK3) in polarized T helper cells
We were interested in the possible mechanisms involved in the desensitization of the 
PGE2 and/or fenoterol effects in polarized Th1 and Th2 cells. Desensitization of the 
β2-adrenergic receptor can be induced by either downregulation of mRNA and protein 
levels of the receptor [26] or by phosphorylation of the receptor, which results in 
functional uncoupling from the Gs protein and internalization of the receptor. First, 
the expression level of mRNA was determined using RT-PCR. We observed that, 
similar to freshly isolated T cells, β2-AR mRNA was clearly expressed in both Th1 and 
Th2 subsets (Fig. 5A). Thus, downregulation of β2-AR mRNA is not likely the cause of 
desensitization of the β2-adrenergic system in Th1 and Th2 cells. G protein-coupled 
receptor kinases (GRKs), as well as protein kinase A (PKA) and protein kinase C (PKC) 
Figure 5. A) β2-AR mRNA is clearly 
expressed in Th1 and Th2 cells. RNA was 
isolated from polarized Th1 and Th2 cells 
and total cellular RNA was analyzed by RT-
PCR. In the upper panel the β2-AR signal 
is shown. The β2µG signal in the lower 
panel shows that comparable amounts of 
product were amplified for each condition. 
Results shown are representative 
of two independent experiments. 
B) Expression of βARK is strongly 
enhanced in polarized Th1, Th2 and Th0 
cells compared to freshly isolated T cells 
(n=3). Expression of βARK in polarized 
Th1 and Th2 cells was analyzed by western 
blotting. βARK is depicted in the upper 
panel and actin is depicted in the lower 
panel. A representative blot is shown. 
The βARK levels in Th1, Th2, Th0 and 
freshly isolated T cells were normalised 
for actin and mean relative βARK values 
± SEM of four different experiments are 
depicted in the corresponding diagram. 
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are able to phosphorylate the β2-AR [27,28]. Enhanced expression and activation of 
βARK is known to induce β2-AR desensitization due to enhanced and more rapid 
phosphorylation of the receptor [29-31]. It has been described that treatment of 
T cells with polyclonal activators (PHA, α-CD3 and IL-2) for 3-7 days results in 
enhanced βARK (GRK3) and GRK6 mRNA and protein levels as well as increased 
activity of both kinases [32]. Therefore, we analyzed the levels of βARK2/GRK3 in 
polarized Th cells and freshly isolated T cells by immunoblotting. As demonstrated 
in fig. 5B, the expression of βARK was dramatically enhanced in polarized Th1 cells 
compared to freshly isolated T cells. The expression in Th2 cells was lower, but still 
strongly enhanced compared to freshly isolated T cells. In addition, we studied the 
expression of βARK in T cells cultured under neutral conditions, which also showed 
defective induction of CREB phosphorylation by fenoterol. In these cells, levels of 
βARK were strongly enhanced compared to freshly isolated T cells as well. Thus, 
polyclonal activation of T cells during polarization might induce an increase in βARK 
expression, which in turn might be involved in the loss of β2-adrenergic control. 
Altered levels of PGE2 receptor subtypes in polarized T helper cells
In addition to β2-adrenergic unresponsiveness, polarized Th1 were unresponsive to 
PGE2. Although, the mechanism of β2AR receptor desensitization has been widely 
described, little information is available about desensitization and internalization 
of the PGE2 receptor. It is known that PGE2 can exert differential effects through 
activation of different subtypes of the receptor. At least four different subtypes 
are known, i.e. the EP1, EP2, EP3 and EP4 subtype. It has been described that EP4 
Figure 6. Altered expression of the EP2 and 
EP3 subtypes of the PGE2 receptor in Th1 
and Th2 cells compared to freshly isolated T 
cells. RNA was isolated from polarized Th1 
and Th2 cells and total cellular RNA was 
analyzed by RT-PCR. In the upper panel, 
the EP2 signal shows reduced expression 
in Th1 and Th2 cells compared to freshly 
isolated T cells. In the middle panel, the 
EP3 signal shows enhanced expression in 
Th1 cells compared to Th2 cells and freshly 
isolated T cells. The β2µG signal is depicted 
in the lower panel. The corresponding 
diagram shows the relative EP2 and EP3 
mRNA values after normalisation for 
β2µG.  Results shown are representative 
of three independent experiments.
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is susceptible to agonist-promoted internalization, whereas the EP2 receptor is 
resistant. EP2 and EP4 are known to be coupled to the Gs protein and induce AC 
activation. On the other hand, activation of EP1 induces Ca
2+ accumulation, while 
the EP3 subtype preferentially couples to Gi, thereby inhibiting cAMP generation [33-
37]. To study if differential expression of the PGE2 receptor could be involved in the 
altered PGE2 signaling in polarized T helper cells, we measured the mRNA expression 
of the Gs-coupled EP2 subtype and the Gi-coupled EP3 subtype of the PGE2 receptor, 
using RT-PCR. As demonstrated in fig. 6, the expression of EP2 was reduced in both 
Th1 and Th2 cells compared to freshly isolated T cells. This may be involved in the 
reduced responsiveness of cytokine production to PGE2 that was observed in both 
Th1 and Th2 cells compared to freshly isolated T cells, yet this does not explain the 
difference of PGE2 reactivity in Th1 and Th2 cells. As described above, PGE2 was able 
to activate the AC/cAMP-dependent pathway in Th2 cells, while this was not the case 
in Th1 cells. In contrast to the Gs-coupled EP2 subtype, the expression of the Gi-
coupled EP3 subtype appeared to be about a two-fold higher in Th1 cells compared to 
freshly isolated T cells as well as Th2 cells (Fig. 6). Since activation of the Gs protein 
is known to result in activation of the AC/cAMP system, while activation of the Gi 
protein is known to inhibit this system, the altered ratio in EP2 and EP3 expression in 
Th1 cells might be an explanation for the net zero effect of PGE2 on cAMP production 
in Th1 cells (see fig. 3B).  Thus, differential expression of subtypes of the PGE2 
receptor might be involved in the unresponsiveness of Th1 cells to PGE2. 
DISCUSSION
Specialized Th1 and Th2 subsets direct immune responses at sites of inflammation 
by the production of a defined pattern of cytokines. An important regulator 
of proinflammatory activity is the cAMP dependent pathway. At sites of tissue 
inflammation, T cells have ample opportunity to encounter cells that produce cAMP 
elevating agents, for example PGE2. The regulatory effects of cAMP have been 
widely studied in freshly isolated T cells and in T cell clones, but not in specialized 
T helper subsets cells, which can be obtained by in vitro differentiation under Th1 
or Th2 polarizing conditions. In the present report we demonstrate that cytokine 
secretion in polarized T helper cells is not strictly controlled by cAMP elevating 
agents. Although the α-CD3/α-CD28 stimulation method can not necessarily be 
extrapolated to the activation of T cells by antigen, our results may have important 
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implications for the regulation of Th1- and Th2-mediated immune responses. Our 
findings are in contrast to the results in freshly isolated T cells, where the production 
of the Th1-like cytokine IFN-γ was almost fully blocked by cAMP elevating substances 
and significant inhibition of Th2-like cytokine (IL-4, IL-5) production was observed. 
The inhibitory effect on IFN-γ secretion appeared to be completely abolished in 
polarized Th1 cells, while the inhibitory effect on IL-4 and IL-5 in polarized Th2 cells 
was reduced compared to freshly isolated T cells. Thus, whereas in freshly isolated 
T cells Th1 cytokine production is more susceptible to cAMP inhibition than Th2 
cytokine production, polarized Th2 cells appear to be more sensitive to PGE2 than 
polarized Th1 cells. PGE2 was able to induce an increase in cAMP production and CREB 
phosphorylation in Th2 cells, while PGE2 was unable to enhance cAMP production and 
subsequently activate downstream signals in Th1 cells. This may have implications 
for the Th1/Th2 balance at sites of tissue inflammation, where specialized Th1 or 
Th2 subsets may be found. Our data indicate that the loss of PGE2 control over IFN-γ 
production in polarized Th1 cells is most likely because of a defect at receptor level 
and is not caused by differential regulation of cytokine production. This is supported 
by the finding that preincubation with db-cAMP, IBMX or NaF significantly enhances 
CREB phosphorylation and strongly inhibits IFN-γ production, indicating that IFN-γ 
production is still under control of the cAMP dependent pathway. Defective induction 
of CREB phosphorylation might indeed lead to a loss of control over IFN-γ production, 
since it has been shown that CREB inhibits Jun-mediated activation of the IFN-
γ promoter by competitive binding [38]. In addition to the regulation of cytokine 
production, the cAMP-dependent pathway has been described to induce apoptosis in 
T lymphocytes [39]. Thus, our results might also have implications for the survival of 
Th1 and Th2 subsets in inflamed tissue, where T cells have opportunity to encounter 
PGE2 secreting cells.
 In contrast to the differential effects of PGE2 in Th1 and Th2 subsets, we 
found  reduced responsiveness to the β2-agonist fenoterol in both Th1 and Th2 cells. 
This seems to be due to a defect at receptor level, since the ability of fenoterol to 
activate the cAMP dependent pathway was impaired in polarized T cells. If the in 
vitro polarized T cells are indeed representative for specialized Th1 and Th2 subsets 
in vivo, our results suggest that the use of β2-mimetics, for instance in asthma, may 
not efficiently inhibit proinflammatory T cell activity. Several mechanisms may be 
responsible for the desensitization of the β2-adrenergic receptor. First, prolonged 
agonist binding can result in downregulation of the total cellular levels of the receptor 
(both mRNA and protein) and contribute to desensitization of the receptors [26]. 
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However, no indications for a prolonged repression of receptor gene transcription, 
resulting in decreased receptor expression, were observed in polarized Th cells; 
mRNA for the β2AR was clearly expressed in polarized Th1 cells and Th2 cells. Thus, 
a functional uncoupling of the β2AR and PGE2 receptor from the Gs protein seems to 
be more likely. This can be caused by phosphorylation of the receptor by G protein-
coupled receptor kinases (GRKs), protein kinase A (PKA) or protein kinase C (PKC) 
[27-28]. Phosphorylation of the active form of the receptor by βARK (also GRK3) 
promotes binding of β-arrestin to the receptor, resulting in uncoupling from the Gs 
protein and finally internalization of the receptor [39]. Enhanced expression and 
activation of βARK may induce β2-adrenergic hyporesponsiveness [29]. It has been 
demonstrated that overexpression of βARK leads to hyporesponsiveness of the β2-
adrenergic receptor due to enhanced and more rapid agonist-induced phosphorylation 
of the receptor [30,31]. Indeed, we found that βARK levels in polarized Th1 and Th2 
cells were strongly enhanced compared to freshly isolated T cells. In addition, high 
levels of βARK were observed in T cells polarized under neutral (Th0) conditions, 
where reduced responsiveness to β2-agonist fenoterol was also found. These data 
suggest that polyclonal activation of T cells during polarization induces upregulation 
of βARK, thereby reducing the responsiveness to β2-agonists. In this way, T cells 
may become less sensitive to circulating β2-agonists (e.g. epinephrine) during the 
induction of cell cycle progression at the initiation of immune responses.  
 So far, little information is available on the regulation of the PGE2 receptor. 
It has been demonstrated that the EP4 subtype of the PGE2 receptor is susceptible 
to agonist-promoted internalization, whereas the EP2 subtype receptor is resistant 
[40]. EP4 desensitization can occur by a similar mechanism as β2-adrenergic 
desensitization, involving βARK and β-arrestin. Therefore, a role for enhanced βARK 
expression in PGE2 unresponsiveness in Th1 cells cannot be excluded, although it 
is not clear why Th2 cells, expressing high levels of βARK, were still responsive to 
PGE2. We show that another possible mechanism involved in reduced responsiveness 
to PGE2 might be the altered balance in EP2/EP3 mRNA expression. EP2 mRNA was 
reduced in both Th1 and Th2 subsets compared to freshly isolated T cells, whereas 
EP3 mRNA expression was only enhanced in Th1 cells. Thus, the reduced expression 
of EP2 could explain why Th2 cells are less responsive to PGE2 than freshly isolated 
T cells, while the additional upregulation of mRNA for the Gi-coupled EP3 receptor 
in Th1 cells may be responsible for the complete unresponsiveness to PGE2 in these 
cells. It is known that activation of the Gi protein by PGE2 and β2-agonists does not 
result in cAMP formation, but instead causes activation of the PI3-kinase-dependent 
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anti-apoptotic pathways [41]. Our data suggest that coupling of the PGE2 receptors 
to the Gi protein is enhanced in polarized Th1 cells compared to freshly isolated T 
cells. This might result in a net zero effect on cAMP production and activation of 
downstream pathways, since activation of Gi counteracts the effects induced by 
activation of the Gs protein. It still remains unclear what causes the Th1 specific 
upregulation of EP3 mRNA. Incubation of T cells with the Th1 directing cytokine IL-
12 alone for prolonged periods did not result in reduced ability of PGE2 to activate 
the cAMP dependent pathway (data not shown). Possibly, entering the cell cycle and 
epigenetic remodeling during Th1 polarization is required to induce upregulation of 
EP3 expression. Another G-coupled receptor that can trigger different intracellular 
events through different receptor subtypes is the histamine receptor. It has been 
demonstrated that histamine reduces cytokine (IL-4, IL-13) production and elevates 
cAMP production in differentiated murine Th2 cells, which preferentially expressed 
the histamine receptor type 2 (HR2) [42]. In contrast, Th1 cells preferentially 
expressed HR1, leading to an increase in calcium influx instead of an increase in 
intracellular cAMP levels upon activation and in addition an upregulation of IFN-γ 
production [42]. Thus, reduced linking of G protein-coupled receptors to the AC 
system seems to be a general phenomenon in polarized Th1 cells. Together, our 
findings suggest that resting T cells in peripheral blood are under strict control of Gs 
protein coupled receptors, while this control is lost when T cells become activated 
at the sites of tissue inflammation and differentiate into effector T cells. The loss of 
control may allow appropriate activation and increase survival of effector Th cells. 
Th1 cells appear to be less responsive to G protein-coupled receptors than Th2 cells, 
favoring activation of the Th1 subtype. 
 In summary, our study demonstrates that polarized T helper cells are less 
responsive to PGE2 and the β2-agonist fenoterol than circulating T cells. This lack 
of negative feedback control may have implications for ongoing inflammatory 
processes, since cytokine production in effector Th2 cells may not be efficiently 
suppressed and the activity of Th1 cells may not be suppressed at all by a β2-agonist 
or PGE2 secreted by surrounding tissue cells. 
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Chapter 5
ALTERED β2-ADRENERGIC REGULATION OF T CELL ACTIVITY AFTER ALLERGEN 
CHALLENGE IN ASTHMA





Background: Airway inflammation in asthma is orchestrated by recruitment of Th2 
lymphocytes to the lung upon allergen challenge and subsequent production of 
Th2-like cytokines. Objective To examine whether allergen-induced dysfunction of 
the β2-adrenergic receptor (β2-AR) contributes to the enhanced T(h2) cell activity 
in asthma. Methods: β2-adrenergic regulation of cytokine mRNA expression was 
studied in α-CD3/α-CD28 activated peripheral blood lymphocytes from 7 asthma 
patients before and 6 hours after allergen challenge, in conjunction with the effects 
of β2-agonist fenoterol on T cell chemotaxis and signaling pathways. Results: We 
observed a complete loss of β2-AR control over expression of the Th2 cytokines 
interleukin (IL)-4, IL-5 and IL-13, but not of the Th1 cytokine IFN-γ, after allergen 
challenge. Furthermore, we found impaired β2-AR regulation of T cell migration as 
well as signal transduction pathways, i.e. the phosphorylation of cAMP-responsive 
element binding protein (CREB) and the inhibition of the mitogen-activated protein 
kinase (MAPK) pathway. The loss of β2-AR control was associated with increased 
βARK expression, which might be involved in β2-AR desensitization. In addition, we 
demonstrate for the first time that T cells exposed to the chemokine TARC show 
hyporesponsiveness to fenoterol. Conclusion: Our results suggest that allergen-
induced loss of β2-AR control, possibly mediated by chemokine release, plays an 
important role in enhanced Th2-like activity in asthma.
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INTRODUCTION
Atopic asthma is a complex disorder characterized by allergen-induced airway 
inflammation with associated eosinophilia, bronchoconstriction, airway wall oedema 
and bronchial hyperresponsiveness [1-3]. Infiltrating T lymphocytes are thought to 
orchestrate the immune response associated with asthma by the production of Th2-
like cytokines, e.g. interleukin (IL)-4, IL-5 and IL-13. Enhanced expression of these 
cytokines has been observed in bronchoalveolar lavage (BAL) and bronchial biopsies 
from asthma patients [4-6]. After allergen challenge, T cell activity increases, as 
reflected by further upregulation of Th2 cytokines, enhanced expression of activation 
markers and migration of T cells into lung tissue [7-11]. Virtually all IL-4+ T helper 
cells that enter the lung upon allergen challenge have been described to express 
the C-C chemokine receptor CCR4 [12,13]. The production of one of the ligands 
for CCR4, i.e. TARC, is enhanced in bronchial tissue after allergen challenge and 
may thus be responsible for the attraction of T cells [12,14]. CCR4 is preferentially 
expressed on Th2 cells [16], suggesting that primarily Th2-like T cells infiltrate lung 
tissue upon allergen challenge. Until now, the mechanisms underlying enhanced 
Th2-type activity in asthma are poorly understood.
 We hypothesized that a defect in the β2-adrenergic system contributes to 
the increased Th2-like activity. The β2-adrenergic system can suppress inflammatory 
activity by activation of the Gs-coupled adenylyl cyclase (AC) system and a subsequent 
rise in intracellular cAMP [16,17].  T cell-mediated responses can be controlled by 
cAMP through inhibition of both Th1 and Th2 cytokines, although the ultimate effect 
of cAMP on Th2 cytokines is dependent on the activation status of the T cell and 
presence of costimulatory signals [18,19,20]. A defect in the β2-adrenergic receptor 
(β2AR)/adenylyl cyclase (AC) system in asthma has been proposed a long time ago. 
The importance of the β2-adrenergic/AC system in asthma was first demonstrated 
by the observation that asthma-like phenotypes develop in mice and rats when the 
b-adrenergic system is defect [21]. In addition, β2-adrenergic unresponsiveness can 
be induced in asthma patients by regular treatment with β2-agonists. This leads to an 
increased sensitivity to allergen exposure, suggesting that β2-adrenergic dysfunction 
may have important implications for allergic airway inflammation [22]. Allergen-
induced dysfunction of the β2-adrenoceptor (β2-AR)/AC system has been observed 
in peripheral blood lymphocytes [23]. Because of the implications for allergic 
airway inflammation, we were interested in the effects of allergen-induced β2-AR 
dysfunction on T cell activity. Lung infiltration of activated T cells as well as β2-AR 
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desensitization in peripheral lymphocytes is thought to occur within 24 hours after 
allergen challenge [24]. Therefore, we studied β2-AR regulation of T cell activity 6 
hours after allergen challenge. We demonstrate that β2-AR control over Th2 cytokine 
production, T cell chemotaxis and signaling pathways is completely abolished after 
allergen challenge and we discuss the possible underlying mechanism.
MATERIAL AND METHODS 
Subjects
Seven patients with a diagnosis of asthma, 18-45 years, were included on the basis 
of a late obstructive airway response after inhalation of house dust mite (HDM), cat 
or grass (forced expiratory volume in one second (FEV1) during the late asthmatic 
response (LAR) < 15%), a provocation-concentration of histamine causing 20% 
fall in FEV1 from the predicted FEV1 value (PC20<8mg/ml) and at least one positive 
skin prick test (for clinical characteristics see table I).  Patients did not receive 
oral corticosteroids on the preceding two months or anti-allergic medication on 
the preceding month, nor did they experience respiratory tract infections or acute 
asthmatic attacks within 4 weeks prior to the start of the study. None of the patients 
were smokers. The Medical Ethics Committee of the University Hospital of Groningen 
approved the study. 
Study design
Blood samples were taken on two subsequent days at similar time points, on the 
control day and the day of allergen challenge. Allergen provocation took place as 
described by Aalbers et al [25] and blood samples were taken 6 hours after the 
induction of an early obstructive reaction, as determined by at least a 20% fall in 
FEV1 within first hour after allergen challenge.
Cell cultures, cytokines and reagentia
Peripheral blood mononuclear cells (PBMC) from asthmatic subjects or healthy 
donors were isolated by Ficoll-Hypaque (Lymphoprep; Nycomed, Oslo, Norway) 
density-gradient centrifugation. T cells were isolated by rosetting with 2-
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aminoethylisothioronium bromide (AET) treated sheep red blood cells (SRBC), as 
described before [18]. After isolation, the PBMCs or T cells were incubated for 30 
min at 37°C in RPMI 1640 (BioWhittaker, Verviers, Belgium) containing 0.5%, 1% 
or 5% fetal calf serum (FCS; Hyclone, Logan, UT, USA), supplemented with 100 
U/ml penicillin and 100 µg/ml streptomycin. T cell-specific stimulation with α-CD3 
and α-CD28 (50 µl/ml) was used to induce cytokine expression, as described before 
[18] Fenoterol (Sigma, St. Louis, MO, USA), PGE2 (Sigma) and Sodium Fluoride 
(Sigma) were used in a concentration of 10 µM, 100 nM and 10 mM, respectively, 
as previously described [26]. TARC (R&D systems, ITK diagnostics, Uithoorn, the 
Netherlands) was used in a concentration of 100 ng/ml.
Measurement of cytokine mRNA expression by LightCycler PCR 
3 x 106 ml/ml PBMCs were stimulated with α-CD3/α-CD28 during 5 hours, in presence 
and absence of fenoterol and PGE2. RNA was isolated using the TRIzol method 
(GIBCOBRL, Burlington, Ontario, Canada) and cDNA was synthesized as described 
before [18]. Expression of cytokine mRNA was analyzed by quantitative realtime-
PCR, using the LightCycler system (Roche, Basel, Switzerland). 2 µl FastStart DNA 
SybrGreen I mix (Roche), 2 mM MgCl2, 0.5 µM of forward and reverse primer and 
2 µl cDNA were used. The threshold cycle (Ct) of the α-CD3/α-CD28-stimulated 
PBMCs in presence of fenoterol or PGE2 was compared to the Ct generated by the 
reference sample (the α-CD3/α-CD28-stimulated PBMCs). Cytokine gene expression 
was normalized to expression of the housekeepking gene β2µG (β-2-microglobulin), 
with approximately equal amplification efficiency. The ∆Ct was calculated as the 
difference between the Ct values, determined using the equation 2-∆Ct. The following 
specific primer pairs for β2µG, IL-4, IL-5, IL-13 and IFN-γ were obtained from Biolegio 
BV (Malden, The Netherlands): β2µG: 5’CCA GCA GAG AAT GGA AAG TC3’ sense 
and 5’GAT GCT GCT TAC ATG TCT CG3’ antisense, IL-4: 5’TGC CTC CAA GAA CAC 
AAC TG3’ sense and 5’AAC GTA CTC TGG TTG GCT TC3’ antisense,  IL-5: 5’GCT TCT 
GCA TTT GAG TTT GCT AGC T3’ sense and 5’TGG CCG TCA ATG TAT TTC TTT ATT 
AAG3’ antisense, IL-13: 5’CGG TCA TTG CTC TCA CTT GCC TT3’ sense and 5’TTA 
CCC CTA CCT AAC CCT CCT T3’ antisense, IFN-γ: 5’GCA GAG CCA AAT TGT CTC 
CT3’ sense and 5’ATG CTC TTC GAC CTC GAA AC3’ antisense. PCR conditions were 
a denaturation step at 94°C for 10 min followed by 40 cycles of 94°C, 10 s; 58°C, 




The migration assay was performed using a microchamber transwell system with 5 
mM pores (Corning Costar Incorporated, New York, MA, USA).  2 x 105 T cells were 
applied to the upper compartment of the transwell system. Migration was induced by 
TARC present in the lower compartment. T cells were allowed to migrate to the lower 
well for 2 hours, in presence and absence of fenoterol added to the upper well (10 
µM). The upper well was removed and the T cells in the lower well were counted and 
expressed as percentage of the total amount of T cells added to the upper well.
Immunodetection by western blotting
Phosphorylation of cAMP responsive element binding protein (CREB) and extracellular 
signal-regulated kinase (ERK) and the expression of βARK were analyzed by western 
blotting. Cells were stimulated with or without fenoterol, PGE2 or NaF for 60 minutes. 
In healthy donors, cells were incubated with or without TARC (100 ng/ml) for 6-12 
hours prior to stimulation. Total cell lysates were prepared, separated by SDS-
10% PAGE and transferred to a nitrocellulose membrane. The immunodetection of 
phospho-CREB, phospho-ERK, (New England Biolabs, Hitchin, Herts, UK), pan-ERK 
and actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was performed according 
the manufacturer’s guidelines (ECL, Amersham, Buckinghamshire, UK). Relative 
protein levels were quantified using the gelscan program ImageMaster (Pharmacia, 
Uppsula, Sweden).
Measurement of IL-5 protein
Freshly isolated T cells (3 x 106) were preincubated with or without TARC for 12 
hours and stimulated with α-CD3/α-CD28 during 8 hours. Fenoterol was added 
prior to stimulation. IL-5 protein was measured in cell-free supernatants, using 
enzyme-linked immunosorbent assay (ELISA), performed as previously described by 
Hoekstra et al [27].
Statistical analysis
Analysis was performed using the Wilcoxon’s signed rank test for paired observations 
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in case of mRNA measurements, migration of T cells and relative protein levels 
detected by immunoblotting. Data are expressed as median (range) or mean ± SEM. 
Statistical significance of the secretion data was set at p<0.05.
RESULTS
β2-AR control over Th2 cytokines, but not Th1 cytokine IFN-γ, is abolished after 
allergen challenge
The α-CD3/α-CD28-induced expression of IFN-γ on the control day was not 
significantly different from the expression after allergen challenge (data not shown). 
On the control day, fenoterol exerted a strong inhibitory effect on α-CD3/α-CD28-
induced IFN-γ mRNA expression (Fig. 1), the median (range) expression being 
reduced from 100% to 45% (21-66%). Six hours after inhalation of the allergen, 
the expression of IFN-γ was still inhibited by fenoterol, median 42% (31-59%), the 
inhibitory effect being not significantly altered. 
Figure 1. mRNA expression of the Th1 cytokine IFN-γ and the Th2 cytokines IL-4, IL-5 and IL-13 in 
PBMCs isolated from 7 asthmatic subjects before (control day) and 6 hours after allergen challenge, 
stimulated with α-CD3/α-CD28 for 5 hours in absence and presence of fenoterol. mRNA levels are 
expressed as percentage of the secretion after stimulation with α-CD3/α-CD28 in absence of fenoterol, 
both before and after allergen challenge. *=p<0.05 and **=p<0.01 between th indicated values. 
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Similarly to IFN-γ, no significant change could be observed in the α-CD3/α-CD28-
induced expression of Th2 cytokines after allergen challenge, although the expression 
of IL-4 (but not IL-5 or IL-13) tended to be upregulated (data not shown). In contrast 
to IFN-γ, β2-AR regulation of Th2-type cytokines was significantly altered after 
challenge. Before allergen challenge, fenoterol modestly but significantly inhibited 
IL-4, IL-5 and IL-13 mRNA expression (median 82% (68-100%), 75% (58-100%) 
and 70% (30-90%), respectively, fig. 1). Allergen inhalation induced a complete loss 
of b2-adrenergic control over Th2 cytokine expression. As shown in fig. 1, IL-4, IL-5 
and IL-13 expressions were no longer significantly inhibited by fenoterol and in some 
patients even an upregulatory effect could be observed (median 104% (72-268%), 
121% (92-200%) and 120% (60-150%), respectively). In contrast to fenoterol, the 
effect of PGE2 on IL-4, IL-5 and IL-13 expression as well as IFN-γ expression was not 
significantly altered upon allergen challenge (data not shown), indicating that the 
allergen-induced changes in Th2 cytokine regulation are specific for β2-AR function. 
The β2-adrenergic system controls chemotactic activity in healthy controls and 
stable asthma
To study if the infiltration of T cells is also controlled by the β2-adrenergic system, 
we examined the migratory response of T cells in vitro. Little information is available 
about β2-adrenergic regulation of T cell migration, therefore we first studied this 
in freshly isolated T cells from healthy controls. Because of its implications for 
asthma, TARC was used to induce T cell migration. As demonstrated in fig. 2a, some 
spontaneous migration was found (mean ± SEM: 2.4±0.7% of the total number of 
T cells, n=8). The number of T cells migrating to the lower well was significantly 
enhanced by the addition of TARC, with a maximal response at 100 ng/ml (Fig. 2A). 
The addition of fenoterol significantly inhibited the TARC-induced T cell migration, by 
approximately 40% (p<0.01, n=8). This indicates that T cells with a functional β2-AR 
have a low migratory capacity. 
 The effect of fenoterol on T cell migration was examined in two asthmatic 
subjects, before and 6 hours after allergen challenge. Before challenge, similar 
results were obtained compared to healthy donors, i.e. TARC induced an 
approximately two-fold increase in T cell migration, which was inhibited by fenoterol 
(Fig. 2B). After allergen challenge, β2-adrenergic control over T cell migration was 
abolished, indicating that the loss of β2-AR control is not specific for Th2-like cytokine 
production and may serve to facilitate T cell migration.
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Impaired CREB phosphorylation by β2-adrenergic stimulation after allergen 
challenge
To investigate whether the reduced sensitivity to fenoterol was caused by the inability 
to activate the AC/cAMP system, we studied the activation of cAMP downstream 
effector CREB. In PBMCs derived on the control day, fenoterol induced an increase 
in the phosphorylation of CREB, which was observed for each patient (Fig. 3A). 
The ability of fenoterol to induce CREB phosphorylation was impaired in PBMCs 
isolated 6 hours after allergen challenge. In some patients, the induction of CREB 
phosphorylation was reduced, while in others no induction of CREB phosphorylation 
could be observed at all. In contrast to fenoterol, both PGE2 and direct activation the 
G protein by NaF induced in a strong, significant increase in CREB phosphorylation 
after challenge (Fig. 3A), suggesting a defect at β2-AR level. The magnitude of 
reduction in fenoterol-induced CREB phosphorylation could not directly be related to 
the magnitude of changes in the regulation of cytokine expression.
Impaired regulation of ERK activity by β2-agonist fenoterol after allergen challenge
Th2-like cytokines are unlikely regulated by CREB, yet may be regulated by the 
interference of cAMP with other pathways. An important pathway in T cell activation 
that is controlled by cAMP is the Ras/Raf/ERK pathway [28]. cAMP can inhibit this 
pathway, whereas the desensitized β2-AR may activate this pathway [29]. We 
Figure 2. A) TARC-induced migration of T cells isolated from healthy donors, in absence and 
presence of fenoterol. Migrating T cells are expressed as percentage of the total amount of 
T cells added to the upper compartment (mean ± SEM, n=8). *=p<0.05 and **=p<0.01 
between the indicated values. B) TARC-induced migration of T cells isolated from two asthmatic 
subjects before (control day) and 6 hours after allergen challenge, in absence and presence of 
fenoterol. T cell migration is expressed as percentage of the total amount of T cells added to the 
upper compartment. Experiments were carried out in duplicate and means ± SEM are shown.
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studied the effect of fenoterol on ERK activation before and after allergen challenge. 
Fig. 3b demonstrates an inhibitory effect of fenoterol on ERK phosphorylation in 
PBMCs isolated on the control day. After allergen challenge, the inhibitory effect of 
fenoterol on ERK phosphorylation was abolished in two out of four patients, while 
ERK phosphorylation was even slightly upregulated by fenoterol in two others. In the 
latter two, we also observed upregulation of Th2 cytokine expression by fenoterol. 
This further illustrates the altered function of the β2-AR upon allergen challenge.
Upregulation of βARK2 expression after allergen challenge
The G protein-coupled receptor kinase (GRK) βARK is involved in phosphorylation and 
desensitization of the β2-AR. Agonist-induced β2-AR desensitization can be enhanced 
by βARK overexpression [29-33]. To study whether or not βARK upregulation may 
play a role in allergen-induced β2-AR desensitization, the protein levels of βARK2 
(GRK3) were analyzed before and 6 hours after an allergen challenge. Interestingly, 
the expression of βARK2 significantly increased about a two-fold after allergen 
Figure 3. Immunodetection of phospho-CREB, 
phospho-ERK and βARK in PBMCs isolated from 
asthma patients before (control day) and 6 
hours after allergen challenge. A) PBMCs were 
stimulated with fenoterol, PGE2 or NaF for 60 
minutes. Phospho-CREB is depicted in the 
upper panel and total protein levels (actin) are 
shown in the lower panel (marked by arrows). 
The phospho-CREB levels were normalized 
for actin and mean relative phospho-CREB 
values ± SEM of seven asthmatic subjects 
are depicted in the corresponding diagram. 
*= p<0.05 and **=p<0.01 between the 
indicated values. B) PBMCs were incubated 
with fenoterol for 60 minutes. Phospho-ERK is 
depicted in the upper panel and total protein 
levels (ERK) are shown in the lower panel 
(marked by arrows). The phospho-ERK levels 
were normalized for actin and mean relative 
phospho-ERK values ± SEM of four asthmatic 
subjects are depicted in the corresponding 
diagram. *= p<0.01 between the indicated 
values. C) βARK is depicted in the upper 
panel and actin in the lower panel. The βARK 
levels were normalized for actin and mean 
relative βARK values ± SEM of 7 asthmatic 
subjects are depicted in the corresponding 
diagram.*=p<0.05 between the indicated 
values. Representative blots are shown.
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challenge (Fig. 3C). This enhanced expression of βARK might contribute to the β2-AR 
hyporesponsiveness.
Activation of chemokine receptor CCR4 by TARC induces β2-adrenergic 
hyporesponsiveness
Because activation of the Gi protein is known to counteract the effects of Gs signaling, 
we hypothesized that the activation of Gi-coupled chemokine receptors might be 
involved in the reduced β2-adrenergic responsiveness. We used TARC to induce CCR4 
activation and studied the effect on β2-adrenergic function and βARK expression 
in T cells obtained from healthy donors. T cells incubated with TARC for 12 hours 
show stronger βARK2 expression compared to T cells incubated without TARC (Fig. 
4A). In addition, incubation with TARC reduced the capacity of β2-agonist fenoterol 
to induce CREB phosphorylation (Fig. 4B). This effect was already observed after 6 
hours, but more pronounced after 12 hours of preincubation. Likewise, preincubation 
with TARC (12 hours) reduced the capacity of fenoterol to control the secretion of 
Th2 cytokine IL-5 (Fig. 4C), while Th1 cytokine IFN-γ was still strongly inhibited (by 
approximately 70%, p=0.01, data not shown). Thus, TARC appears to induce β2-
adrenergic hyporesponsiveness and bARK upregulation, similar to allergen exposure 
in asthma. 
Figure 4. A) Immunodetection of βARK in freshly isolated T cells isolated from healthy donors and 
incubated with and without TARC for 1 hours. βARK is depicted in the upper panel and total ERK is 
depicted in the lower panel. A representative blot of three independent experiments is shown. B) 
Immunodetection of phospho-CREB in T cells from healthy donors, after 12 of preincubation with 
and without TARC and 60 minutes of stimulation with fenoterol. Phospho-CREB is depicted in the 
upper panel and total ERK levels are shown in the lower panel (marked by arrows). A representative 
blot of five independent experiments is shown. C) Secretion of IL-5 protein in T cells isolated from 
healthy donors that were preincubated with TARC for 12 hours and subsequently stimulated with α-
CD3/α-CD28 for 8 hours in absence and presence of fenoterol. IL-5 protein levels are expressed as 
percentage (x ± SEM, n=8) of the secretion after stimulation with in absence of fenoterol. *=p<0.05 




Allergen-induced bronchoconstriction is known to be associated with enhanced 
Th2 activity in asthma [7-11]. In the present study we show that a defect in the 
β2-adrenergic system may contribute to Th2-mediated inflammation. Allergen 
inhalation induces a loss of β2-AR control over the activity of T cells, leading to an 
enhanced T cell activation profile in asthma patients. While the β2-agonist fenoterol 
exerted inhibitory effects on both Th1-like and Th2-like cytokines in stable asthma, 
Th2 cytokines were no longer inhibited after allergen challenge, whereas the control 
over Th1 cytokine IFN-γ remained. This may thus favor Th2 activity at the sites of 
allergen-induced inflammation, where T cell cytokine production is induced. The 
reduced sensitivity of peripheral T cells to fenoterol appears to be a consequence of 
impaired activation of the cAMP-dependent pathway. The associated upregulation 
in βARK expression may be one of the mechanisms involved in allergen-induced 
β2-adrenergic desensitization. Our findings may explain why airway inflammation 
in asthma cannot be suppressed by the treatment with β2-agonists and why β2-
AR desensitization in vivo upon regular use of β2-agonists renders airways more 
sensitive to allergen [22].
 In addition to the inhibition of T cell cytokine production, we observed 
that fenoterol inhibited T cell migration, suggesting that the β2-adrenergic system 
functions to retain T cells in the circulation. This inhibitory effect of fenoterol on T 
cell chemotaxis was abolished upon allergen challenge. Thus, particularly T cells that 
lose their β2-adrenergic control may infiltrate the lung upon allergen challenge. A part 
of the T(h2) cells may already have migrated to the lung six hours after challenge. 
However, based on a previous study where  priming for IL-5 production was found 
in peripheral blood lymphocytes after 24 hours [34], we expect that a substantial 
number of Th2 cells is still present in the circulation six hours after challenge.
 Previously, it has been demonstrated that allergen challenge induces 
impaired AC activity in response to β2-agonists. This was observed in lymphocytes 
from asthma patients, but not from healthy controls [23]. Furthermore, obstructive 
reactions caused by histamine inhalation did not impair β2-AR function [35], 
indicating that the release of inflammatory mediators during the allergic reaction 
rather than the stress induced by airway obstruction is responsible for the β2-AR 
dysfunction. This is further supported by the observation that epinephrine levels are 
not increased upon allergen exposure in asthma [36], suggesting the involvement 
of heterologous factors.
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 Our findings concerning CREB indicate that the reduced sensitivity of T 
cells to β2-agonist fenoterol is a consequence of impaired activation of the cAMP-
dependent pathway, specific for the β2-AR.  Activation of the Gs protein/AC-coupled 
PGE2 receptor and direct activation of the G protein by NaF still clearly induced CREB 
phosphorylation after challenge. Thus, coupling of the β2-AR to the Gs protein/AC 
system might be reduced. A well-known mechanism involved in the desensitization 
of the β2-AR is the activation of the G protein-coupled receptor kinase (GRK) βARK 
[30-32]. βARK phosphorylates the β2-AR and enables its binding to β-arrestin, which 
prevents coupling of the receptor to the Gs protein [29,31,33]. Overexpression of 
βARK promotes agonist-induced phosphorylation of the β2-AR [31]. A βARK-mediated 
mechanism may be involved in the allergen-induced β2-adrenergic dysregulation, 
since we observed that the βARK expression was increased upon allergen challenge. 
Instead of activation of the AC/cAMP pathway, after its coupling to β-arrestin the β2-
AR has been described to induce a new set of signaling events, including activation 
of the MAPK pathway [29].  Indeed, we found that the inhibitory effect of fenoterol on 
ERK activation was abrogated after allergen challenge and in some patients we even 
observed induction of the MAPK/ERK pathway. This might lead to a more activated 
status of T cells and contribute to the upregulation of Th2 cytokines as observed in 
some patients. 
 In a previous study, loss of β2-adrenergic control over both IFN-γ and IL-5 has 
been observed 24 hours after allergen challenge [34]. This is in contrast to our findings 
and possibly the result of further downregulation of β2-AR function or downregulation 
in another T cell subset. In contrast to Th2 cytokines, IFN-γ expression remained 
inhibited by fenoterol after allergen challenge in our setting. Since production of 
IFN-γ appears to be more sensitive to cAMP than production of Th2 cytokines, the 
resting activity of the desensitized β2-adrenergic AC/cAMP system might still be able 
to efficiently inhibit IFN-γ. Another explanation for the differential effect on Th1 and 
Th2 cytokines might be that β2-adrenergic desensitization predominantly occurs in 
Th2-like cells. Since virtually all T cells that enter lung tissue after allergen challenge 
have been demonstrated to express the Th2 specific chemokine receptor CCR4, it 
is tempting to speculate that particularly these cells loose their negative feedback. 
The limited quantity of sampled blood did not allow us to study the composition of 
T cells both before and after allergen challenge. Because the migratory response 
of T cells was in general inhibited by fenoterol, we do not render it likely that the 
reduced β2-AR function in peripheral blood is caused by a selective efflux and lung 
recruitment of T cells expressing a functional β2-AR.  Instead, our observation 
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suggests that impaired β2-adrenergic function may be a prerequisite for T cells to 
enter the lung. TARC is one of the ligands for CCR4 and the release of TARC into 
the circulation may be responsible for the attraction of peripheral T cells to the lung 
after allergen challenge [12,14,37]. Most chemokines induce migration through 
the activation of the receptor-associated Gi protein. The activation of Gi-coupled 
receptors is known to counteract the effects of the Gs protein and may induce βARK-
mediated desensitization of G protein-coupled receptors [38-40]. We found that in 
vitro preincubation with TARC induced β2-adrenergic hyporesponsiveness in T cells 
from healthy donors, with similar alterations as observed in asthmatic subjects. 
Because T cell migration was inhibited by fenoterol, the TARC-induced β2-adrenergic 
desensitization might facilitate the migration of CCR4+ cells. Thus, upon the allergen-
induced release of TARC into the circulation, peripheral CCR4+ T cells may change 
their β2-AR function. As a consequence, the impaired negative feedback control may 
lead to enhanced activity of the T cells that enter the inflamed tissue. Recently, it 
has been described that β-arrestin-2 is required for the accumulation of T cells in 
the airways and the development of asthma in allergen-sensitized mice [41]. Since 
β-arrestin is involved in β2-AR desensitization [29], this further supports a role for 
impaired β2-AR/Gs signaling in the pathophysiology of asthma.
 In summary, our data demonstrate a loss of β2-adrenergic control in 
peripheral blood lymphocytes six hours after allergen challenge. This impaired β2-
AR function is reflected by a loss of control over TARC-induced T cell migration and 
Th2 cytokine expression, but not Th1 cytokine expression. The loss of β2-adrenergic 
control may promote T cell-mediated inflammation and contribute to enhanced Th2-
like activity after allergen exposure in asthma. 
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Chapter 6
EXPOSURE TO TARC ALTERS β2-ADRENERGIC RECEPTOR SIGNALING IN HUMAN 
PERIPHERAL BLOOD T LYMPHOCYTES





The β2-adrenergic receptor (β2-AR) negatively regulates T cell activity through the 
activation of the Gs protein and the adenylyl cyclase/cAMP pathway. Desensitization 
of the β2-AR, which can be induced by its phosphorylation, may have important 
consequences for the regulation of T cell function. In the present study we 
demonstrate that the C-C chemokine thymus and activation regulated chemokine 
(TARC) impairs the ability of β2-agonist fenoterol to activate the cAMP downstream 
effector cAMP-responsive element binding protein (CREB) in freshly isolated 
human T cells. The TARC-induced activation of Src kinases resulted in membrane 
translocation of both βARK and β-arrestin. Moreover, TARC was able to induce Src-
dependent serine phosphorylation of the β2-AR as well as its association with βARK 
and β-arrestin. Finally, in contrast to CREB, phosphorylation of Src and extracellular 
signal-regulated kinase (ERK) was enhanced by fenoterol upon TARC pretreatment. 
In summary, we show for the first time that TARC exposure impairs β2-AR function 
in T cells. Our data suggest that this is mediated by the Src-dependent activation 
of βARK, resulting in receptor phosphorylation, binding to β-arrestin and a switch 
from cAMP-dependent signaling to activation of the MAPK pathway. This may induce 
enhanced T cell-mediated inflammation in presence of circulating endogenous β2-
agonists.
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INTRODUCTION
The β2-adrenergic receptor (β2-AR) is expressed on a variety of cell types, including 
T lymphocytes, and belongs to the family of cell surface receptors referred to as G 
protein coupled receptors (GPCR). Upon binding of β2-agonists (e.g. epinephrine) 
to their cognate receptor, the β2-AR associates with the Gs protein, which triggers 
adenylyl cyclase (AC) activity and subsequently results in the formation of intracellular 
cAMP [1]. The cAMP-dependent pathway is widely known as a negative regulator of 
T cell activity. Upon prolonged or repeated agonist binding, uncoupling of the β2-
AR from the AC/cAMP system can be induced. This desensitization is regulated by 
receptor phosphorylation and receptor internalization. β2-AR internalization proceeds 
slower than phosphorylation. It is not strictly required for β2-AR desensitization and 
is thought to be an early step in β2-AR downregulation and/or resensitization [2-5]. 
Phosphorylation of the β2-AR can be induced by several kinases. Most described 
candidates are the G-coupled receptor kinases (GRK) and protein kinase A (PKA), 
which are activated upon stimulation of the β2-AR [6]. β2-AR phosphorylation 
mediated by GRK2 and GRK3, also called βARK1 and βARK2, creates a binding site 
for β-arrestin [6-9], which inhibits β2-AR function by preventing association with the 
Gs protein [9]. Furthermore, β-arrestin has been described to recruit c-Src to the 
receptor, thereby linking the receptor to Ras/Raf/ERK activation [10]. In addition 
to βARK and PKA, various heterologous stimuli (e.g. growth factors and cytokines) 
have been described to phosphorylate the β2-AR, for example by the activation of 
PKC, tyrosine kinases or PI3-kinase [11-14].
 Since the β2-AR system functions to suppress T cell-mediated responses, 
β2-AR desensitization may have important implications for the pathophysiology of 
several diseases, including atopic asthma. Impaired function of the β2-AR system has 
been observed in peripheral blood lymphocytes during allergen-induced inflammatory 
reactions in asthma (15-17). The origin of this β2-adrenergic dysfunction is still 
largely unclear, however it is unlikely caused by enhanced endogenous β2-agonist 
levels [18]. It has been proposed that the release of proinflammatory mediators 
from the lung into the circulation is responsible for the β2-AR dysfunction in asthma 
[19]. In this respect, chemokines may be of interest, since certain chemokines (e.g. 
C-C chemokine TARC) are thought to play a crucial role in the T cell-mediated allergic 
airway inflammation [20, 21]. Most chemokine receptors are Gi protein-linked, 
leading to the release of Gβγ subunits, Src tyrosine kinase activation and subsequent 
induction of the Shc/SOS/Ras pathway upon agonist binding [23]. Additionally, Gi 
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activity is known to counteract the AC system and has been implicated in β2-AR 
dysfunction [22]. Furthermore, chemokines have been described to induce activation 
of GRKs and β-arrestin [24-26]. Based on these characteristics, we hypothesized 
that chemokines may not only induce cytoskeletal changes required for migration, 
but also alter Gs-coupled receptor function. To investigate this, we analyzed the 
effects of TARC on β2-AR signaling in freshly isolated human T cells.
MATERIALS AND METHODS
Isolation of the T cells 
Peripheral blood mononuclear cells (PBMC) from healthy donors were isolated by Ficoll-
Hypaque (Lymphoprep; Nycomed, Oslo, Norway) density-gradient centrifugation. 
T cells were isolated by rosetting with 2-aminoethylisothioronium bromide (AET) 
treated sheep red blood cells (SRBC). The SRBC were lysed with 155 mmol/L NH4Cl, 
10 mmol/L KHCO3 and 0.1 mmol/L EDTA. The remaining cell preparations contained 
more than 98% T cells, as assessed by flow cytometric analysis after staining with 
α-CD2 (Becton Dickinson, Erebodegem-Aalst, Belgium). T cells were incubated 
overnight at 37°C in RPMI 1640 (BioWhittaker, Verviers, Belgium) containing 0.5-
1% fetal calf serum (FCS; Hyclone, Logan, UT, USA), supplemented with 100 U/ml 
penicillin and 100 μg/ml streptomycin.
Immunodetection by western blotting
The phosphorylation of cAMP responsive element binding protein (CREB), extracellular 
signal-regulated kinase (ERK) and Src family kinases was analyzed by western 
blotting. T cells were pretreated with 10 μM PP2 (Calbiochem, Omnilabo International 
bv, Breda, The Netherlands) or 100 ng/ml Pertussis Toxin (Calbiochem, Omnilabo 
International) for 1 and 3 hours, respectively, and subsequently incubated with or 
without TARC (250 pg/ml to 100 ng/ml) for 4-6 hours. Next, cells were stimulated 
with 10 μM fenoterol (Sigma, St. Louis, MO, USA) or 10 mM NaF (Sigma) for 0, 10, 
30, 60, 90 or 180 minutes. Cells were harvested and spun down at maximum speed 
during 30 seconds. Total cell lysates were obtained by resuspension of the pellets in 
1 x Sample buffer (containing 2% SDS, 10% glycerol, 2% β-mercaptoethanol, 60 
mM Tris-HCl PH 6.8 and bromophenol blue) and boiling for 5 minutes. Samples were 
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loaded on a SDS 10% PAGE gel (acrylamide:bisacrylamide 173:1) and transferred 
to a PVDF membrane (Millipore, Bedford, MA, USA). Immunodetection of phospho-
CREB, phospho-ERK, phospho-Src  (New England Biolabs, Hitchin, Herts, UK), pan-
ERK or actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was performed by 
standard procedures and the detection was performed according the manufacturer’s 
guidelines (ECL, Amersham, Buckinghamshire, UK). Relative protein levels were 
quantified using the gelscan program ImageMaster (Pharmacia, Uppsula, Sweden) 
and normalized for total protein levels.
Migration assay
The migration assay was performed using a microchamber transwell system with 5 
μM pores (Corning Costar Incorporated, New York, MA, USA).  T cells were incubated 
in RPMI 1640/1% FCS with or without 10 μM PP2 and 100 ng/ml PTX for 1 and 3 
hours, respectively. Next, 2 x 105 T cells were applied to the upper compartment of 
the chamber. Migration was induced by 5, 20, 100 or 500 ng/ml TARC (R&D systems, 
ITK diagnostics, Uithoorn, the Netherlands) in RPMI 1640/1% FCS present in the 
lower compartment of the chamber. T cells were allowed to migrate to the lower 
compartment for 2 hours at 37°C. The upper well was removed and the T cells in the 
lower well were counted and expressed as percentage of the total amount of T cells 
added to the upper well.
Cytosolic and membrane fractionation
10 x 106 T cells were pretreated with PP2 (10 μM) or SU6656 (1 μM), for 1 hour in 
RPMI 1640/0.5% FCS and subsequently incubated with or without TARC for 1 to 4 
hours. Cells were harvested and washed with ice cold PBS containing 1 mM Sodium 
orthovanadate and 1 mM PMSF, lysed in 200 μl hypotonic lysis buffer (10 mM Tris 
pH 7.4, 1.5 mM MgCl2, 5 mM KCl, 1 mM DTT, 1 mM Sodium orthovanadate, 10 U/
ml aprotonin, 1 μM pepstatin, Complete (Roche, Basel, Switzerland) and 1 mM 
PMSF) at 4 °C. Cell lysates were homogenized by sonification. After the removal of 
intact cells, nuclei and cell debris by centrifugation at 800 x g for 8 min at 4°C, the 
membrane fractions were spun down at maximum speed for 60 minutes at 4°C. 
The cytosol fraction was suspended in 5 x Sample buffer, boiled for 5 minutes and 
stored at -80°C. The sedimented membrane fraction was washed with hypotonic 
lysis buffer, spun down at maximum speed for 30 seconds and resuspended in 1x 
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Sample buffer, boiled for 5 min and stored at -80°C. Samples were loaded on SDS 
10% PAGE gels and blotted to a PVDF membrane. Immunodetection was performed 
with antibodies against βARK/GRK2, β-arrestin-2, IL-1R and tubulin (Santa Cruz 
Biotechnology) using ECL according to the manufacturer’s guidelines.
Immunoprecipitation
10 x 106 T cells were pretreated with 10 μM PP2 for 1 hour in RPMI 1640/0.5% FCS 
and subsequently incubated with TARC (100 ng/ml) for 1 to 4 hours. Cells were 
harvested, washed with ice-cold PBS containing 1 mM Sodium orthovanadate and 
1 mM PMSF and subsequently lysed in 500 μl lysis buffer (50 mM TRIS, pH 7.4, 
10% glycerol, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM DTT, 1 μM pepstatin, 1 
μg/ml aprotonin, Complete, 1 mM PMSF and 1 mM Sodium orthovanadate) for 10 
min on ice. Cell lysates were clarified at 10000 x g for 15 min and precleared with 
30 μl Protein A Sepharose beads (in a 50% slurry) for 1 hour at 4°C. After 1 min 
centrifugation at 300 x g, the cell lysates were subjected to immunoprecipitation 
with antibodies specific for β2-AR, β-arrestin-2 (Santa Cruz Biotechnology) or βARK/
GRK2-agarose conjugate (GRK2-AC, Santa Cruz Biotechnology) and incubated 
rotating at 4°C for 3 hours or overnight. In case of immunoprecipitation with β2-AR 
and β-arrestin, Protein A sepharose beads were added to each sample and incubated 
rotating overnight to bind to the primary antibodies. Next, immune complexes were 
washed three times with lysis buffer. The precipitates were subjected to SDS 10% 
PAGE, immunoblotted on PVDF membrane and immunocomplexes were detected 
using ECL, which was performed according to the manufacturer’s guidelines. The 
phospho-serine antibody was purchased from Zymed Laboratories (SANBIO, Uden, 
The Netherlands).  
RESULTS
TARC preincubation reduces the ability of β2-agonist fenoterol to activate CREB
We examined whether TARC induces alterations in β2-AR signaling by studying the 
effect on cAMP downstream effector CREB. In freshly isolated T cells, incubation 
with fenoterol (10 μM) resulted in a clear induction of CREB phosphorylation. This 
was already observed after 10 min of stimulation, with a maximal response (5-fold 
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induction) between 60 and 90 min (Fig. 1A). Incubation with TARC for 60 min (data 
not shown) or 6 hours (Fig. 1B) had no effect on CREB phosphorylation. When T 
cells were preincubated with TARC for 6 hours and subsequently stimulated with 
Figure 1. The ability of β2-agonist fenoterol and NaF to induce CREB phosphorylation. A) Freshly isolated 
T cells were stimulated with fenoterol or NaF for 0, 10, 30, 60, 90 or 180 min. Total cell lysates were 
prepared and phosphorylated CREB was detected by western blotting (n=2). B) T cells were preincubated 
with 100 ng/ml TARC for 5 min or 6 hours and subsequently stimulated with fenoterol for 60 min. Total 
cell lysates were prepared and phosphorylated CREB was detected by western blotting (n=3). C) T cells 
were preincubated with 250 pg/ml, 5 ng/ml or 100 ng/ml TARC for 6 hours and subsequently stimulated 
with fenoterol for 60 min. Total cell lysates were prepared and phosphorylated CREB was detected by 
western blotting (n=3). D) T cells were incubated with TARC for 6 hours and subsequently stimulated 
with NaF for 60 min. Total cell lysates were prepared and phosphorylated CREB was detected by western 
blotting (n=3). Phospho-CREB is depicted in the upper panels and total ERK or actin levels are shown 
in the lower panels as a control for equal loading (marked by arrows). Representative blots are shown.
fenoterol for 60 min, the ability of fenoterol to induce CREB phosphorylation was 
markedly reduced (approximately 2-fold, fig. 1B). This was also found at lower TARC 
concentrations, and at 250 pg/ml we still observed a suppressive effect (Fig. 1C). 
The effect of TARC may not be mediated by direct inhibition of the Gs protein, since 
5 min of preincubation with TARC did not alter the ability of fenoterol to induce CREB 
phosphorylation (Fig. 1B). In order to investigate whether TARC directly affects the 
AC system or induces alterations at receptor level, we used NaF for direct activation of 
the G protein. NaF (10 mM) induced a strong increase in CREB phosphorylation (Fig. 
1A), which was not reduced upon preincubation with TARC (Fig. 1D). This suggests 
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that the effect of TARC is mediated upstream from the Gs protein at receptor level, 
probably by reducing the association of the β2-AR with the Gs/AC/cAMP pathway.
TARC induces Gi activation and Src kinase activity 
To further identify the mechanism of TARC-induced desensitization of the β2-AR, we 
investigated the pathways induced by TARC stimulation. Most chemokine receptors 
are coupled to Gi proteins, leading to Gβγ release and Src activation upon chemokine 
binding [23]. We tested the involvement of the Gi protein and Src family kinases in 
TARC-induced T cell migration by using the Gi inhibitor pertussis toxin (PTX) and the 
selective Src family kinase inhibitor PP2 in the migration assay. As depicted in fig. 
2A, T cells show some spontaneous migration, but T cell chemotaxis is considerably 
enhanced in the presence of TARC, with a maximal response at 100 ng/ml (3.5-fold 
induction). Preincubation of the T cells with both PTX and PP2 blocked the migratory 
response to TARC (Fig. 2B), indicating the requirement of Gi signaling and Src kinase 
activation. 
Figure 2. TARC-induced T cell 
migration. T cells were added 
to the upper well of a transwell 
system. A) Migration was induced 
by the presence of 0, 5, 20, 100 or 
500 ng/ml TARC in the lower well. 
Migrating T cells are expressed as 
percentage of the total amount 
of T cells added to the upper 
well. B) T cells were incubated 
with or without Src inhibitor PP2 
or Gi inhibitor PTX for 1 and 3 
hours, respectively. Migration 
was induced by the presence of 
100 ng/ml TARC. T cell migration 
is expressed as percentage of 
the total amount of T cells added 
to the upper well. Experiments 
were carried out in duplicate with 
T cells from 2 healthy donors 
and means ± SEM are shown.
In fig. 3A the involvement of Src family kinases is further supported, showing an 
increase in Src kinase phosphorylation in T cells after 5 min of TARC stimulation. 
Phosphorylated Src was completely absent in the presence of PP2 (Fig. 3A). We used 
PTX in these experiments to underscore the involvement of Gi activity. The TARC-
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Figure 3. TARC induces Gi-dependent activation of  Src kinases and this is involved in the suppressive 
effect on β2-AR function. A) Freshly isolated T cell were stimulated with TARC (100 ng/ml) for 5, 
15 and 30 min. 1 hour prior to stimulation, PP2 was added. Total cell lysates were prepared and 
phosphorylated Src was detected by western blotting (n=3). B) T cells were stimulated with TARC 
(100 ng/ml) for 5 min. Prior to stimulation, PTX was added. Total cell lysates were prepared. Phospho-
Src was detected by western blotting (n=3). C) Freshly isolated T cells were preincubated with 100 
ng/ml TARC for 6 hours. Prior to TARC incubation, PP2 was added. Next, T cells were stimulated 
with fenoterol for 60 min. Total cell lysates were prepared and phospho-CREB was detected by 
western blotting (n=4).Representative blots are shown. Phospho-Src and phospho-CREB are 
depicted in the upper panels and total ERK levels are shown in the lower panel (marked by arrows).
induced Src phosphorylation could be blocked by treatment with PTX (Fig. 3B). In 
accordance, PTX and PP2 pretreatment blocked the TARC-induced phosphorylation 
of ERK (data not shown). 
Activity of Src family kinases is critically involved in TARC-induced β2-adrenergic 
dysfunction
Next, we studied whether or not Src kinase activation is critical for the suppressive 
effect of TARC on fenoterol-induced CREB phosphorylation. To establish the role of 
Src kinases in this process, T cells were preincubated with PP2, followed by exposure 
to TARC. As demonstrated in fig. 3C, the fenoterol-induced phosphorylation of CREB 
was suppressed by TARC (0.51±0.03 fold n=4), yet this was no longer observed 
when T cells were pretreated with PP2 (1.1±0.16 fold, n=4). This indicates that Src 
kinase activity in response to TARC is critically involved in the suppressive effect 
of TARC on the fenoterol-induced activation of the cAMP-dependent pathway. PP2 
incubation alone did not result in stronger fenoterol-induced CREB phosphorylation 
or higher basal CREB phosphorylation. This indicates that fenoterol does not induce 
(sufficient) Src activation to reduce β2-AR function (at least not within 60 minutes) 
and that basal Src activity does not affect β2-AR function.
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TARC induces Src kinase-dependent membrane translocation of βARK and β-
arrestin
It is conceivable that Src kinase activity is involved in β2-AR desensitization, since 
Src kinases have been described to phosphorylate and subsequently activate βARK 
[27,28]. Therefore, we tested whether TARC was able to induce Src-dependent 
membrane translocation of βARK. In resting T cells, βARK was localized in both 
cytosolic and membrane fractions. TARC exposure reduced the expression of βARK 
in the cytoplasm and increased the expression in the membrane fraction (Fig. 4). 
As control for the purity of the subcellular fractions, IL-1R was used as membrane 
marker and tubulin was used as cytosolic marker. The increased membrane 
translocation of βARK was already seen after 1 hour of TARC exposure (data not 
shown) and remained for at least up to 4 hours (Fig. 4). The effect of TARC on βARK 
location was inhibited by both PP2 (Fig. 4) and the selective Src inhibitor SU6656 
(data not shown), indicating that TARC-induced Src kinase activity is responsible for 
the membrane translocation of βARK. Interestingly, incubation with TARC triggered 
the membrane translocation of β-arrestin as well (Fig. 4), which was again blocked 
by PP2 pretreatment. The TARC-induced membrane translocation of βARK and β-
arrestin might affect β2-AR function and expression. Immunoblotting and RT-PCR 
studies demonstrated no change in β2-AR membrane expression and β2-AR mRNA 
levels, indicating that TARC does not alter β2-AR function by internalization or 
downregulation of receptor expression  (data not shown).
Figure 4. TARC exposure induces Src kinase-
dependent membrane translocation of βARK and 
β-arrestin. Freshly isolated T cells were challenged 
with 100 ng/ml TARC for 4 hours. Prior to TARC 
incubation, PP2 was added. Cells were harvested and 
subjected to subcellular fractionation. The expression 
of β-arrestin and βARK in cytosol and membrane 
fractions were detected by western blotting and 
indicated by arrows. IL-1R and tubulin indicate purity 
of the membrane and cytosolic fractionation and were 
used to establish equal loading. A representative 
blot of four independent experiments is shown
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Figure 5. Exposure to TARC increases serine phosphorylation of the β2-AR and association of the β2-AR 
with βARK and β-arrestin. A) T cells were incubated with TARC for 3 hours, in presence and absence of 
PP2. Whole cell lysates were prepared and subjected to immune precipitation with anti-β2-AR. Immune 
complexes were subjected to SDS 10% PAGE and immunoblots were stained with anti-phospho-serine 
and anti-β2-AR to establish equivalent loading. A representative blot of two independent experiments is 
shown (n=3). B) T cells were incubated with TARC for 3 hours, in absence and presence of PP2. Whole cell 
lysates were prepared and subjected to immune precipitation with anti-βARK/GRK2 (agarose conjugated). 
Immune complexes were subjected to SDS 10% PAGE and immunoblots were stained with anti-β2-AR and 
anti-βARK to establish equivalent loading (n=3). C) T cells were incubated with TARC for 3 hours, in absence 
and presence of PP2. Whole cell lysates were prepared and subjected to immune precipitation with antibody 
against β-arrestin. Immune complexes were subjected to SDS 10% PAGE and immunoblots were stained with 
anti-β2-AR as well as anti-β-arrestin to establish equivalent loading (n=3). Representative blots are shown.
TARC exposure induces serine phosphorylation of the β2-AR and association to 
βARK and β-arrestin
Next, we questioned whether or not the effects of TARC as described above alter the 
phosphorylation status of the β2-AR. To this end, we determined the phosphoserine 
content of the β2-AR after immunoprecipitation. As demonstrated in fig. 5A, the 
levels of serine-phosphorylated β2-AR were increased by approximately 1.5 fold 
when T cells were exposed to TARC (3 hours), which was observed in absence 
of a β2-agonist. In addition, we studied the association of βARK and β2-AR by co-
immunoprecipitation. As depicted in fig. 5B, the association between β2-AR and βARK 
was markedly increased when T cells were exposed to TARC, supporting a role for 
βARK in the β2-AR serine phosphorylation. Furthermore, by co-immunoprecipitation 
of β-arrestin and β2-AR we observed that TARC induces recruitment of β-arrestin 
to the β2-AR (Fig. 5C). In accordance to the effects as described in the previous 
paragraphs, the TARC-induced β2-AR phosphorylation and recruitment of βARK and 
β-arrestin were blocked by PP2 (Fig. 5A-C). Together, these data suggest that the 
activation of Src family kinases by TARC induces βARK-mediated phosphorylation 
of the β2-AR and subsequent complex formation with β-arrestin in an agonist-
independent manner. 
 Finally, we tested whether this TARC-induced recruitment of β-arrestin to 
the β2-AR results in a switch to activation of the Src/MAPK pathway. To this end, we 
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studied whether or not fenoterol was able to induce phosphorylation of Src family 
kinases and ERK in T cells that were exposed to TARC (3 hours). In resting T cells, 
basal Src kinase activity was inhibited by fenoterol after 10 and 60 min of incubation 
(Fig. 6A). In contrast, fenoterol induced a modest increase in Src phosphorylation 
when T cells were first exposed to TARC. Similarly, fenoterol enhanced ERK 
phosphorylation after preincubation with TARC (Fig. 6B). This indicates that TARC 
exposure switches β2-AR function from activation of the Gs/AC/cAMP system, which 
negatively regulates the Src/SOS/MAPK pathway, to activation of the Src/MAPK 
pathway. Thus, after TARC exposure, T cell activity may be enhanced instead of 
inhibited by the β2-AR system.
Figure 6. TARC preincubation induces 
the ability of β2-agonist fenoterol 
to enhance Src kinase and ERK 
phosphorylation. A) Freshly isolated 
T cells were incubated with 100 ng/ml 
TARC for 6 hours and subsequently 
stimulated with fenoterol for 60 min. 
Total cell lysates were prepared and 
phosphorylated Src was detected 
by western blotting (n=3). B) Freshly 
isolated T cells were incubated with 
100 ng/ml TARC for 6 hours and 
subsequently stimulated with fenoterol 
for 60 min. Total cell lysates were 
prepared and phosphorylated ERK 
was detected by western blotting 
(n=3). Representative blots are shown.
DISCUSSION
The β2-AR is linked to the Gs protein and AC/cAMP activation, thereby providing 
negative feedback control over various proinflammatory cells. Prolonged or repeated 
binding of the agonist as well as exposure to various heterologous stimuli (e.g. 
growth factors and cytokines) may induce desensitization of the β2-AR, resulting 
in impaired activation of the cAMP-dependent pathway [11, 13]. In this report we 
demonstrate for the first time that activation of the C-C chemokine receptor CCR4, 
which is expressed on approximately 50% of the memory T helper cells [29], by 
TARC induces heterologous desensitization of the β2-AR in peripheral T lymphocytes. 
Our results demonstrate that TARC induces Src-dependent membrane translocation 
of βARK and β-arrestin, resulting in β2-AR phosphorylation and defective cAMP-
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dependent signaling. This observation may have important implications for T 
cell-mediated immune responses, including airway inflammation in asthma, since 
T cell activity is normally inhibited by the β2-AR/AC system. In the past, it has 
been demonstrated that allergen exposure reduces β2-AR function in peripheral 
lymphocytes from asthma patients [15,19]. This is thought to involve the allergen-
induced release of proinflammatory mediators, although the identity of the factors 
responsible for the β2-AR desensitization has remained unclear.
 Most chemokine receptors activate the Gi protein, which induces activation 
of Rho GTPases, PI3-kinase and Src/SOS-dependent signaling. This leads to changes 
in the cytoskeleton and cellular responses required for directional migration [23]. 
In addition, Gi signaling is known to counter-regulate the function of the Gs protein. 
Downstream effects of  GPCR activation are in part mediated by the release of 
Gβγ subunits from the heterotrimeric Gαβγ complex. This can induce activation and 
membrane translocation of βARK, resulting in GPCR phosphorylation and recruitment 
of the β-arrestin/Src complex [10,30]. In addition to the Gs-coupled β2-AR, the 
Gi-coupled MCP-1 receptor CCR2 has been reported to undergo agonist-induced 
βARK-mediated phosphorylation [25]. Furthermore, it has been demonstrated that 
the activation of GRKs and β-arrestin is crucial for chemokine-induced cytoskeletal 
reorganization and migration [24,26,31]. Accordingly, it has recently been reported 
that β-arrestin-2 is crucial for Th2 migration to the lung in a mouse model of 
asthma. β-arrestin-2 knockout mice did not accumulate T cells in the lung and had 
defective MDC-mediated T cell migration [32]. These chemokine-induced effects 
may affect β2-AR function. In the present study we demonstrate that TARC exposure 
reduces cAMP-dependent signaling upon stimulation with the β2-agonist fenoterol 
in peripheral T cells. This is likely mediated upstream from the Gs/AC system at 
receptor level and not by direct inhibition of the AC system, in view of the results 
with NaF. Our data suggest the involvement of Gi-dependent activation of Src family 
kinases. We observed that TARC induces Src-dependent membrane translocation 
of βARK and β-arrestin. Although Gβγ subunits are thought to be essential for the 
membrane anchoring of βARK [30], our results indicate that Src activation is also 
required for the TARC-induced membrane translocation of βARK and subsequent β2-
AR phosphorylation. This is in accordance with the findings of Sarnago et al [28], 
demonstrating that Src activation induces βARK phosphorylation and activation. In 
addition, the findings of Fan et al demonstrate that Src activation precedes βARK-
mediated receptor phosphorylation and binding to β-arrestin [27]. Src is known to 
associate with β-arrestin upon β2-AR stimulation [10], but the role of Src kinases 
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in β-arrestin localization has to our knowledge not been described before. In this 
report we show that Src kinase activation induces the membrane translocation and 
recruitment of β-arrestin to the β2-AR. As a consequence, β-arrestin can promote 
the complex formation of β2-AR/Src [10], which might be responsible for the 
observed switch of β2-AR signaling to activation of the MAPK pathway. 
 Our findings suggest that TARC does not facilitate agonist-induced β2-AR 
desensitization, but induces β2-agonist independent desensitization of the β2-AR. So 
far, it has been assumed that βARK mediates homologous desensitization of GPRCs, 
as βARK preferentially phosphorylates the agonist-occupied receptor. However, 
agonist-independent phosphorylation of the β2-AR has been demonstrated in other 
cell systems. For instance, insulin can induce agonist-independent phosphorylation 
of the β2-AR in A431 cells [14]. In addition, it has recently been described in HEK-
293 cells that EGF receptor internalization is triggered by β2-AR stimulation in 
absence of EGF, in a βARK and β-arrestin-dependent manner [33]. These findings 
clearly illustrate that βARK-mediated desensitization is not restricted to homologous 
desensitization. Furthermore, chemokines have been demonstrated to induce cross-
desensitization of another G protein-coupled receptor, i.e. the μ-opioid receptor, 
yet the mechanism remained undefined [34]. In addition to TARC, we observed 
that  the chemokines MCP-1 and IP-10 reduced β2-AR signaling (data not shown), 
indicating that chemokines in general have an important role in the regulation of 
β2-AR function in T cells. Our findings may also have implications for additional 
cell types, including mast cells and eosinophils, which are known to be controlled 
by the β2-AR. Additionally, smooth muscle cells are regulated by β2-agonists and 
express various chemokine receptors [35]. Thus, the release of chemokines during 
inflammatory responses might also affect smooth muscle tonus. 
 In summary, we demonstrate that exposure of T cells to TARC alters the 
function of the β2-AR, resulting in impaired ability to activate the cAMP-dependent 
pathway and a switch to Src/MAPK activation. This may be mediated by the Src-
dependent membrane translocation of βARK, phosphorylation of the β2-AR and 
recruitment of β-arrestin and result in dysregulated and enhanced activity of T cells 
by circulating endogenous β2-agonists.
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1   SUMMARY
Atopic asthma is a complex obstructive lung disorder, with an inflammatory process 
in the airways underlying its pathophysiology. T cells from the Th2 activation type 
are thought to orchestrate the airway inflammation in asthma by the production 
of Th2-like cytokines, e.g. IL-4, IL-5 and IL-13.  IL-4 plays a central role in the 
IgE-mediated response to allergen [1], while IL-5 is crucial for the activation and 
attraction of eosinophils [2,3]. IL-13 has also been described to promote eosinophilia 
[4], while both IL-4 and IL-13 have been demonstrated to induce mucus production 
by goblet cells [4-6]. In addition, both IL-4 and IL-13 may promote fibroblast 
proliferation and airway remodeling in asthma through their effect on bronchial 
epithelial cells [7]. Furthermore, IL-5 and IL-13 are thought to play an important 
role in the development of airway hyperresponsiveness [4,8]. An enhanced T cell 
activation profile is observed in asthma patients versus healthy controls, reflected 
by enhanced expression of the Th2-like cytokines IL-4, IL-5 and IL-13 in lung tissue 
and increased expression of T cell activation markers in both peripheral blood and 
lung [9-18]. Allergen exposure induces a further increase in T(h2) cell activity and 
infiltration of T cells into the lung [12-14]. The mechanisms underlying the enhanced 
T cell activity and production of Th2 cytokines in asthma are still poorly understood. 
One of the possible mechanisms involved in the aberrant T(h2) activity might be a 
defect in negative feedback regulation. In this respect, impaired regulation by the 
β2-adrenergic system may be of interest. The β2-adrenergic system is coupled to Gs 
protein, leading to activation of the adenylyl cyclase (AC) system and subsequent 
cAMP formation upon agonist binding. cAMP is known to suppress T cell activation 
and cytokine production. A general defect in the AC/cAMP system in asthma has 
been proposed a long time ago. Although this system may function normally in 
stable asthma, allergen exposure has been described to induce desensitization of the 
β2-adrenergic/AC system in peripheral blood lymphocytes [19], by a yet undefined 
mechanism. The production of both Th1 and Th2 cytokines by T lymphocytes is 
under control of the cAMP-dependent pathway [20-23]. However, the regulation of 
Th1 and Th2 cytokines involves different signaling pathways and the effect on Th2-
like cytokine expression is dependent on (co)stimulatory signals [23-25]. Inhibitory 
effects on Th2 cytokines have been reported in freshly isolated T cells when 
stimulated with α-CD3/α-CD28 antibodies, while upregulatory effects were observed 
after stimulation with phorbol ester and calcium ionophore and in Th2 clones. Thus, 
an enhanced T cell activation status may lead to alterations in the regulation of 
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Th2 cytokines by cAMP. Until now, it has remained unclear whether diminished β2-
adrenergic/AC regulation contributes to the aberrant Th2-like activity as observed 
in asthma. Furthermore, the mechanisms responsible for changes in the regulation 
of Th2 cytokines by the β2-adrenergic/AC system have been poorly understood. We 
hypothesized that the release of proinflammatory mediators may be involved in 
the dysregulation of T cell activity upon allergen exposure in asthma. In addition to 
alterations in β2-adrenergic/AC function, these mediators may modulate additional 
signaling pathways involved in Th2-like cytokine production. To summarize, the 
following questions were addressed in our studies: 
I) Which factors are responsible for the priming of peripheral T cells to    
 produce Th2-like cytokines (chapter 2)? 
II) How does the Gs-coupled AC/cAMP system regulate Th2-like cytokine    
 production and how is the regulation of Th2-like cytokines by Gs-coupled   
 receptors altered (chapter 3, 4, 6)?
III) Is a dysfunctional β2-adrenergic/AC system after allergen challenge    
 involved in the enhanced Th2-like activity in asthma (chapter 5)?
IV) Which possible mechanisms are responsible for the allergen-induced β2-  
 adrenergic desensitization in peripheral blood lymphocytes (chapter 5, 6)?
In order to test whether extrinsic factors, e.g. soluble mediators released from the 
lung, are able to induce changes in regulation of cytokine production in peripheral T 
cells, we used T cells derived from healthy controls and studied the effects of various 
proinflammatory mediators.
  In chapter 2, we studied the ability of IL-6, a cytokine that can be secreted 
by various cell types including airway macrophages and epithelial cells, to prime 
for Th2 activity in freshly isolated human T cells. We observed that short-time 
preincubation with IL-6 promoted the capacity of α-CD3/α-CD28-stimulated T cells 
to produce the Th2-like cytokines IL-4 and IL-5. After longer periods of preincubation 
(12-24 hours), the effect on IL-4 was gradually lost, while the effect on IL-5 became 
more pronounced. In contrast, a slight but significant inhibitory effect on the α-
CD3/α-CD28-induced production of Th1 cytokine IFN-γ was observed after 24 hours 
of IL-6 exposure. The short-term (five minutes) preincubation effect of IL-6 on IL-5 
production appeared to be mediated by the p38-dependent upregulation of JunB 
binding, while the long-term effect was dependent on the presence of IL-2. We 
found that IL-2 promoted GATA-3 expression after 24 hours of exposure, which 
may be involved in its up-regulatory effect on Th2 cytokine IL-5. In conclusion, 
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we demonstrate that IL-6 has short-term and long-term upregulatory effects on 
Th2-like cytokines and a long-term downregulatory effect on the production of Th1 
cytokine IFN-γ. These effects of IL-6 are mediated by different, IL-2-dependent and 
independent mechanisms.
 In chapter 3 we demonstrate that IL-2 has an additional effect on Th2-
like cytokine production, i.e. IL-2 reduces the sensitivity to the cAMP-dependent 
pathway. Both inhibitory and upregulatory effects of cAMP have been described 
on Th2-like cytokine production [20-25]. Since the ultimate effect of cAMP on Th2 
cytokine production is dependent on (co)stimulatory signals, we were interested in 
the mechanisms that modulate the sensitivity of Th2 cytokines to cAMP. We observed 
that costimulation with IL-2 reduces the inhibitory effect of cAMP elevating agents on 
α-CD3/α-CD28-induced IL-5 secretion in freshly isolated peripheral blood T cells. Our 
findings suggest that IL-2 does not induce defects at receptor level, but counteracts 
the cAMP-mediated inhibitory effects on IL-5 secretion by the modulation of PI3-K-
dependent signaling. Two well-known cAMP effectors, i.e. CREB and small GTPase 
Rap1, are unlikely involved in the protective effect of IL-2. Instead, the effect of IL-2 
may be mediated by PI3-K-dependent inactivation of forkhead-related transcription 
factor FKHR-L1, down-regulation of p27kip and abrogation of cAMP-mediated inhibition 
of AP-1 binding activity. In conclusion, enhanced IL-2 signaling in the airways of 
asthmatic subjects may protect Th2-like cytokine production from the inhibitory 
effects of cAMP elevating agents, for instance PGE2 secreted by surrounding cells. 
 When T cells infiltrate the lung upon allergen inhalation and become activated 
by antigen presenting cells, differentiated Th2 effector cells may develop. The 
induction of cell cycle progression during T cell differentiation may lead to alterations 
in chromatin structure, expression of transcription factors and their binding activity 
to promoter elements. Therefore, in chapter 4 we questioned whether the 
regulation of cytokines by the cAMP-dependent pathway was different in effector 
Th1 and Th2 cells compared to peripheral T cells. To obtain differentiated T helper 
cells, we polarized naive (CD4+CD45RO-) T cells in vitro for 7 days in the presence 
of IL-12 plus α-IL-4 to generate Th1 cells and in the presence of IL-4 plus α-IL-12 to 
generate Th2 cells. In contrast to freshly isolated T cells, the α-CD3/α-CD28-induced 
cytokine production in polarized Th cells was not strictly controlled by the activation 
of the Gs/AC-coupled β2-adrenergic and PGE2 receptor. In Th2 cells, PGE2 could still 
activate the AC/cAMP system, subsequently induce CREB phosphorylation and inhibit 
cytokine production, whereas PGE2 was unable to do so in Th1 cells. In both Th1 
and Th2 cells, the regulation by β2-agonist fenoterol was impaired. Furthermore, 
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our data suggest that the defective control by fenoterol and PGE2 was likely induced 
at receptor level and not the result of a defect in the cAMP-dependent pathway. 
While enhanced expression of βARK may explain the impaired β2-adrenergic function 
in both Th1 and Th2 cells, altered expression of PGE2 receptor subtypes may be 
responsible for the inability of PGE2 to activate the cAMP-dependent pathway in Th1 
cells. In conclusion, our findings suggest that differentiated Th1 and Th2 subsets, 
which may be found at the sites of inflammation, are not under strict control of Gs 
protein-coupled receptors.
 In chapter 5 we studied whether allergen-induced alterations in the β2-
adrenergic system might contribute to a Th2-like activation profile. In addition, we 
investigated the possible mechanisms involved in the alterations in β2-AR function. 
Peripheral blood mononuclear cells were isolated from 7 asthma patients before and 
six hours after allergen challenge. The effect of β2-agonist fenoterol was studied 
in vitro on α-CD3/α-CD28-induced cytokine mRNA expression, TARC-induced T cell 
migration and on signaling pathways (i.e. phosphorylation of CREB and ERK). We 
observed that allergen challenge induced a complete loss of β2-adrenergic control 
over the expression of the Th2 cytokines IL-4, IL-5 and IL-13. In some patients the 
inhibitory effect of fenoterol was reduced, while in others even an upregulatory 
effect could be observed.  In contrast, the expression of Th1 cytokine IFN-γ was still 
under strict control of the β2-adrenergic system. In addition to the expression of Th2 
cytokines, we observed that the inhibitory effect of fenoterol on T cell migration was 
abolished after allergen challenge. Furthermore, we observed impaired activation 
of cAMP effector CREB by fenoterol upon allergen challenge. Additionally, the 
inhibitory effect of fenoterol on ERK phosphorylation was abolished or turned to 
be upregulatory after allergen challenge. The impaired activation of the AC/cAMP 
dependent pathway appeared to be specific for the β2-AR. One of the mechanisms 
that may contribute to the impaired β2-AR function is the upregulation of βARK, wich 
was observed in PBMCs isolated after allergen challenge. Finally, we demonstrate that 
the release of the chemokines (e.g. TARC) may be responsible for the changes in β2-
adrenergic function after allergen challenge. TARC exposure resulted in impaired β2-
adrenergic function and upregulation of βARK expression in peripheral T cells from 
healthy controls. Together, our results suggest that the allergen-induced changes 
in β2-adrenergic function, possibly induced by chemokine release, contribute to the 
upregulation of Th2-like activity in asthma.
 In chapter 6 we further investigated the mechanism of TARC-induced 
β2-adrenergic desensitization, in order to examine if the release of TARC might 
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be responsible for the allergen-induced alterations in β2-adrenergic function. We 
exposed peripheral T cells from healthy controls to TARC and studied the effects on 
β2-AR function. We observed that TARC induced Gi-dependent activation of Src family 
kinases and demonstrate that this is likely responsible for the suppressive effect of 
TARC on the activation of the cAMP-dependent pathway by fenoterol. We further show 
that activation of Src family kinases by TARC results in the membrane translocation 
of βARK and β-arrestin, βARK-mediated phosphorylation of the β2-AR and altered 
receptor function due to β-arrestin binding. In conclusion, we demonstrate that 
exposure to TARC alters β2-AR function in peripheral T cells, resulting in an impaired 
ability to activate the cAMP-dependent pathway and a switch to Src/MAPK activation. 
This may lead to dysregulated and enhanced activity of peripheral T cells in presence 
of endogenous β2-agonists.
2  GENERAL DISCUSSION
T cells from asthma patients display enhanced activity and are primed for the 
production of Th2-like cytokines.  After allergen exposure, Th2 activity is further 
upregulated and T cells infiltrate the lung tissue, where enhanced expression of 
Th2 cytokines is observed. We were interested in the mechanisms responsible for 
this aberrant T cell activity. Since T cells lose their negative feedback control by the 
Gs-coupled β2-adrenergic receptor (β2-AR) after allergen challenge, we questioned 
if a dysfunctional Gs/adenylyl cyclase (AC) system contributes to the enhanced Th2 
activation profile and whether additional factors might be involved. Indeed, our 
findings in chapter 5 suggest that alterations in β2-AR function signaling may induce 
a shift towards Th2-like activity in asthma. Furthermore, we show that the cytokines 
IL-6 and IL-2 may play a Th2 directing role in asthma.
 Previously, a study of Borger et al has demonstrated that the loss of β2-
adrenergic control 24 hours after allergen inhalation coincides with increased capacity 
of peripheral T cells to produce IL-5 [26]. This was observed after in vitro stimulation 
with α-CD3/α-CD28 in absence of β2-agonists, indicating that additional factors are 
involved in the priming for Th2-like cytokine production. A factor of interest is 
the cytokine IL-6, which can be produced by alveolar macrophages and bronchial 
epithelium. Studies concerning the release of IL-6 by monocytes/macrophages have 
suggested that IL-6 secretion may play an important role in the development of Th2-
mediated immune responses [27,28]. Although we did not measure plasma levels of 
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IL-6, increased levels have been observed in asthma patients during acute asthma 
attacks and after allergen challenge [29]. Thus, our findings may offer a plausible 
explanation for the priming of IL-5 production as observed by Borger et al 24 hours 
after allergen exposure. 24 hours of preincubation with IL-6 resulted in a two-fold 
increase in α-CD3/α-CD28-induced IL-5 secretion in peripheral human T cells when 
compared to stimulation in the absence of IL-6. In contrast, the secretion of IFN-γ 
was slightly but significantly inhibited. The study of Borger et al [26] did not show a 
significant decrease in α-CD3/α-CD28-induced IFN-γ mRNA expression, although a 
trend towards downregulation was observed. Thus, in allergic asthma, the presence 
of high levels of IL-6 may render T cells more prone to the production of Th2-like 
cytokines. Short-time incubation with IL-6 promoted the production of both IL-4 and 
IL-5 (chapter 2). In accordance with the finding that the up-regulatory effect of IL-6 
on IL-4 production was most pronounced after six hours of exposure, we found that 
higher levels of IL-4 mRNA were expressed six hours after challenge, however this 
was not significant (chapter 5). Furthermore, we observed in chapter 2 that both 
IL-4 and IL-5 expression were upregulated when IL-6 was added 5 minutes prior to 
stimulation, whereas IFN-γ expression was not. This suggests a shift towards Th2-
like activity when T cells enter the lung and become activated by allergen-presenting 
cells in the presence of surrounding IL-6-secreting cells. Together our findings suggest 
that the release of IL-6 may promote Th2-like activity in asthma. In addition to these 
findings, IL-6 has been described to have anti-inflammatory effects [30,31]. These 
effects of IL-6 may be exerted by the inhibitory on tumor necrosis factor (TNF)-α, IL-
1, metalloproteinases and superoxide production and on the induction of apoptosis 
[30]. Thus, during inflammatory processes, the release of IL-6 by macrophages and 
epithelial cells may serve as a protective, counter-regulatory mechanism. However, 
the effect of IL-6 release may be dual, since Th2-mediated inflammation may be 
promoted at the same time, as demonstrated by the upregulatory effect of IL-6 on 
Th2 cytokines by our study (chapter 2) and studies of others [27,28,32]. 
 In contrast to its short-term effect, we observed that the long-term effect 
of IL-6 was dependent on the presence of IL-2 (chapter 2). Although IL-2 has been 
considered as a Th1-like cytokine, IL-2 is known to be required for the differentiation 
towards both Th1 and Th2 effector cells. Our results clearly demonstrate that the 
preincubation of peripheral T cells with IL-2 in absence of Th1-directing cytokines, e.g. 
IL-12, leads to the upregulation of the α-CD3/α-CD28-induced production of Th2-like 
cytokine IL-5 (but not of Th1-like cytokine IFN-γ). Furthermore, we show that this 
effect may be accomplished by the upregulation of Th2 specific transcription factor 
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GATA-3. Interestingly, increased expression of GATA-3 is also observed in lung tissue 
from asthmatic subjects [33]. A role for IL-2 in the upregulation of Th2 cytokines 
in asthma is further supported by the enhanced airway IL-2 mRNA expression and 
increased expression of the IL-2 receptor on lymphocytes observed after allergen 
challenge in asthma patients [11,34].  Most IL-2 mRNA positive cells consist of CD3+ 
cells [10], which implies that IL-2 has an autocrine action in the upregulation of 
Th2-like cytokine production in the airways. In addition, it has been described that 
mast cells stimulated by FcεRI cross-linking
 are potent producers of IL-2 [35]. It is 
therefore tempting to speculate that allergen-activated mast cells play a role in the 
upregulated Th2-like cytokine production by T cells in atopic asthma. 
 In addition to its upregulatory effect on Th2-like cytokine production, we 
found that IL-2 may reduce the negative feedback control of T cells by β2-agonists 
or PGE2 (chapter 3). In human airways, β2-ARs may be activated by circulating 
catecholamines, e.g. epinephrine, as well as by norepinephrine released by 
surrounding nerve endings. Another receptor coupled to the Gs protein/AC system 
is the PGE2 receptor. Bronchial epithelial cells, macrophages and fibroblasts are 
well-known PGE2 producers and their release of PGE2 may serve to control T cell-
mediated inflammatory activity. PGE2 and β2-agonists exert their inhibitory effects 
on T cell activity by the activation of the AC system and subsequent cAMP formation. 
Our results suggest that enhanced IL-2 signaling protects T cell activity from the 
suppressive effects of cAMP. Various signaling pathways may be involved in cAMP-
mediated inhibition of T cell cytokine production (as described in chapter 1.2.3), 
including the upregulation of p27kip (chapter 3). The reduced sensitivity of IL-5 
production to cAMP in the presence of exogenously added IL-2 is likely mediated by 
counter-regulatory effects of IL-2 on cAMP downstream signaling, i.e. the PI3-kinase 
dependent down-regulation of Forkhead transcription factor and p27kip (chapter 
3). In addition to cAMP-mediated inhibition, the release of transforming growth 
factor (TGF)-β by bronchial epithelial cells and regulatory T cells may provide an 
important negative regulatory mechanism of T cell-mediated responses [36]. TGF-β 
is known to inhibit T cell proliferation as wells as cytokine production [37,38]. The 
inhibitory effects of TGF-β may be mediated by various signaling events, including 
the regulation of p27kip [39]. Since our studies suggest that the protective effect of 
IL-2 on cAMP-mediated inhibition involves regulation of p27kip, it would be of interest 
to study if IL-2 also reduces T cell sensitivity to TGF-β. Our findings indicate that IL-2 
is not responsible for the impaired β2-AR function after allergen challenge, since IL-2 
affected the cAMP downstream pathway and did not induce defects at receptor level 
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(chapter 3). Thus, other factors are more likely involved in the specific downregulation 
of β2-AR function as observed after allergen challenge. Still, the protective effect of 
IL-2 on cAMP-mediated inhibition may contribute to the aberrant cytokine production 
of T cells infiltrated in the bronchial tissue upon allergen exposure in asthma. 
 Th2 effector cells are thought to orchestrate the inflammatory response 
in the airways of asthma subjects. In chapter 4 we show that during the 
differentiation towards Th2 cells, T cells may lose their β2-adrenergic control. The 
differentiation of naive T helper cells towards effector cells with either a Th1-like 
or a Th2-like activation profile diminished the responsiveness to cAMP elevating 
agents. These changes are likely mediated at receptor level, since the AC/cAMP 
downstream pathway appeared to be intact in these highly polarized T cells. One 
of the mechanisms that may underlie the impaired β2-adrenergic regulation of 
polarized T helper cells is the upregulation of βARK2. The expression of βARK2 was 
markedly increased during cell cycle progression under Th0, Th1 or Th2 polarizing 
conditions. Since the β2-adrenergic system is known to inhibit T cell proliferation, the 
upregulation of βARK and subsequent β2-adrenergic desensitization might constitute 
an important mechanism to allow cell cycle progression. In accordance with the 
findings in polarized T cells, preliminary results have indicated that βARK2 is highly 
expressed in the T cell line Jurkat. Preliminary findings have indicated that the β2-AR 
protein levels are not reduced in Jurkat cells compared to freshly isolated T cells. 
However, Jurkat cells showed impaired activation of the cAMP-dependent pathway 
by β2-agonist fenoterol, supporting a role for βARK. Indeed, it has been described 
that overexpression of βARK results in enhanced and more rapid agonist-induced 
desensitization of the β2-AR [39]. In accordance to these findings, we observed that 
both allergen challenge and TARC exposure induce up-regulation of βARK expression 
as well as β2-adrenergic unresponsiveness in peripheral T cells. 
 In addition to the β2-AR, we found reduced regulation by the PGE2 receptor 
in polarized T helper cells. Although the PGE2 receptor may be sensitive to βARK-
mediated desensitization [40], the differential PGE2 effects in Th1 and Th2 effector 
cells suggest an additional mechanism in downregulation of PGE2 receptor function. 
In contrast to the effect of β2-agonist fenoterol, Th2 cytokine production could still be 
partly inhibited by PGE2 in polarized Th2 cells, whereas Th1 cytokine production was 
completely unresponsive to PGE2. As described in chapter 4, this may be the result 
of differential expression of subtypes of the PGE2 receptor. Our findings suggest that 
Th2-mediated responses can be controlled by PGE2-secreting cells, although T cells 
that differentiate into Th2 cells at the sites of inflammation may be less sensitive 
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to PGE2 than peripheral T cells. On the contrary, differentiated Th2 cells may be 
completely unresponsive to β2-agonist-mediated inhibition. These findings seem to 
be in consistence with the observation that airway inflammation in asthma can be 
suppressed by the inhalation of PGE2, while it has been reported that treatment with 
β-agonists fails to suppress the inflammatory response in the airways of asthma 
patients [41-44]. The latter observation may also be partly explained by the finding 
that allergen exposure induces a loss of β2-adrenergic control in T cells. 
 The differentiation into Th2 effector cells does not likely account for the 
diminished β2-adrenergic function observed in peripheral blood lymphocytes after 
allergen challenge. Highly polarized T helper cells may exist at sites of inflammation 
during ongoing immune responses, but we do not expect them to be present in 
peripheral blood. Instead, peripheral blood memory T cells are likely to have a 
more intermediate T helper phenotype and may be more strictly controlled by cAMP 
elevating agents, e.g. endogenous β-agonists. Indeed, we observed that Th2 cytokine 
production of peripheral blood T lymphocytes is controlled by the β2-adrenergic 
system in stable asthma (chapter 5). Yet, this effect was completely abolished six 
hours after allergen exposure, suggesting that the release of (a) soluble factor(s) 
rapidly diminishes β2-adrenergic function in peripheral lymphocytes. We have not 
investigated T cell subpopulations to test if an altered composition of peripheral 
blood T lymphocytes is responsible for the allergen-induced changes in β2-adrenergic 
function. Since we observed that the migratory response of T cells is negatively 
controlled by the β2-adrenergic system, we do not render it likely that the impaired 
β2-adrenergic function in peripheral blood is caused by an efflux of T cells with a 
functional β2-AR. More likely, the function of the β2-AR expressed on peripheral blood 
T cells is reduced. We found that the changes in T cell regulation six hours after 
allergen challenge were specific for the β2-AR. In contrast, it has been previously 
demonstrated by Meurs et al that the basal AC activity as well as the AC response to 
β2-agonists and NaF is impaired 24 hours after allergen challenge [19]. This suggests 
a defect at Gs protein level (i.e. heterologous desensitization). Although the response 
to PGE2 was slightly decreased after allergen challenge in our setting, no significant 
differences could be observed with respect to PGE2 regulation (chapter 5). These 
findings are in accordance with the study of Borger et al, demonstrating that the 
dose-dependent inhibition by PGE2 of Th1 cytokine IFN-γ was not altered 3 and 24 
hours after allergen challenge [26]. Furthermore, we observed that direct activation 
of the G protein by NaF strongly induced activation of cAMP downstream effector 
CREB after allergen challenge. Thus, our study indicates that the defect induced at 
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six hours after allergen challenge is upstream from the Gs/AC system and specific 
for the β2-AR. Furthermore, our data suggest that the upregulation of βARK may be 
involved in the allergen-induced desensitization of the β2-AR (chapter 5). Although 
βARK is known to be involved in agonist-induced β2-adrenergic desensitization, we 
do not render it likely that endogenous β2-agonists, e.g. epinephrine, are responsible 
for the allergen-induced changes in β2-AR function. As described in chapter 1.3.2, 
the release of inflammatory mediators during the allergen-induced asthmatic 
response rather than the stress induced by airway obstruction is responsible for the 
β2-adrenergic dysfunction. This indicates that the release of soluble inflammatory 
mediators from the lung into the circulation may be responsible for the allergen-
induced β2-AR desensitization. 
 We hypothesized that chemokines may be important soluble mediators 
in this respect. The release of chemokines into the circulation is responsible for 
the attraction of proinflammatory cells to the inflamed tissue. Not only do most 
chemokine receptors activate the Gi protein, which counteracts Gs signaling, but 
also have βARK and β-arrestin been implicated in the chemokine-induced migration 
of inflammatory cells [46-48]. Our findings in chapter 5 indicate that the release 
of TARC after allergen exposure may be responsible for the reduced β2-adrenergic 
responsiveness observed in peripheral lymphocytes after allergen exposure. By 
increasing the expression of βARK2, TARC may enhance the agonist-induced 
desensitization of the β2-AR. However, our findings in chapter 6 suggest that TARC 
may not only facilitate agonist-induced desensitization of the β2-AR, but that it is 
able to induce βARK-mediated β2-AR phosphorylation in a β2-agonist-independent 
manner. This is an interesting observation, since βARK-mediated phosphorylation 
has been considered to be restricted to homologous β2-adrenergic desensitization. 
An overview of the proposed mechanism of chemokine-induced β2-AR desensitization 
is given in figure 1. 
 We have not measured the plasma levels of TARC, however increased TARC 
release may be expected after allergen challenge. First, this is suggested by the 
increase in lung T cells that bear the TARC receptor CCR4 after allergen exposure 
[49]. Second, increased levels and enhanced expression of TARC have been observed 
in BAL and bronchial epithelium upon allergen challenge in asthma patients [49,50]. 
Thus, allergen exposure may increase the secretion of TARC in the asthmatic 
airways, which in turn may reduce β2-adrenergic responsiveness of peripheral T 
cells. The impaired β2-adrenergic function may have important consequences for the 
activation status of peripheral T cells. These cells may not only lose their negative 
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feedback regulation, our results also suggest that the desensitized β2-AR is linked to 
the Src/MAPK kinase pathway, resulting in positive regulation by the β2-AR pathway 
after allergen challenge. These alterations may contribute to the upregulatory effect 
of β2-agonist fenoterol on Th2 cytokine production that was observed in some 
Figure 1.  Putative mechanism of chemokine-induced β2-AR desensitization.
patients. Together, our findings suggest that an imbalance in Gs/Gi signaling may 
lead to the enhanced Th2-like activity that is observed in asthma. In contrast to 
Th2 cytokines, we observed that Th1 cytokine IFN-γ was still under strict control 
of the β2-AR six hours after allergen challenge. This differential effect of β2-agonist 
fenoterol on Th1 and Th2 cytokine production may have several explanations. Since 
the production of IFN-γ is more sensitive to cAMP, the residual activity of the β2-
adrenergic AC/cAMP system might still be able to efficiently inhibit (certain signaling 
events involved in) IFN-γ transcription after allergen challenge. We observed that the 
ability of fenoterol to induce CREB phosphorylation was completely abolished after 
challenge. This seems to contradict the involvement of CREB in the regulation of the 
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IFN-γ gene, which contains a CRE in its promoter. However, we do not exclude the 
possibility that fenoterol is still able to induce phosphorylation of CREB, but that this 
effect is extinguished rapidly due to reduced Gs coupling of the β2-AR after allergen 
challenge. Another interesting explanation for the differential effects in Th1 and Th2 
cells is that particularly Th2 cells loose their negative feedback control. This suits the 
hypothesis of TARC-mediated desensitization, since especially Th2 cells have been 
described to express CCR4 [51]. Specific down-regulation of β2-adrenergic function 
in CCR4+ T cells may result in predominant infiltration of Th2-like cells in the airways. 
We observed that in addition to Th2-like cytokine production, the suppressive effect 
of TARC on β2-adrenergic control may serve to facilitate the infiltration of T cells 
(chapter 5).
 While our data suggest that endogenous β2-agonists suppress the migratory 
response of peripheral T cells and may retain T cells in the circulation, the 
chemokine-induced loss of β2-adrenergic control may be required for appropriate 
migration of T cells. A conceptual problem arises, since chemokine exposure may 
also induce rapid desensitization of the chemokine receptor itself [52]. However, 
our preliminary results have indicated that β2-AR desensitization can be induced 
by relatively low concentrations of TARC. In contrast, desensitization of the CCR4 
receptor was only observed after exposure to high levels of TARC. Thus, while the 
release of chemokines into the circulation may induce optimal unresponsiveness 
to β2-AR-mediated inhibition, the migratory capacity of T cells may be fully 
retained. We have also observed that other chemokines were able to reduce β2-
AR responsiveness, indicating that chemokines in general might play a role in the 
regulation of β2-AR function. The infiltration of T cells in lung tissue is an important 
aspect of the inflammatory response in asthma and therefore our observations may 
have implications for the pathophysiology of asthma. In chapter 6 we demonstrate 
that the Src-dependent activation of βARK and β-arrestin are likely involved in the 
TARC-induced effects on T cell regulation. Indeed, it has recently been described 
that β-arrestin-2 is required for the accumulation of Th2 cells in the airways and the 
development of asthma in allergen-sensitized mice [53]. Furthermore, it has been 
demonstrated that the activation of the Gi protein and Src family kinases is crucial 
for the trafficking of Th2 cells to the lung and the development of Th2-mediated 
inflammation in mouse models of asthma [54,55]. This further suggests that the 
pathways induced by TARC may be important in the development of a Th2-mediated 
inflammatory reaction in asthma. Thus, the release of TARC and possibly other 
chemokines by epithelial cells and/or macrophages in the airways upon allergen 
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exposure may reduce β2-AR function in peripheral lymphocytes. As a consequence, 
this may promote T(h2) lymphocyte recruitment to the lungs. Furthermore, the 
reduced β2-AR function as well as the release of IL-6 and IL-2 by resident cells in the 
lung, including mast cells and macrophages, may facilitate the production of Th2-
like cytokines in the airways. Subsequently, the production of Th2 cytokines results 
in further defects in the repair response of the bronchial epithelium [56] and β2-
adrenergic hyporesponsiveness of the smooth muscle [57]. Moreover, Th2 cytokines 
can increase the production of chemokines (e.g. TARC) by the bronchial epithelium 
Figure 2. Proposed mechanism of allergen-induced airway inflammation.
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as well as smooth muscle cells and thus participate in a positive feedback loop [58, 
59]. In this way, the loss of β2-AR control in T lymphocytes not only contributes to 
the onset of the allergen-induced airway inflammation, but also leads to progression 
of the airway inflammatory response and airway hyperresponsiveness in asthma 
patients.
 In conclusion, our findings suggest that β2-AR unresponsiveness, possibly 
induced by chemokines, may contribute to a shift towards Th2-like activity in asthma. 
Thus, a good β2-AR function may be of importance for the suppression of the Th2-
mediated airway inflammation, which is supported by the observation that the use 
of β-blockers increases the sensitivity to the allergen in asthma patients [60]. The 
diminished β2-AR function observed after allergen exposure cannot be expected to 
be the only determinant in the development of Th2-mediated airway inflammation. 
We show that in addition to the allergen-induced defect in β2-AR function, the release 
of IL-6 and IL-2 may promote the Th2-mediated inflammation. Together, the release 
of cytokines and chemokines by resident cells in the lung may contribute to the 
enhanced activation profile of T cells as observed in atopic asthma. An overview of 
the Th2-mediated inflammation in asthma is given in figure 2.
FUTURE PERSPECTIVES
The activation of T cells plays an important role in the type of airway inflammation 
that is underlying the bronchoconstrictive reaction in asthma. T cells are known to 
orchestrate the inflammatory response by the production of Th2 cytokines (e.g. IL-
4, IL-5, IL-13). Upon allergen challenge, both peripheral blood and lung T cells show 
enhanced activity, reflected by the upregulation of Th2 cytokines. In the present 
thesis we have studied the possible mechanisms involved in the up-regulation 
of T(h2) activity after allergen exposure. Our findings suggest that the allergen-
induced alterations in β2-AR function contribute to the enhanced Th2-like activity in 
asthma. More specifically, the release of TARC may be one of the factors responsible 
for the allergen-induced defects in β2-AR function. Further studies concerning the 
mechanisms of allergen-induced β2-adrenergic desensitization will be required to 
support the role for TARC and possibly other chemokines. For instance, it is still 
unknown if enhanced membrane localization of βARK and β-arrestin, which were 
induced by TARC exposure, can also be observed in peripheral T cells upon allergen 
challenge. Another question that remains unsolved is whether the allergen-induced 
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alterations are present in a specific T cell subset or are general for the total T 
cell population. In contrast to the production of Th2 cytokines, the β2-adrenergic 
regulation of Th1 cytokine IFN-γ was not altered six hours after allergen challenge. 
It is not clear yet whether this is due to the fact that IFN-γ is more sensitive to 
cAMP and is still inhibited by the residual activity of the β2-AR/AC system after 
allergen challenge or if particularly Th2 cells lose their β2-adrenergic control. Since 
predominantly Th2 cells are known to express the TARC receptor CCR4, the latter 
suggestion fits the hypothesis of TARC-mediated β2-adrenergic desensitization. It is 
of interest to investigate if the number of CCR4+ cells in peripheral blood of asthma 
subjects is high enough to account for the allergen-induced changes in β2-AR function. 
To answer these questions, it would be worthwhile to study if the allergen-induced 
β2-adrenergic desensitization in asthma patients can be addressed to a specific T cell 
subset, if TARC exposure induces similar alterations and if the expression of CCR4 on 
peripheral lymphocytes is increased in asthma patients versus healthy controls. The 
Th2 directing cytokine IL-4 has been shown capable of increasing the expression of 
CCR4 in T cells [61]. Given the Th2 promoting capacity of IL-6 (chapter 2), it would 
be of interest to study if IL-6 can induce similar changes. The upregulation of CCR4 
expression may enhance the responsiveness of peripheral T cells to TARC. Another 
mechanism that may contribute to the imbalance in Gs/Gi signaling as suggested by 
our studies is the increase the Gi expression. This can for instance be induced by 
inflammatory cytokines [62]. It would be interesting to compare the Gi expression in 
T cells from asthma patients with the expression in healthy controls. In contrast to 
our findings, the study of Borger et al has demonstrated that β2-adrenergic control 
over IFN-γ production is completely abolished 24 hours after allergen challenge 
[26]. This suggests further β2-AR downregulation or downregulation in another T cell 
subset, which may for instance be induced by the release of additional chemokines 
after longer time periods. Moreover, the findings of Meurs et al suggest general 
desensitization of Gs protein-coupled receptors 24 hours after allergen challenge 
[19]. Therefore, it would be of interest to study if the release of additional factors is 
involved in the β2-AR/AC unresponsiveness 24 hours after allergen challenge.  
  It remains to be elucidated how allergen challenge induces the release of 
factors (e.g. TARC) that alter T cell regulation in asthmatic subjects. Because of the 
fundamental abnormalities in the phenotype of the asthmatic bronchial epithelium, 
we propose to study the release of epithelial mediators. The bronchial epithelium 
not only firstly contacts the allergen, but is also a source of a wide array of 
proinflammatory mediators that may attract and activate T cells, including chemokines 
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and IL-6 [63,59]. The bronchial epithelium of asthma patients is thought to have 
a defective repair response to damaging stimuli, such as proteases derived from 
allergens [64,65]. This may be responsible for the activated phenotype of bronchial 
epithelial cells as observed in asthma and lead to the release of proinflammatory 
factors [65]. More insight in the dysregulation of peripheral T cells in asthma and 
their interaction with epithelial mediators may be provided by studying the effect 
of supernatant derived from allergen-activated epithelium on the regulation of T 
cells. Furthermore, with respect to our findings in chapter 5 and 6, it is of interest to 
study the release of TARC by bronchial epithelial cells after allergen stimulation and 
particularly to compare TARC production in epithelial cells derived from asthmatic 
subjects with healthy controls. Additional valuable information may be obtained by 
studying the migratory response of T cells to supernatant derived from allergen-
activated epithelial cells from asthmatic subjects and by characterization of the T cell 
subset that is attracted. The infiltration of T cells in the lung is not only dependent 
on chemokines, but also on the functionality and expression of adhesion molecules. 
Chemokines have been described to stimulate integrin-dependent T cell adhesion, 
whereas the β2-AR system may negatively regulate adhesion of inflammatory cells 
by the inhibition of adhesion molecule expression [66-68]. Thus, an interesting 
question that remains is whether impaired β2-AR function and an imbalance in Gs/Gi 
signaling may have implications for the adhesion of T cells to the endothelium and 
thus T cell infiltration in the airways. 
 In chapter 5, we observed a high variation in the β2-adrenergic 
responsiveness after allergen challenge between the asthma patients. In some 
patients, the inhibitory effect of fenoterol on Th2 cytokine expression was only 
reduced, while in others even a strong upregulatory effect could be observed after 
allergen challenge. One of the factors that may contribute to this variation is the 
variability in the β2-AR gene. Several β2-AR polymorphisms have been identified, 
which differ in their responsiveness to agonist-induced desensitization. Although the 
frequencies of these polymorphic forms are not different in asthma patients and 
healthy controls, the polymorphic form that displays enhanced desensitization may 
promote asthmatic phenotypes [69]. Instead, the form that is relatively resistent to 
agonist-induced desensitization may protect against bronchial hyperresponsiveness 
[69]. It is tempting to speculate that the β2-AR polymorphism that displays enhanced 
desensitization induces stronger allergen-induced alterations with respect to β2-AR 
regulation of cytokine production.  The investigation of β2-AR polymorphisms might 
provide insight in the variable β2-AR responsiveness after allergen challenge and 
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possibly also in the sensitivity to the allergen.
 In addition to the suppression of T cell activity, the β2-AR system has been 
described to have an important role in the regulation of smooth muscle tone, 
mediator release of mast cells and eosinophils and proliferation of epithelial cells 
[70]. Diminished β2-AR function in these cells may have important implications 
for pathophysiology of asthma. We suggest that similar mechanisms as in T cells, 
involving the activation of the Gi protein and upregulation of βARK and β-arrestin, 
may be involved the desensitization of the β2-AR on other cell types, e.g. smooth 
muscle cells and eosinophils [71-74]. Studies concerning β2-AR function and 
Gs/Gi signaling in various cell types may lead to increased understanding of the 
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Astma is een aandoening die wordt gekenmerkt door vernauwing van de luchtwegen 
(oftewel bronchoconstrictie) na inademing van verschillende specifieke prikkels 
(zoals huisstofmijt, boompollen en huisdierhuidschilfers, ook wel allergenen 
genoemd) en aspecifieke prikkels (zoals bijvoorbeeld rook en mist). Verhoogde 
luchtwegreactiviteit (het versterkt reageren op aspecifieke prikkels, ook wel 
hyperreactivitieit genoemd) is een kenmerk van astma. Dit wordt over het algemeen 
niet aangetroffen bij gezonde personen. De meest voorkomende vorm van astma 
is de allergeen-geïnduceerde vorm (allergisch astma), waarbij bronchoconstrictie 
optreedt na inademing van een bepaald allergeen. Deze vorm van astma wordt in dit 
proefschrift  besproken. 
 Er wordt aangenomen dat een ontstekingsreactie in de luchtwegen van 
astmapatiënten ten grondslag ligt aan de hyperreactiviteit en bronchoconstrictie in 
reactie op het inademen van verschillende prikkels. Bij de totstandkoming van deze 
ontstekingsreactie zijn meerdere factoren betrokken, zowel erfelijke (genetische) 
factoren als omgevingsfactoren. Herhaalde blootstelling aan allergenen kan leiden 
tot de ontwikkeling van luchtwegontsteking en verhoogde luchtwegreactiviteit. 
Meerdere cellen van het immuunsysteem zijn betrokken bij de ontstekingsreactie in 
de luchtwegen en er worden dan ook verschillende ontstekingscellen  aangetroffen 
in het longweefsel van astmapatiënten. Dit zijn onder meer eosinofiele cellen 
(eosinofielen), mestcellen en T-lymfocyten (T-cellen). Van mestcellen wordt 
aangenomen dat ze een belangrijke rol spelen bij de directe reactie op inademing 
van het allergeen in de luchtwegen (de vroege astmatische reactie), die binnen 
enkele minuten optreedt. Eosinofielen spelen waarschijnlijk een meer centrale rol in 
de late astmatische reactie, die enkele uren na allergeen blootstelling optreedt en 
wel vierentwintig uur kan aanhouden. Zowel mestcellen als eosinofielen scheiden 
bepaalde stoffen (mediatoren) uit, die zorgen voor samentrekking van de gladde 
spiercellen rondom de luchtwegen. Daarnaast scheiden ze mediatoren uit die andere 
kenmerken van de astmatische reactie veroorzaken, zoals slijmproductie (mucus 
secretie) en oedeemvorming, waardoor de luchtwegen nog verder vernauwen. 
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De rol van T-cellen in de allergische ontstekingsreactie in de luchtwegen
T-cellen spelen een cruciale rol bij de aansturing van de allergische ontstekingsreactie 
in de luchtwegen van patiënten met astma. Er bestaan meerdere typen T-cellen, 
waaronder de helper T-cellen. De belangrijkste functie van helper T-cellen is het 
uitscheiden van signaalstoffen (cytokines) en daarmee het bevorderen van een 
bepaalde immuun respons. Cytokines kunnen andere cellen van het immuunsysteem 
aantrekken naar de plaats van ontsteking en/of voor activering van deze cellen zorgen. 
De T-cellen in de luchtwegen van astmapatiënten scheiden met name cytokines uit 
van het T-helper 2 (Th2)-type, te weten interleukine (IL)-4, IL-5 en IL-13. Deze 
cytokines spelen een zeer belangrijke rol in de allergische luchtwegontsteking, 
onder andere door het aantrekken en activeren van eosinofielen. Er is gebleken dat 
de activiteit van T-cellen bij astmapatiënten duidelijk verhoogd is ten opzichte van 
gezonde personen, wat zich onder meer kenmerkt door de verhoogde aanmaak van 
Th2-cytokines in het longweefsel en een verhoogd vermogen om deze cytokines aan 
te maken in het perifere bloed. Na inhalatie van het allergeen neemt de activiteit 
van T-cellen bij astmapatiënten verder toe. Er wordt een toename gevonden in 
het vermogen Th2-cytokines te produceren en daarnaast gaan T-cellen vanuit de 
bloedcirculatie het longweefsel infiltreren. 
 Wanneer T-cellen vanuit de bloedbaan in een weefsel terechtkomen, kunnen 
zij worden aangezet tot het aanmaken van cytokines door cellen in de omgeving. 
Bepaalde cellen in het weefsel zijn in staat de T-cel te activeren door het aanbieden 
van een lichaamsvreemde stof (een antigeen, waaronder ook de hierboven 
genoemde allergenen) en worden daarom antigeen presenterende cellen (APC’s) 
genoemd. T-cellen bezitten bepaalde moleculen op hun oppervlak (receptoren) die 
de lichaamsvreemde stof op de APC herkennen. Na aanbieding van het antigeen aan 
de T-cel vindt er signaaloverdracht (signaaltransductie) plaats binnen de T-cel. Dat 
wil zeggen, overdracht van een signaal via bepaalde eiwitten in de cel, uiteindelijk 
resulterend in een aantal specifieke gebeurtenissen in deze cel. De overdracht 
van een bepaald signaal gebeurt veelal via het overdragen van een fosfaatgroep 
(fosforylering), waardoor een eiwit geactiveerd raakt. Het eiwit dat als laatste in een 
reeks geactiveerd wordt, wordt transcriptiefactor genoemd. De transcriptiefactor kan 
binden aan het DNA in de T-cel en ervoor zorgen dat een bepaald gen afgeschreven 
gaat worden. In het geval van T-cel activering door een APC, leidt bovengenoemde 
signaaltransductie tot het afschrijven van genen coderend voor bepaalde cytokines. 
Hierdoor zullen bepaalde cytokines aangemaakt en uitgescheiden worden. Een 
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aantal signaaltransductie-eiwitten is betrokken bij de aanmaak van cytokines van 
zowel het Th1- als het Th2-type. Additionele signalen kunnen de activering van 
bepaalde eiwitten specifiek voor Th1- of Th2-cytokines aanzetten. Het is inmiddels 
gedeeltelijk bekend welke signaaltransductie-eiwitten betrokken zijn bij de aanmaak 
van Th2-cytokines. Echter, het is tot op heden onduidelijk waardoor de activering 
van deze eiwitten op gang wordt gebracht bij allergisch astma en wat de oorzaak 
is van de verhoogde productie van Th2-cytokines. Een van de mogelijk betrokken 
oorzaken is verminderde controle door het zogenaamde adenylyl cyclase (AC)/
cyclisch AMP (cAMP)-systeem. 
Mogelijke rol van het β2-adrenerge/AC systeem bij de verhoogde T-cel activiteit in 
astma
Het AC/cAMP-systeem is een signaaltransductiesysteem dat in de cel kan worden 
aangezet door binding van het hormoon adrenaline aan zijn receptor, de β2-adrenerge 
receptor genaamd. Naast de effecten op hartslag en bloedvaten, kan de binding van 
adrenaline (of soortgelijke stoffen, zgn. β-agonisten) aan β2-adrenerge receptoren 
zorgen voor zowel  ontspanning van de gladde spiercellen in de luchtwegen als 
remming van activiteit van ontstekingscellen.  Het luchtwegverwijdende effect 
is één van de belangrijkste aanleidingen voor het medicamenteuze gebruik van 
β-agonisten bij astma. Het effect van β-agonisten wordt bewerkstelligd via een 
signaaltransductie-systeem dat aan de β2-adrenerge receptor is gekoppeld, het AC/
cAMP-systeem. AC is een eiwit dat voor de productie van het molecuul cAMP zorgt. Dit 
signaalmolecuul veroorzaakt in T-cellen  remming van de signaaltransductiewegen 
die op gang worden gebracht door antigeen presentatie. De remmende werking van 
cAMP op signaaltransductie-eiwitten kan in T-cellen leiden tot verminderde aanmaak 
van bepaalde cytokines. 
 Er wordt reeds lange tijd gedacht dat bij astmapatiënten het β2-adrenerge/
AC-systeem niet goed functioneert. Het is gebleken dat de β2-adrenerge receptor 
zich in T-cellen niet afwijkend gedraagt tijdens de stabiele fase van astma. De 
functionaliteit van de receptor in T-cellen uit het perifere bloed neemt echter sterk 
af na inhalatie van het allergeen. Omdat dit mogelijk leidt tot verlies van controle 
over T-cel activiteit (zoals cytokine productie), zou een verminderde functie van het 
β2-adrenerge/AC systeem betrokken kunnen zijn bij de verhoogde T-cel activiteit die 
bij astma gevonden wordt na blootstelling aan het allergeen. De oorzaak van het 
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verlies van β2-adrenerge functie (ook wel β2-adrenerge desensitisatie genoemd) is 
nog onduidelijk, maar er zijn verschillende aanwijzingen gevonden dat het vrijkomen 
van mediatoren van de allergische ontstekingsreactie na blootstelling aan het 
allergeen hierbij betrokken zijn.
Vraagstelling en doel van het onderzoek
De belangrijkste vraagstelling in dit proefschrift is waardoor de ontregelde/verhoogde 
T-cel activiteit en verhoogde aanmaak van Th2-cytokines in allergisch astma wordt 
veroorzaakt. Draagt een verminderde werking van het β2-adrenerge/AC-systeem 
(wat negatieve controle bewerkstelligt) hieraan bij? Zijn mogelijk ook andere 
factoren betrokken bij de veranderingen die worden aangetroffen in de regulatie 
van T-cellen in het perifere bloed van astmapatiënten? Daarnaast wilden wij graag 
onderzoeken waardoor de disfunctionaliteit van het β2-adrenerge/AC-systeem  in T-
cellen van astmapatiënten ontstaat.
 Wij veronderstelden dat het vrijkomen van bepaalde mediatoren vanuit de 
longen in de bloedcirculatie betrokken is bij de verminderde negatieve regulatie en 
verhoogde activiteit van T-cellen na blootstelling aan het allergeen. Daarom hebben 
we onderzocht of het uitscheiden van bepaalde (oplosbare) mediatoren door cellen in 
het longweefsel verantwoordelijk zou kunnen zijn voor het verhoogde vermogen van T-
cellen om Th2-cytokines te produceren en of bepaalde mediatoren of omstandigheden 
het functioneren van het β2-adrenerge/AC-systeem kunnen beïnvloeden. Dit 
hebben wij gedaan door T-cellen van gezonde donoren te isoleren en deze onder 
verschillende condities en in aanwezigheid van verschillende ontstekingsmediatoren 
te kweken. Vervolgens hebben we bestudeerd of er ontregeling van T-cel activiteit 
optrad, zoals dit bij astma gevonden wordt. Daarnaast hebben wij onderzocht hoe 
de β2-adrenerge controle over T-cel activiteit verandert na allergeen inhalatie bij 
astmapatiënten. Om de activering van T-cellen door antigeen presenterende cellen 
na te bootsen, hebben wij deze cellen gestimuleerd met antilichamen die dezelfde 
receptoren activeren als die door APC’s worden geactiveerd (het zogenaamde anti-
CD3 en anti-CD28). Hiermee kan de aanmaak van cytokines in T-cellen geïnitieerd 
worden en konden vervolgens de effecten van verschillende ontstekingsmediatoren 
alswel cAMP verhogende stoffen worden bepaald. 
Belangrijkste bevindingen van het onderzoek
In hoofdstuk 2 hebben wij bestudeerd of  het cytokine interleukine (IL)-6 voor een 
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verhoogd vermogen kan zorgen om Th2 cytokines aan te maken. IL-6 kan worden 
aangemaakt door verschillende cellen in het longweefsel en er wordt verondersteld 
dat de aanmaak van IL-6 toeneemt onder bepaalde ontstekingscondities. Daarnaast 
is beschreven dat de IL-6 spiegels in het bloed van astmapatiënten toenemen 
na allergeeninhalatie. Wij hebben het effect van IL-6 bestudeerd op de aanmaak 
van de Th2-cytokines IL-4 en IL-5, belangrijke mediatoren van de allergische 
ontstekingsreactie in de luchtwegen. Ook hebben we het effect op de aanmaak van 
interferon (IFN)-γ onderzocht. Dit cytokine wordt geproduceerd door een ander type 
T-cel, namelijk de Th1-cel, die niet betrokken is bij de allergische reactie en mogelijk 
zelfs verlaagd is bij astma. Wij vonden na een korte periode van IL-6 blootstelling 
een toename in het  vermogen van T-cellen om IL-4 en IL-5 te produceren. Na 
een langere periode van incubatie verdween het effect op IL-4, terwijl de IL-5 
aanmaak duidelijker werd verhoogd. De effecten van IL-6 op korte en lange termijn 
bleken via verschillende signaaltransductiewegen te worden gereguleerd. Voor het 
langetermijneffect op IL-5 is de aanwezigheid van een ander cytokine noodzakelijk, 
te weten IL-2. Dit cytokine wordt onder andere door T-cellen zelf aangemaakt, maar 
kan bijvoorbeeld ook door mestcellen worden geproduceerd. In tegenstelling tot 
IL-5,  bleek na langere periode van incubatie met IL-6 de aanmaak van het Th1 
cytokine IFN-γ enigszins te zijn afgenomen. Wij concluderen dat wanneer T-cellen 
worden geactiveerd in de aanwezigheid van IL-6, dit mogelijk leidt tot een verhoogde 
activatie van Th2-cellen.
 In hoofdstuk 3 hebben we onderzocht of het hierboven genoemde cytokine 
IL-2 ook de controle van het AC/cAMP-systeem over de productie van Th2-cytokines 
kan veranderen. Hiervoor zijn in het verleden al enige aanwijzingen gevonden. 
Daarnaast is beschreven dat IL-2 verhoogd wordt aangemaakt in het longweefsel van 
astmapatiënten na allergeeninhalatie. Een verminderde negatieve controle over Th2-
cytokine productie onder invloed van IL-2 zou belangrijke gevolgen kunnen hebben 
voor de Th2-gestuurde allergische reactie in de luchtwegen van astmapatiënten. 
In T-cellen van gezonde controles bleek inderdaad het remmende effect van 
verschillende stoffen die het AC/cAMP-systeem activeren (cAMP verhogende stoffen) 
over Th2-cytokine productie verloren te gaan in aanwezigheid van IL-2. Dit bleek 
echter niet het gevolg van een defect op niveau van de β2-adrenerge receptor, 
zoals aangetroffen in perifere bloed T-cellen na inhalatie van het allergeen, maar 
het gevolg van een verminderde werking van het cAMP. IL-2 bleek de remmende 
werking van cAMP op een bepaald signaaltransductiepad (de PI3-kinase route) op te 
heffen, wat resulteerde in verlaagde expressie van een negatieve regulator van T-cel 
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activiteit (het eiwit p27kip) en verhoogde DNA-binding van de transcriptiefactor AP-1. 
Dit effect van IL-2 zorgt daarmee mogelijk voor een verminderde controle van cAMP 
over de aanmaak van Th2-cytokine IL-5.
 In hoofdstuk 4 hebben we onderzocht of T-cellen die meer zijn 
uitgekristalliseerd in hun functie, de zogenaamde gepolariseerde (of effector) 
Th1- en Th2-cellen, anders reageren op cAMP verhogende stoffen dan T-cellen uit 
het perifere bloed. Gepolariseerde helper T-cellen kunnen zich ontwikkelen op de 
plaats van ontsteking (zoals b.v. in het longweefsel), wanneer zij gedurende langere 
periode worden gestimuleerd door antigeen presenterende cellen in aanwezigheid 
van bepaalde cytokines. Wij hebben deze condities nagebootst en vervolgens de 
effecten van cAMP verhogende stoffen bepaald. Naast de β2-agonist fenoterol, 
hebben we naar het effect gekeken van prostaglandine (PG)E2, een stof die ook het 
AC/cAMP-systeem activeert. Hieruit is gebleken dat gepolariseerde helper T-cellen 
veel minder gevoelig zijn voor cAMP verhogende stoffen dan T-cellen die vers uit het 
bloed zijn geïsoleerd. Dus wanneer T-cellen reeds langere tijd in het longweefsel van 
astmapatiënten aanwezig zijn, staan ze mogelijk niet meer goed onder controle van 
cAMP verhogende stoffen zoals adrenaline. Het defect in deze gepolariseerde cellen 
bleek op niveau van de β2-adrenerge en PGE2 receptor op te treden. Hoewel deze 
bevindingen inzicht geven in de regulatie van T-cellen op de plaats van ontsteking 
en de manier waarop ontkoppeling van de β2-adrenerge receptor en het AC/cAMP-
systeem kan ontstaan, kunnen zij geen verklaring bieden voor de ontkoppeling 
van de β2-adrenerge receptor zoals die gevonden wordt in het perifere bloed van 
astmapatiënten.
 Om verder inzicht te krijgen in het mechanisme van verminderde 
gevoeligheid (desensitisatie) van de β2-adrenerge receptor na allergeeninhalatie 
alswel de gevolgen van deze desensitisatie voor de activiteit van T-cellen, hebben 
wij in hoofdstuk 5 de functie van de β2-adrenerge receptor bestudeerd in lymfocyten 
geïsoleerd voor en na allergeeninhalatie in astmapatiënten. We hebben in deze 
lymfocyten gekeken naar het vermogen om Th1 en Th2 cytokines aan te maken, 
naar de expressie en activering van bepaalde signaaltransductie-eiwitten en naar 
het vermogen van T-cellen om weefsel te infiltreren, in aan- en afwezigheid van een 
β2-agonist. We vonden dat zowel Th1- als Th2-cytokines voor allergeen inhalatie 
geremd worden in aanwezigheid van de β2-agonist. Opmerkelijk genoeg vonden we 
dat  de remmende werking van de β2-agonist over de aanmaak van Th2 cytokines 
volledig verloren was gegaan na inhalatie van het allergeen en dat de β2-agonist 
zelfs de Th2-cytokine productie kon verhogen in sommige patiënten, terwijl het Th1-
NEDERLANDSE SAMENVATTING
154
cytokine nog steeds sterk geremd werd. Naast het effect op Th2 cytokines, bleek 
de remmende werking van de β2-agonist over het infiltratievermogen van T-cellen 
verloren te gaan. De β2-agonist bleek verder niet meer goed in staat de cAMP-
signaaltransductie op gang te brengen. Mogelijk treedt dit defect voornamelijk op 
in Th2 cellen, een andere mogelijkheid is dat de resterende productie van cAMP nog 
wel voldoende is om Th1-cytokines te remmen, daar deze sterker onder controle 
staan van cAMP. Het defect in de β2-adrenerge functie wordt mogelijk veroorzaakt 
door de verhoogde expressie van een eiwit genaamd bARK, dat de werking van de 
β2-adrenerge receptor kan verminderen. Uit ons onderzoek blijkt dat het verlies van 
β2-adrenerge controle na inhalatie van het allergeen kan leiden tot een verhoogde 
Th2-activiteit.
 Bij de migratie en infiltratie van T-cellen in het ontstoken weefsel zijn 
bepaalde aantrekkingsstoffen betrokken, de zogeheten chemokines. Wanneer 
een T-cel in de circulatie een chemokine tegenkomt, kan deze worden aangezet 
om te migreren in de richting van hogere concentraties van dit chemokine in het 
weefsel. Bij de infiltratie van T-cellen in het longweefsel van astmapatiënten wordt 
gedacht dat er een belangrijke rol is weggelegd voor het chemokine genaamd TARC. 
Dit chemokine kan onder andere worden aangemaakt door het epitheel van de 
luchtwegen. Een bijkomstige interessante vinding in hoofdstuk 5 is dat TARC niet 
alleen zorgt voor migratie van T-cellen, maar ook kan zorgen voor verminderde 
negatieve controle van T-cel activiteit door de β2-adrenerge receptor. In hoofdstuk 
6 hebben we het mechanisme bestudeerd dat betrokken is bij het effect van  TARC 
op de β2-adrenerge functie. We vonden dat de blootstelling van T-cellen aan het 
chemokine TARC een defect veroorzaakt op niveau van de receptor. Bij dit defect 
bleek het eiwit βARK een belangrijke rol te spelen. Via het aanzetten van een 
specifiek signaaltransductiepad bleek TARC voor activering van het eiwit βARK te 
zorgen, resulterend in een verminderde koppeling van de β2-adrenerge receptor aan 
het AC/cAMP-systeem. In plaats van koppeling aan het AC/cAMP-systeem ontstond 
er een nieuwe koppeling van de receptor aan een signaaltransductie-systeem dat in 
T-cellen juist kan leiden tot verhoogde activering. Dus blootstelling van T-cellen aan 
TARC kan de functie van de β2-adrenerge receptor volledig veranderen en daarom 
kan het vrijkomen van TARC bij astma belangrijke gevolgen hebben voor de regulatie 
van T-cellen door stoffen als adrenaline.
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Betekenis van het onderzoek
In dit proefschrift hebben wij onderzoek gedaan naar de mogelijke oorzaak van 
verhoogde T-cel activiteit bij allergisch astma. Wij hebben gevonden dat het 
verminderde functioneren van het β2-adrenerge/AC systeem, wat optreedt na 
allergeeninhalatie, voor een verschuiving in de richting van de aanmaak van Th2 
cytokines kan zorgen. Op deze manier kan het bijdragen aan de verhoogde Th2-
activiteit in astma. Een interessante bijkomstige vinding is dat de β2-adrenerge 
desensitisatie in perifere bloed T-cellen de migratie naar longweefsel kan bevorderen. 
Een van de mogelijke oorzaken voor het verlies van β2-adrenerge controle is het 
vrijkomen van het chemokine TARC na allergeeninhalatie. Gezien de resultaten 
Figuur 1. Schematische weergave van de allergische (Th2-gemedieerde) ontstekingsreactie in de longen 
van astmapatiënten. Blootstelling aan  allergeen kan het luchtwegepitheel en/of APC’s aanzetten bepaalde 
chemokines (o.a. TARC)  en cytokines (o.a. IL-6) uit te scheiden. Mogelijk komen deze in de bloedbaan 
terecht, waar zij T-cellen gevoeliger kunnen maken voor de productie van Th2-cytokines en kunnen zorgen 
voor het verdwijnen van blokkade door de β2-adrenerge receptor (β2-AR) in Th2 cellen. Vervolgens kunnen 
deze cellen naar de longen migreren, alwaar zij door APC’s worden aangezet om Th2-cytokines aan te maken.
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betreffende (het ontbreken van) β2-adrenerge controle over Th2-cytokines na 
allergeeninhalatie en in gepolariseerde Th2-cellen, kan niet worden verwacht dat 
het inademen van β2-agonisten een onderdrukkend effect uitoefent op de Th2-
gemedieerde allergische ontsteking. In plaats daarvan zou het mogelijk zinvol zijn 
te onderzoeken hoe de aanmaak van TARC kan worden geremd of hoe de expressie 
van het eiwit βARK omlaag kan worden gebracht, om zo mogelijk een betere functie 
van de β2-adrenerge receptor te bewerkstelligen. In de zoektocht naar een betere 
behandeling van de Th2-gemedieerde ontsteking bij astma is het noodzakelijk om 
beter te begrijpen hoe het defect in β2-adrenerge functie na allergeeninhalatie 
precies ontstaat. Wij tonen aan dat, naast het verlies van β2-adrenerge controle, de 
aanwezigheid van de cytokines IL-6 en IL-2 de Th2-gemedieerde ontsteking in astma 
kan bevorderen. Ook hier kan een mogelijkheid liggen tot betere behandeling van 
de allergische ontstekingsreactie in de luchtwegen, al zal wel eerst moeten worden 
uitgezocht waar de verhoogde producties van IL-2 en IL-6 hun oorsprong vinden. 
Uiteindelijk verwachten wij dat het onderzoek naar de verhoogde aanmaak van 
ontstekingsmediatoren (onder andere chemokines en cytokines) in het longweefsel 
van astmapatiënten belangrijke implicaties kan hebben voor de T-cel activiteit en 
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